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ABSTRACT 
 
Kara Lynne Conway: Mechanisms of anti-Sm B cell activation in autoimmune Fas-deficient 
mice 
(Under the direction of Dr. Stephen H. Clarke) 
 
 Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the 
production of anti-nuclear autoantibodies to Smith (Sm), a component of a ribonucleoprotein 
complex.  Anti-Sm transgenic mice (2-12H) develop large numbers of anti-Sm B cells but do 
not develop elevated anti-Sm titers, indicating that anti-Sm B cells are regulated.  However, 
2-12H mice with the lpr mutation of the pro-apoptosis gene Fas (Faslpr) develop high anti-
Sm titers and anti-Sm antibody secreting cells (ASCs) in multiple tissues.  This loss of 
tolerance is coincident with an autoantigen-specific depletion of marginal zone (MZ) and B-1 
B cells and a bypass in the early pre-plasma cell (PC) tolerance checkpoint.    
 To demonstrate the involvement of each mature B cell subset in the anti-Sm response 
in Faslpr mice, I adoptively transferred sorted 2-12H splenic B cells to Faslpr or Faswt 
recipients.  I demonstrate that both anti-Sm follicular (FO) and MZ B cells are precursors to 
early pre-PCs.  In addition, MZ B cells and early pre-PCs give rise to immediate, short-lived 
ASC responses, while anti-Sm FO B cells give rise to a delayed, long-lived ASC response 
after transfer to Faslpr recipients.  These findings indicate that all anti-Sm B cell subsets are 
activated in autoimmunity but follow different activation programs, paralleling their 
responses to foreign antigens.   
 I also demonstrate that immature bone marrow-derived DCs (BMDCs) and ex vivo 
DCs that have phagocytized Sm-bearing apoptotic cells (ACs) induce anti-Sm MZ B cell 
 iv 
differentiation to ASCs in vivo and in vitro.  This MZ B cell activation is antigen-specific, T 
cell-dependent, cell-contact dependent, and dependent upon IL-1β, CD40L, and BAFF 
production.  Interestingly, BMDCs and ex vivo DCs from Faslpr mice activate anti-Sm MZ B 
cells regardless of AC phagocytosis or maturation status.  The restricted ability of immature, 
non-autoimmune DCs to activate anti-Sm MZ B cells after AC phagocytosis is likely to 
prevent concomitant T cell activation and to induce only a short-lived B cell response.  In 
contrast, the loss of these restrictions by Faslpr DCs is likely to allow concomitant T cell 
activation, resulting in long-lived, T cell-dependent responses.  These data provide a possible 
mechanism for long-lived, anti-self responses in SLE.
 v 
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CHAPTER 1:  INTRODUCTION
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 B lymphocytes, the effectors of the humoral immune response, have evolved to 
recognize a variety of foreign antigens from viral, bacterial, and fungal pathogens.  
These antibody-producing cells are thus able to assist in mounting efficient, specific 
immune responses against invading organisms.  In creating this diverse repertoire of B 
cells, autoreactive specificities are inevitably generated.  Many mechanisms of 
regulation have evolved to prevent anti-self B cell activation.  Understanding how 
autoreactive B cells are regulated and how these mechanisms are compromised in 
autoimmunity is important for treatment of autoimmune diseases such as systemic lupus 
erythematosus (SLE). 
 
A.  B CELL DEVELOPMENT 
 
 B cell development is a series of intricate processes aimed at creating a diverse 
repertoire of B cells capable of responding to a seemingly infinite number of foreign 
antigens.  This goal must be achieved while maintaining tolerance to self, which is 
controlled by both positive and negative selection processes. Stromal cells in the bone 
marrow (BM) provide signals to guide the generation of B cells from lymphoid 
progenitors.  B cell lymphopoiesis begins in the BM and fetal liver and, unlike T cells, 
most of their development is completed in these lymphoid compartments before 
migrating to the periphery.   
 
1.  Central B Cell Development 
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 Common lymphoid progenitors begin B cell differentiation after receiving both 
membrane-bound and secreted signals from BM stromal cells, the most important of 
which is interleukin-7 (IL-7).  Upon receiving stromal survival signals, common 
lymphoid progenitors enter the pro-B cell stage under the direction of EBF, E2A, and 
Pax-5, transcription factors controlling B cell development(1-5).  Pax-5, which is 
involved in suppressing lineage-inappropriate genes, has been shown to be indispensable 
for pro-B cell development(3, 6, 7).  B cell immunoglobulin (Ig) diversification begins 
in this pro-B cell stage, as recombination activating genes (RAG) 1 and 2 aid in VHDHJH 
heavy chain recombination(8-12).  If productive heavy chain rearrangement occurs, the 
B cell progresses into the pre-B cell stage in which the µ heavy chain is expressed.  The 
µ heavy chain can pair with the surrogate light chain, forming the pre-B cell receptor 
(pre-BCR)(13-15).  The pre-BCR associates with the Igα and Igβ signaling components, 
and signals through this pre-BCR will lead to light chain VLJL rearrangement(16-19).  
Pre-BCR signals are imperative for B cell progression and survival, as B cells from µMT 
mice, which do not express H chain on the surface, and Igα/β-deficient mice, which 
cannot transduce signals through the pre-BCR, do not survive past the pre-B cell 
stage(20-22).   
 Once a complete BCR with heavy and light chains has been rearranged, 
assembled, and expressed on the surface, the cell is now considered an immature B cell.  
Immature B cells are involved in both positive and negative selection in the BM(22-29).  
As I mentioned above, at the pre-B cell stage, immature B cells are also eliminated if 
incapable of signaling through the BCR, allowing only productive rearrangements to 
progress.  This process is referred to as positive selection and is defined by the BCR 
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interacting with self antigen weakly (25, 29, 30).  On the other hand, immature B cells 
that strongly bind self antigen can undergo a secondary light chain rearrangement, called 
receptor editing, in an attempt to avoid autoreactivity by its BCR(31).  If editing does not 
eliminate self-antigen binding, the immature B cell will undergo apoptosis (25, 29).  
This process is referred to as central deletion, a mechanism of negative selection.  
Immature B cells that possess a functional and non-autoreactive BCR are then able to 
migrate to the peripheral lymphoid organs where they are referred to as transitional B 
cells(32). 
 
2.  Peripheral B Cell Development 
 Newly generated immature B cells migrate to the spleen to continue B cell 
development and differentiate into mature B cells.  The spleen is composed of the red 
pulp, which is the region responsible for red blood cell clearance and recycling, and the 
white pulp, which is the region where lymphocytes reside(33).  In the white pulp, T cells 
are located around a central arteriole in an area called the periarterial lymphoid sheath 
(PALS), while the B cells are organized outside of this region in follicles(33).  The 
marginal zone (MZ) area, straddling both the red and white pulp of the spleen, is 
composed of B cells, dendritic cells (DCs), and macrophages(33). 
 Immature B cells, now termed transitional B cells, home to the follicles via 
chemokine receptor expression(33-36).  There are several sub-stages of transitional B 
cells that are somewhat controversial and definitively unclear.  T1, T2, and T3 subsets 
have been described and re-classified recently, however new evidence suggests the 
professed T3 subset may not even be a transitional population but a non-functional 
 5 
(anergic) group of autoreactive B cells (37).  The T1 and T2 transitional subsets can each 
undergo further selection processes, representing late stage regulation of autoreactive B 
cells(38-40).  Autoreactive T1 B cells undergo peripheral deletion, as BCR ligation leads 
to apoptosis, while T2 B cells undergo positive selection (30, 38-42).  This evidence 
supports the idea that tonic BCR signals are required throughout all stages of B cell 
development.  Transitional B cells express high levels of surface IgM and begin to 
increase expression of CD23 and CD21 at later stages before becoming mature(38). 
 
3.  Mature B Cell Subsets 
 While the phenotype and functions of the mature B cell subsets are fairly well-
established, much controversy remains in determining how these mature subsets arise.  
Through the use of transgenic models overexpressing BCR positive regulators or lacking 
BCR negative regulators, several groups have provided evidence suggesting MZ and B-1  
B cells arise from the transitional subset after receiving strong BCR signals, while 
follicular B cells arise after receiving low BCR signals(43, 44).  Other groups argue just 
the opposite, highlighting the intricacy of the process used to generate mature B cells(43, 
44).  The properties of these mature subsets are outlined below, yet clearly much 
remains to be learned about these populations.   
a.  Follicular (FO) B Cells 
 FO B cells (sIgMlow, CD21int, CD23+), as their name suggests, primarily reside in 
the follicles in the spleen, however they also re-circulate in the blood and lymph(20, 41, 
45).  FO B cells respond to T-dependent (TD) antigens to produce high-affinity, isotype-
switched antibodies.  Unlike transitional B cells, BCR engagement of FO B cells leads to 
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activation, proliferation, and upregulation of the co-stimulatory molecules CD80, CD86, 
and CD40(40, 46-50).  The primary cells responsible for germinal center (GC) 
formation, FO B cells migrate to the T-B border upon activation where they proliferate 
before returning to the follicle to initiate the GC reaction(51, 52).  FO B cells in GC 
responses undergo somatic hypermutation (SHM) in response to antigen, resulting in 
affinity maturation, the generation of higher affinity immunoglobulins(51-54).  The 
products of a GC are long-lived plasma cells (PCs) and memory B cells(51).  This 
process will be further described below. 
 
b.  Marginal Zone B Cells 
   B cells (sIgMhi, CD21hi, CD23lo/int) are non-circulating, antigen-experienced B 
cells that respond primarily to T-independent type 2 (TI-2) antigens(55-58). This 
population resides in the MZ and thus are some of the first cells to come into contact 
with circulating antigens and immune complexes (ICs)(57, 59).  The MZ repertoire is 
highly autoreactive and polyreactive, suggesting that self-antigens may be involved in 
their positive selection.  These anti-self cells may have a normal physiological function 
such as to assist in apoptotic cell (AC) clearance and/or to mount a response against 
potential cross-reactive epitopes on pathogens(55).  These cells are pre-activated and 
thus able to rapidly differentiate upon antigen exposure, aiding in rapid, early TI 
responses to blood-borne pathogens(59, 60).  MZ B cells also migrate to the T-B border 
when activated where they proliferate, yet instead of initiating a GC reaction, these cells 
quickly differentiate to short-lived PCs(59, 60).  While generally thought of as TI 
antigen responders, MZ B cells have also been shown to contribute to TD responses and 
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are able to undergo somatic hypermutation (SHM) (59, 61, 62).  Interestingly, as 
described below, many groups have highlighted the involvement of MZ B cells in the 
development of autoimmunity.   
 
c.  B-1 B cells 
 
 B-1 B cells (IgMhi, Mac-1+, CD5+/-) primarily reside in the peritoneal cavity and 
have also been implicated in autoimmunity, as many of these B cells are also 
autoreactive(63, 64).  There are varying schools of thought on B-1 B cell development: 
some propose a distinct progenitor cell subtype differentiates into the B-1 cell 
compartment, while others suggest these cells are derived along normal B cell 
development pathways but delineate after being positively selected(65, 66).  
Interestingly, these cells have the ability to self-renew and are long-lived B cells that are 
the source of most of the circulating IgM and natural antibodies(63, 64).  The B-1 B cell 
compartment is composed of two subsets based on CD5 expression: B-1a (CD5+) and B-
1b (CD5-)(63, 64).  B-1a B cells are similar in function to the splenic MZ compartment, 
as they are usually self-reactive and are thought to be involved in protection from TI 
antigens, such as enteric bacteria(63, 67-71). 
 
B.  B CELL FUNCTIONS 
 
 B cells have many different functions apart from their most important role as 
antibody producers.  While the predominant effector cell type in the humoral immune 
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response, B cells also assist in innate immune defense as well as in adaptive immune 
responses.  Highlighted below are the major B cell functions in our immune system. 
 
1.  Immunoglobulin (Ig) Production 
 Igs, or antibodies, are produced by B cells and are simply secreted forms of the B 
cell’s BCR.  Igs possess two identical heavy chains and two identical light chains, and 
both the heavy and light chains have constant and variable regions.  The variable regions 
determine antigen specificity while the constant region of the heavy chain (Fc) 
determines the class of Ig(72).  As described above, there are several processes during B 
cell development that aid in antigen diversity, creating a large repertoire of antigenic 
specificities, including VDJ/VJ rearrangement, the pairing of the heavy and light chains, 
and SHM in the periphery.   
 There are five Ig subtypes: IgM, IgD, IgE, IgA, and IgG(72).  Only one type of 
Ig is expressed on and/or in the B cell at a time, with the observed exception of IgM and 
IgD co-expression.  IgM, which exists primarily as a pentamer when secreted, is the first 
class of Ig made by every B cell.  Upon antigen encounter and cognate T cell help, the B 
cell can undergo class switch recombination (CSR) to acquire a more appropriate or 
potent antibody needed for the current immune response(73-75).  Functionally, IgM is 
known to provide assistance in primary, innate responses and is responsible for the 
production of natural antibodies.  The function of IgD is unknown yet exists only as a 
surface receptor and is not secreted.  IgE is involved in allergy responses where it is 
captured by mast cells and/or eosinophils via Fc receptors to assist in removal of 
parasites or worms, often through antibody-depedent cell-mediated cytotoxicity, or 
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ADCC.  IgA, which exists most often as a dimer, is involved in mucosal immunity.  IgG 
is produced in response to TD antigens and provides long-term protective immunity.  
The effector functions of the various Ig subtypes further increases the specificity of a 
particular immune response, adding more complexity to an already intricate process(72). 
 
2.  Complement Cascade Initiation  
 B cells are also involved in initiating one branch of the complement cascade 
pathway.  The complement system is comprised of many small, plasma proteins that are 
involved in initiation of inflammation and assistance in opsonization(76-79).  
Complement is activated in response to intricate cleavage events which eventually lead 
to destruction of a pathogen.  There are three complement pathways: the classical 
pathway, the alternative pathway, and the mannose-binding lectin pathway.  The 
classical pathway is the one branch that is initiated by B cells, where complement forms 
immune complexes (ICs) with IgM or IgG antibodies to initiate the complement 
signaling cascade.  This antibody-mediated event ends in the production of the 
membrane attack complex (MAC), effectively lysing some pathogens(76-80).  The 
alternative and mannose-binding lectin pathways do not involve B cells, however, and 
are solely part of the innate immune system. 
 
3.  Antigen Presenting Cell (APC) Capability 
 B cells are also able to be APCs, as they are capable of ingesting, processing, and 
presenting antigen on MHC class II molecules(81-83).  While B cells themselves do not 
recognize processed peptides, they are able as APCs to present antigen to cognate T cells 
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as well as provide the “second signal” needed for T cell activation through CD80 and 
CD86 signals.  Moreover, several studies have demonstrated that B cells are the 
necessary APC required for the break in T cell tolerance in several autoimmune 
diseases(81-83).   
 
4.  Cytokine Production 
 While much focus is put on the cytokine signals B cells require for development, 
activation, and differentiation, B cells themselves produce a variety of Th1 and Th2 
cytokines.  For example, B cells produce IL-10 and IL-6, both typically thought of as 
Th2 cytokines, which can act on B cells in an autocrine fashion as well as affect other 
lymphocyte populations(84-87).  B cells can also produce a very potent Th1-family 
cytokine, TNF-α, which has been demonstrated to have profound effects on 
macrophages and CD8+ T cells(86, 87).  Clearly B cells do not merely respond to the 
polarizing Th1 or Th2 cytokines, but actually contribute to the cytokine 
microenvironment and perhaps skew the response(88-90). 
 
C.  B CELL ACTIVATION 
 
 B cells can be activated by several different types of signals contributing to both 
the innate and adaptive immune response.  T-independent (TI) responses occur without 
T cell help and are characterized as an innate, rapid response.  For example, B cells can 
detect pattern-associated molecular patterns (PAMPs) on pathogens and immediately 
proliferate and secrete antibody(91-93).  T-dependent (TD) responses, on the other hand, 
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require T cell help and are characterized by a longer, typically germinal center (GC) 
response.  The nature of some of these B cell activation responses are outlined below. 
 
1.  Toll-like Receptor (TLR)-Mediated Activation 
 TLRs are a set of highly conserved pattern recognition receptors (PRRs) that 
detects pathogen-associated molecular patterns (PAMPs) including ligands on bacteria, 
viruses, parasites, and fungi(76, 94).  There are 10 (TLR1-10) of these innate detectors 
expressed in a variety of epithelial and immune cells in mice and man, three of which are 
expressed intracellularly (TLR3, 7, and 9).  TLRs provide an immediate, innate defense 
to invasive pathogens and are thus indispensable in many ways, yet these receptors also 
play a crucial role in adaptive immunity(95-100).  MyD88 is the key adaptor protein 
involved in the signaling in most TLR pathways and thus is a very important immune 
system regulator(94, 101).  Activation of NF-κB is the primary consequence of TLR 
signaling, resulting in the production of cytokines and other crucial mediators(102, 103). 
TLRs have recently been implicated in autoimmunity as several of them can recognize 
self ligands, initiating an immune response against host antigens.   
 B cells express and typically respond robustly to several TLR ligands, including 
LPS, ssRNA, and CpG DNA.  LPS, whose receptor is TLR4, has long been known as a 
polyclonal B cell activator, yet recent attention has focused on TLR7 and TLR9 ligands 
and B cell activation(92, 93, 104-107).  Interestingly, B cell tolerance was lost after 
simultaneous stimulation of BCR and TLR7 or TLR9 which results in B cell activation 
and antibody secreting cell (ASC) formation(92, 104-107).  As mentioned above, this 
establishes an important link between TLRs and the development of autoimmunity.  
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2.  BCR-Mediated Activation 
 Unlike T cells, which require antigen processing and peptide presentation, B cells 
recognize soluble antigens.  Interesting new data is emerging suggesting that membrane-
bound, unprocessed antigen on dendritic cells (DCs) is even more efficient at eliciting B 
cell activation than free, soluble antigen, proposing a direct B cell/DC relationship(108).  
Upon specific-antigen exposure, BCR crosslinking occurs, initiating B cell activation.  
The BCR possesses a co-receptor complex, which includes CD19 and CD21, that 
enhances BCR signals(109-111).  Additionally, the membrane Ig is associated non-
covalently with immunoreceptor tyrosine-based activation motif (ITAM)-containing 
heterodimers, Igα/β, which are responsible for the initiation of BCR signals(112).  Once 
the BCR is crosslinked, the BCR signals induce upregulation of co-stimulatory 
molecules, including CD80, CD86, CD40, and MHC class II.  These cell surface 
receptors poise the partially activated B cell to receive the needed signals from T cells to 
fully initiate responses.  The “second signal” required for B cell activation after BCR 
cross-linking is engagement of CD80/86 with CD28 expressed on Th cells.  Antigen-
experienced B cells upregulate CD40 to allow for efficient ligation of CD40L on T cells.  
This is an essential interaction for proficient B cell activation and downstream GC 
reactions(113-115).  While much is known about this initial B cell activation process, it 
has become increasingly clear that many factors dictate how the B cell will respond, 
including the nature of the antigen (affinity/avidity), the nature of the response (TI/TD), 
the cellular and cytokine environment in which the response is occurring, and the actual 
subset of the responding B cell.   
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3.  Germinal Center (GC) and Extrafollicular Responses 
 An activated B cell can then partake in one of two different responses: an 
extrafollicular response or a GC response.  In an extrafollicular response, an activated B 
cell forms a foci at the B-T border and bridging channels, rapidly differentiates, and 
becomes an ASC.  This is achieved by the induction of a plasma cell (PC) transcription 
program.  These responses are usually short-lived and seem to be predominantly 
generated from MZ B cells in a TI-manner(53, 116).   
 The availability of T cell-help leads most antigen-activated B cells to form a 
germinal center (GC).  Two of the most important transcription factors involved in the 
GC reaction are Bcl-6 and Pax-5(117, 118).  Bcl-6 promotes B cell proliferation and 
inhibits B lymphocyte induced maturation protein 1 (Blimp-1), the terminal plasma cell 
(PC) differentiation factor(118-121).  Moreover, mice lacking Bcl-6 do not develop 
GCs, suggesting this transcription factor is crucial to this process(118, 120, 122).  Pax-5 
is also important in that it represses X-box binding protein 1 (XBP-1), another factor 
essential for PC differentiation through its involvement in the unfolded protein 
response(117, 121, 123, 124).   
 After approximately 8-10 days, this focus of cells polarizes with proliferating B 
cells (centroblasts) on the T cell side and with the resting B cells (centrocytes) on the 
other.  The centroblasts are in an area now called the dark zone, while the centrocytes 
are in an area referred to as the light zone(51, 52).  Centroblasts will undergo SHM and 
cycle into the light zone for selection via antigen on the surface of follicular dendritic 
cells (FDCs)(52-54).  Those B cells with a high affinity BCR survive, while those with a 
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weak or moderate affinity either die immediately or cycle back through the dark zone 
and the light zone(52, 116, 125).  T cells provide signals to the high affinity B cells to 
undergo CSR to increase the specificity of the response(52-54).  Once selected to 
survive, the B cells from the GC reaction either become memory B cells or long-lived 
PCs(51, 126, 127).  What signals dictate whether a particular B cell will become a 
memory B cell or a PC are unknown.  While PCs are immediate antibody secretors, 
usually long-lived PCs when exiting from a GC reaction and short-lived when deriving 
from an extrafollicular response, memory B cells differentiate to PCs after a secondary 
antigen challenge.  Both memory B cell and PC humoral cell functions are essential in 
mounting and maintaining an efficient immune response. 
 
4.  Memory B Cells 
 Memory B cells generated in a GC response are long-lived, Ig-expressing cells 
that are poised to rapidly respond without T cell assistance upon subsequent antigen 
exposure(128).  These cells maintain Pax-5 expression, perhaps in response to CD40 
signals, until reactivation at which time the responding cells can either differentiate into 
PCs, and likewise acquire a PC transcriptional program (described below), or replenish 
the memory B cell population(121, 129).  Amidst much debate, it is now fairly well-
accepted that antigen is not required for memory B cell persistence in humans(130).  
Importantly, memory B cells secrete high-affinity, mutated, and often class-switched 
antibodies, again aiding in the rapid and robust secondary response(128).  While there is 
evidence of several different subsets of murine memory B cells that exhibit differential 
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responses upon secondary challenge, these are not well characterized or understood(54, 
129). 
 
5.  Plasma Cells (PCs) 
 The B cell effector population, PCs, is defined by decreased surface IgM, B220, 
CD19, and MHC class II and increased expression of intracellular IgM and CD138, the 
archetypal PC marker(116).  PCs generated from extrafollicular responses are generally 
short-lived while those generated from a GC reaction are long-lived, often homing back 
to the BM where they can persist for months.  These long-lived PCs have increased 
survival due to the upregulation of receptors for survival factors, such as BAFF and 
other stromal cell signals(53, 116).   
 
a.  PC Transcription Program 
 Unlike GC and memory B cells, PCs have low levels of Pax-5 expression, as 
other transcription factors repress this transcriptional repressor(117, 123).  Likewise, 
Bcl-6, the GC transcription factor that promotes cellular proliferation, is also 
downregulated(118, 120).  Bcl-6 and Pax-5 downregulation relieves repression of 
Blimp-1 expression, and Blimp-1 acts to further repress Pax-5 and Bcl-6.  Blimp-1 is 
required for PC differentiation of B cells, since Blimp-1 deficient mice fail to develop 
PCs in response to a TD antigen(117, 131).  While it has long been thought that Blimp-1 
is the “master regulator” of PC differentiation, recent studies have revealed that this 
factor, perhaps required for terminal differentiation, may not be necessary for PC 
commitment.  Other factors are also required for this PC differentiation process, 
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including XBP-1 and IRF-4(124).  Recent studies have highlighted the importance of  
IRF-4, proving it is required for terminal differentiation through its ability to upregulate 
Blimp-1 expression.  Mice lacking IRF-4 expression consequently lack serum Ig(132, 
133).  Continuing to identify how this complex network of transcription factors is 
promoting PC differentiation is imperative to truly understand the end stages of B cell 
activation. 
 
b.  PC Homing 
 One interesting and very important change that occurs upon PC differentiation is 
the alteration of chemokine receptor expression.  These alterations are essential as they 
allow PCs to home back to the BM where they persist as long-lived, antibody-secreting 
PCs.  PCs downregulate the chemokine receptor CXCR5 to allow these effector cells to 
migrate from the follicle, as they will no longer be sensitive to CXCL13 signals provided 
by FDCs and stromal cells(134, 135).  Concurrently, PCs upregulate the chemokine 
receptor CXCR4 which promotes PC migration to the bone marrow where they can 
interact with the CXCR4 ligand, stromal derived factor 1 (SDF-1), and most likely reside 
until they turnover(133, 136). 
 
c.  PC Intermediates 
 While much effort has focused on the generation and function of mature B cells, 
much remains to be learned about the steps incurred by a mature B cell in becoming a 
PC.  Over the last 5-7 years several groups have attempted to describe “PC 
intermediates,” many of which possess different phenotypical and functional attributes, 
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suggesting mature B cell differentiation and activation is more complex than previously 
appreciated.  PC intermediates are generated in response to both TD and TI antigens. 
 One example of PC intermediates generated in response to TD antigens includes 
a population identified in the BM.  These cells express the PC marker CD138 and low 
levels of IgM but are not antibody secreting cells (ASCs)(137).  Interestingly, another 
study shows immunization with mouse mammary tumor virus (MMTV) results in the 
induction of an extrafollicular response in which CD138int cells are generated, yet these 
cells migrate to the BM before acquiring a full PC phenotype(138).  Many groups have 
also demonstrated the generation of PC intermediates in extrafollicular responses to TI 
antigens(117, 139, 140).  Our group has recently described an early pre-PC intermediate 
population in mice defined by CD19 and B220 expression accompanied by CD138 
intermediate expression(141).  These PC precursors are antigen-experienced and highly 
autoreactive but are not ASCs (141).  These cells form a relatively stable population 
(half-life=21 days) and appear to be a population of antigen-experienced cells that are 
capable of rapid PC differentiation.  Clearly many PC intermediate populations exist and 
these and other recent studies have elucidated the importance of better defining these 
stages of late B cell differentiation into PCs. 
 
D.  B CELL TOLERANCE 
 
 The V(D)J rearrangement process to produce a diverse B cell repertoire 
inevitably generates autoreactive B cells.  In healthy individuals and mice, several 
tolerance mechanisms exist to prevent anti-self B cell activation and subsequent 
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secretion of pathogenic autoantibodies.  However, in some individuals these tolerance 
mechanisms fail and cause autoimmune diseases.  Here I will briefly discuss some of 
these central and peripheral tolerance mechanisms.  Much of our knowledge of these 
mechanisms has come from studies in transgenic models that bind self- or neoself-
antigens. 
 
1.  Receptor Editing and Central Deletion 
 As described above, B cells at the immature B cell stage in the BM will undergo 
receptor editing if they possess an anti-self BCR(31, 142, 143).  The B cells undergoing 
this process typically rearrange their light chain, although there are reports of heavy 
chain rearrangement, in an attempt to become non-self(31, 142, 144).  If the B cells are 
unable to successfully acquire a non-autoreactive BCR specificity, they undergo 
apoptosis, a process referred to as central deletion.  Central deletion is clearly illustrated 
in the neo-self antigen hen egg lysozyme (HEL) system, as anti-HEL B cells are deleted 
only in the presence of membrane-bound HEL (mHEL) antigen(145, 146, 147).  B cells 
that successfully rearrange their BCR to no longer be self-reactive will survive and 
continue differentiation. 
 
2.  Peripheral Deletion 
 Peripheral deletion is discussed in depth above and is a mechanism of peripheral 
self-tolerance employed at several B cell development stages. Importantly, anti-self B 
cells appear to be sensitive to negative selection via BCR ligation at any stage, 
suggesting autoreactive B cells that escape from the BM are still able to be deleted at the 
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transitional B cell stage and perhaps beyond.  BCR signals at the transitional B cell stage 
induce cell death rather than proliferation.  Approximately 60% of transitional B cells 
are deleted at the T2 to mature B cell differentiative step, indicating a major tolerance 
checkpoint for autoreactive B cells. 
 
3.  Anergy 
 Anergy, defined as functional unresponsiveness, is an important regulation 
mechanism for autoreactive B cells in the periphery(145, 148-150).  There appear to be 
multiple mechanisms of anergy and which is employed by a given B cell is likely 
dependent upon the nature of the antigen and the antigen concentration in the 
environment.  The HEL system again provides insight into this regulation mechanism as 
anti-HEL B cells become mature, FO B cells but are anergic in the presence of soluble 
HEL (sHEL) antigen.  These anti-HEL B cells were classified as anergic due to their 
lack of BCR responsiveness, low sIgM expression and negligible response to LPS(145, 
151, 152).  Another form of anergy was described in the Ars/A1 (anti-ssDNA cross-
reactive antigen) model in which the B cells, despite expressing normal levels of IgM, 
possess attenuated BCR signals and a reduced half-life.  In addition, anti-Sm B cells in 
the 2-12H/Vκ8 are able to mature, maintain sIgM expression, and signal in response to 
BCR stimulation yet do not proliferate in response to BCR signals.  Moreover, they are 
instrinsically defective in responses to LPS.  The mechanism(s) by which anergy is 
induced in autoreactive B cells is not entirely clear, but it appears the presence of antigen 
is required for these processes(145, 148-150, 153).  For example, constant antigen 
engagement has been shown to induce BCR uncoupling and subsequent desensitization, 
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as the Igα/β signaling components of the BCR are sequestered from the external µ 
receptor(154-156).  Recently DC-secreted factors, including IL-6, CD40L, and TNF-α, 
have been shown to repress anti-Sm B cells, providing evidence for the involvement of 
extrinsic factors in the maintenance of B cell anergy(157, 158).   
 
E.  DENDRITIC CELLS 
 
 Dendritic cells (DCs) are professional antigen presenting cells (APCs) that 
provide a crucial link between innate and acquired immunity as they are able to both 
initiate and dictate immune responses(164).  There are many different DC subsets with 
distinct functions during an immune response.  Here I will offer further insight into DC 
immunobiology with particular emphasis on their involvement in B cell regulation. 
 
1.  DC Function 
 DCs, like B cells, are generated in the BM and migrate into peripheral lymphoid 
and non-lymphoid tissues upon differentiation(165).  These professional APCs are 
largely responsible for ingestion and antigen presentation of foreign antigens and possess 
specialized detectors, including TLRs (discussed in depth above), that continually 
sample their local environment(76).  DCs phagocytose foreign pathogens through the 
use of phagocytic receptors, including Fc receptors (FcRs), CD14, and others(166-168).  
The goal of DC microbe ingestion is to process these pathogenic antigens and present 
microbial peptides on their surface MHC molecules to elicit specific T cell help.  As I 
mentioned above, DCs harnass membrane-bound, intact antigen to aid in B cell 
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stimulation, however T cell activation requires DC-processing and presentation of a 
particular peptide, as opposed to whole, soluble antigen.   
 
2.  DC Maturation 
 DC function is highly influenced by their activation or maturation status.  
Immature DCs, which have not been exposed to foreign antigen, have not upregulated 
co-stimulatory molecules such as CD80, CD86, and CD40, and thus are unable to 
engage T cells and subsequently elicit T cell help(173). However, importantly, immature 
DCs are very efficient at phagocytosis and thus are the important initiators of an immune 
response(173),  since they will be the first antigen presenting cell (APC) to acquire 
antigen. 
 Signals through several receptors can induce DC maturation, including CD40, 
TLRs, and Fas(95, 173-177).  Upregulation of these receptors leads to an increase in co-
receptor expression, making mature DCs very efficient T cell activators, unlike 
immature DCs.  After foreign pathogen signals and/or ingestion, DCs acquire a mature 
phenotype, defined by co-stimulatory molecule upregulation and pro-inflammatory 
cytokine secretion, including TNF-α, IL-12 and IL-1β(164).  Activated, mature DCs are 
highly migratory and migrate to lymphoid tissues where they encounter T cells.  DCs 
that already reside in lymphoid organs, such as the spleen, tend to be non-migratory and 
continually sample the local lymphoid environment to aid in immune response 
initiation(178-181).   
  
3.  DC Subsets 
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 In addition to maturity status, there are many different DC subsets that are also 
phenotypically and functionally distinct.  As my dissertation focuses primarily on 
murine splenic DCs, I will briefly introduce the splenic subsets: lymphoid, myeloid, and 
plasmacytoid DCs.  Lymphoid DCs (CD11c+CD11b-CD8α+CD4-) are located primarily 
in the T cell-rich areas of the spleen, including the PALS, and are involved in activating 
CD8+ CTLs, initiating Th1 differentiation.  Myeloid DCs (CD11c+CD11b+CD8α-CD4+/-) 
are located in the MZ area and thus are able to sample foreign antigens in the blood as it 
empties into the spleen.  Myeloid DCs are able to present to both CD4+ and CD8+ T cells 
yet predominantly induce Th2 differentiation.  Lastly, plasmacytoid DCs 
(CD11c+CD11b-B220+Gr1+/- ) are responsible for extensive type 1 interferon production 
during anti-viral responses(184, 185).  Outside of the spleen, specialized DC subsets also 
exist that are involved in ingesting pathogens from peripheral tissues, including the 
blood and skin.  It is clear distinct anatomical locations, receptor expression profiles, and 
presentation capabilities demonstrate the highly specialized and vast amount of DC 
functions in the murine spleen. 
 
4.  Apoptotic Cells (ACs) and DCs 
 DCs not only ingest and process foreign antigens to mount immune responses but 
are also efficient phagocytes of ACs.  Efficient phagocytosis of ACs by DCs, through 
receptors such as the receptor tyrosine kinanse MerTK, complement receptor C1qR, 
ανβ5 integrin, and the phosphatidlyserine receptor, is ideal as ACs expose nuclear 
proteins on their outer leaflets, providing a pool of self-antigen(186-188).  Immature, but 
not mature, DCs are able to efficiently ingest ACs, and this process itself does not 
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mature the DCs(173).  DCs that have phagocytized ACs possess an impaired ability to 
stimulate T lymphocytes and exhibit a reduced capacity to produce pro-inflammatory 
cytokines after stimulation(189, 190).  This is important in that the failure of DCs to 
mature after AC ingestion prevents cognate autoreactive T cells from responding and 
initiating a pathogenic response.  Moreover, DCs that phagocytized ACs for 0.5-3 hours 
are refractory to LPS stimulation, however in the data presented in this dissertation, we 
show DCs pulsed with ACs for 24 hours are able to mature in response to TNF-α(173).   
 
5.  DCs and B Cells 
 While DC-mediated T cell activation has garnered much focus over the years, 
recent studies have revealed direct DC interactions with B cells.   
 
a.  DCs and B Cell Activation 
 DCs have been shown to play a role in Ig class-switch, B cell activation, and B 
cell antibody production(191-193).  Germain and colleagues demonstrated through 2-
photon intravital imaging that antigen-bearing DCs that come in direct contact with B 
cells results in B cell Ca2+ signaling, antigen acquisition, and extrafollicular 
accumulation(194).  Kearney and colleagues have demonstrated DC involvement in 
responses to a TI-2 antigen by showing blood DCs transporting bacteria to the MZ 
where they activate MZ B cells(195).  They also showed that this activation is dependent 
upon BAFF secretion by DCs(195).  Moreover, Vilen and colleagues showed a DC-
mediated repression of anergic, autoreactive B cells that requires direct cell contact and 
secretion of the cytokines IL-6 and TNF-α(157, 158).  Thus, a picture is emerging of 
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DCs having a direct role in B cell activation.  Chapter 4 of my dissertation will discuss 
our recent finding contributing to this growing body of literature. 
 
b.  BAFF  
 B cell activating factor (BAFF), also known as BLyS, TALL-1, and THANK, is 
a member of the TNF family and is a strong promoter of B cell survival(196-198).  
BAFF is produced by many cell types including monocytes, macrophages, DCs, and 
radiation-resistant stromal cells and exists in both secreted and membrane-bound forms. 
BAFF’s pro-survival functions are illustrated by groups that have shown transgenic mice 
with excess BAFF have increased mature B cell numbers(199-201).  Moreover, the 
administration of recombinant BAFF to mice induces a similar B cell expansion(197, 
202).    
 A proliferation-inducing ligand (APRIL) is a member of this TNF family and 
competes for two of BAFF’s three receptors(199).  BAFF and APRIL share two 
receptors, transmembrane activator and CAML interactor (TACI) and B cell maturation 
antigen (BCMA), and BAFF’s additional receptor for which it is the only ligand is 
BAFF-R(199, 203-206).  TACI, expressed on both FO and MZ mature B cell subsets, 
behaves as a negative B cell regulator, as mice deficient in this receptor develop an 
increased number of peripheral B cells and autoimmunity(207).  BCMA, on the other 
hand, is expressed highly on pre-PCs and PCs, suggesting this receptor plays a role in 
promoting PC survival(207).  BAFF-R, the receptor for which BAFF is the sole ligand, 
is a promoter of B cell survival, as B cell development is halted at the T1 stage in BAFF-
R deficient mice(207).  While several different signaling pathways seem to be involved 
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in BAFF-induced survial, the inhibition of Bim, a pro-apoptotic protein, seems to be the 
common effector. 
 Beyond providing survival signals during B cell development, BAFF is also 
important in B cell activation and PC survival.  BAFF signals allow the B cell to respond 
more vigorously upon activation by promoting survival as well as enhancing cell 
metabolism and cell-cycling.  BAFF has also been shown to promote other B cell 
activation processes including CSR.  Important to my dissertation, DCs that have 
ingested ACs have increased expression of surface BAFF, thus creating a scenario in 
which autoantigen and increased BAFF could stimulate autoreactive B cells(208).  
Combined with the association between increased BAFF levels and autoimmunity in 
mice and man, DCs providing autoantigen and BAFF may lead to autoreactive B cell 
tolerance loss(209).  
 
F.  B CELLS AND AUTOIMMUNITY 
  
 Autoimmune diseases develop as a result of immune responses against self-
antigens.  The development of autoreactive BCRs and TCRs during lymphocyte 
development is inevitable as a result of the randomness involved in receptor gene 
rearrangements.  Multiple forms of B cell regulation have evolved to prevent anti-self B 
cell maturation and activation.   However, loss of tolerance occurs in some individuals, 
resulting in autoimmune disease.  Similarly, mechanisms of T cell regulation have been 
described as well which are important in preventing T cell-mediated autoimmune 
diseases, including Type 1 Diabetes(210-212).  Both genetic and environmental factors 
 26 
have been shown to contribute to autoimmune diseases.  While many human 
autoimmune diseases are classified as B cell- or T cell-mediated, it has become 
increasingly clear that development of autoimmunity is a complex process frequently 
involving both B and T cells.   
 
1.  Systemic Lupus Erythematosus (SLE) 
 SLE is a human autoimmune disease characterized by the development of anti-
nuclear autoantibodies including anti-DNA, anti-chromatin, and anti-Smith (Sm).  Sm is 
a component of a ribonucleoprotein complex involved in RNA splicing and is unique, 
and thus diagnostic of, SLE.  SLE is a systemic disease, thus affecting several target 
organs throughout the body.  Immune complex deposition in vital organs, particularly in 
the kidney glomeruli, ultimately leads to inflammation, tissue destruction, and possibly 
death.  Recent studies in humans, as well as in mice, have focused on the role of 
hormones in development of disease, as SLE primarily affects women (10:1)(213, 214).  
Both estrogen and prolactin, female hormones, have been shown to play a role in anti-
DNA B cell maturation and activation(215, 216).  Interestingly, SLE is also skewed in 
terms of race distribution, as individuals of African American descent are three times 
more likely to develop the disease than Caucasians(215).  While many factors contribute 
to the development of SLE, recent studies have elucidated that the production of anti-
nuclear antibodies may be a result of exposure of these self-antigens during cell 
apoptosis(217-219).  Indeed, increases in AC burdens correlate with the development of 
SLE and other autoimmune diseases. 
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2.  Murine models of SLE 
 Studying SLE in humans is very difficult, as acquiring tissues in which pertinent 
affected cell populations are present is not practical or common.  Hence most human 
studies are limited to analysis of only the circulating B cell populations isolated from 
peripheral blood samples.  Therefore, much investigation of SLE-specific autoreactive B 
cell regulation has been and continues to be done in murine SLE models.  Many of these 
strains, similar to human SLE, are characterized by hyperactivated B cells, pathogenic 
autoantibody production, and subsequent immune complex deposition in vital 
organs(220).  The two most intensely studied murine autoimmune strains that develop 
spontaneous SLE-like diseases are the following: (a) (NZBxNZW) F1 and NZM2410 
and (b) MRL/lpr (220, 221).  Studies in the NZBxNZW F1 strain mimics human SLE in 
that there is a female bias for the development of disease, autoantibodies against nuclear 
components develop, and immune complex deposition in the kidneys leads to severe 
glomerulonephritis(220).    
 MRL/Faslpr mice develop a disease that closely resembles human SLE including 
the production of anti-Sm antibody, a marker SLE antibody(220, 221).  Unlike the 
NZBxNZW F1 strain, disease incidence between males and females in MRL/Faslpr mice 
is equal.  MRL background genes are required for anti-Sm production, but the genes 
predisposing to autoimmunity have not yet been identified.  One gene that can contribute 
to both murine and human autoimmunity is the pro-apoptosis gene Fas. The lpr mutation 
of Fas (Faslpr) is sufficient to induce SLE, but the severity is dependent upon the 
background genes.  It accelerates and exacerbates the disease induced by MRL 
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background genes, but induces only a mild disease on the otherwise non-autoimmune 
C57BL/6 (B6) background (220, 221). 
 In addition to these spontaneous SLE-like murine models, many groups have 
developed transgenic and knockout mice to further study B cells specific for SLE-
associated  self-antigens.  The focus for my dissertation has been on the regulation and 
activation of anti-Sm B cells, and I have done this through the use of  a heavy chain 
transgenic mouse, 2-12H(222).  A summary of our findings in this mouse are detailed in 
the following section.  
 
3.  Anti-Sm Response in SLE 
 Sm is part of the small nuclear ribonuclear protein (snRNP) complex involved in 
RNA splicing and is composed of seven proteins with three of them, SmB, SmB’, and 
SmD, targeted in human SLE(223).  While only ~30% of SLE patients develop an anti-
Sm titer, it is specific for, and thus diagnostic of, SLE.  Those individuals who develop 
anti-Sm antibodies, however, typically have exacerbated disease symptoms and an 
overall poorer prognosis of disease(224-227).  Because of this correlation and the 
exclusivity of anti-Sm antibodies in SLE, our lab became interested in studying the 
regulation and activation of this particular autoreactive B cell specificity.  2-12 fixed 
heavy chain transgenic mice were generated from the 2-12 hybridoma of MRL/Faslpr 
origin using a rearranged, unmutated VH J558(222).  Over 30% of peripheral B cells in 
the 2-12H mice bind Sm strongly but these mice do not have elevated anti-Sm antibodies 
in circulation.  Thus, 2-12H mice are a useful system for studying anti-Sm B cell 
regulation and activation(222). 
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a.  Anti-Sm B Cell Regulation 
  While 2-12H mice develop large numbers of anti-Sm B cells, these mice do not 
develop elevated anti-Sm titers, indicating that the autoreactive B cells are regulated.  At 
least some anti-Sm B cells in these mice are functional, however, as (a) they respond to 
LPS stimulation in vitro and (b) AC immunization induces a transient anti-Sm response 
in vivo(222, 228).   
 We have demonstrated that unlike many other autoreactive B cell specificities, 
anti-Sm B cells are both positively and negatively selected.  We have demonstrated that 
2-12H mice employ both central and peripheral deletion of anti-Sm B cells possessing 
either high- or moderate-affinity BCRs(70, 228).  Anti-Sm B cells with low-affinity 
BCRs migrate to the spleen but are rendered anergic.  Anti-Sm MZ and B-1 B cells, on 
the other hand, are positively selected and functionally responsive to TLR stimulation 
and in vivo AC immunization, yet are not actively secreting in vivo(70, 229, 230).   
 We have recently identified early pre-PC anti-Sm B cells (CD19+CD138int) 
which are also positively selected and activated yet fail to terminally differentiate into 
PCs in vivo(231).  These cells have a short half-life and are VAD-FMK positive 
suggesting the induction of apoptosis.  In contrast, early pre-PCs in non-transgenic mice, 
which have a longer half-life and low frequency of apoptosis, have upregulated Blimp-1 
and are able to secrete antibodies.  Therefore, we believe this early pre-PC population 
represents a late-stage of autoreactive B cell regulation(231).  In Chapters 2 and 4 I will 
demonstrate that this population is functional as well as demonstrate how it contributes 
to the development of autoimmunity. 
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b.  Anti-Sm B Cell Activation 
 Tolerance to Sm was lost  in 2-12H mice with autoimmune backgrounds or 
susceptibility genes(230).  Faslpr mice, which do not typically develop an anti-Sm 
response, acquired elevated anti-Sm titers and developed anti-Sm antibody secreting 
cells (ASCs) in the BM, spleen, mesenteric lymph node (MLN) and lamina propria (LP).  
We have demonstrated that B-1 B cells are activated to produce ASCs in the MLN and 
LP and that the early pre-PC tolerance checkpoint is bypassed.  Moreover, marginal zone 
(MZ) B cell numbers, like B-1 B cell numbers, decrease, concurrent with an increase in 
serum anti-Sm, suggesting that anti-Sm MZ B cells are also activated(230).  We 
demonstrated the spleen and lymph nodes of Faslpr mice have an increased AC burden 
which we hypothesize is a contributing factor to the development of disease(230, 232).  
These studies detailing anti-Sm B cell activation in autoimmune strains are described in 
Chapter 2. 
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A.  ABSTRACT  
 
Murine autoreactive anti-Smith (Sm) B cells are negatively regulated by anergy 
and developmental arrest, but are also positively selected into the marginal zone (MZ) 
and B-1 B cell populations.  Despite positive selection, anti-Sm production only occurs 
in autoimmune-prone mice.  To investigate autoreactive B cell activation, an anti-Sm 
transgene was combined with the lpr mutation, a mutation of the pro-apoptotic gene Fas 
(Faslpr), on both autoimmune (MRL) and non-autoimmune backgrounds.  Faslpr induces 
a progressive and autoantigen-specific loss of anti-Sm MZ and B-1 B cells in young 
adult Faslpr and MRL/Faslpr mice that does not require that Faslpr be B cell intrinsic.  
This loss is accompanied by a bypass of the early pre-plasma cell tolerance checkpoint.  
Although the MRL background does not lead to a progressive loss of anti-Sm MZ or B-1 
B cells, it induces a robust bypass of the early pre-PC tolerance checkpoint.  Faslpr mice 
have a high frequency of apoptotic lymphocytes in secondary lymphoid tissues and a 
macrophage defect in apoptotic cell phagocytosis.  Since Sm is exposed on the surface of 
apoptotic cells, we hypothesize that anti-Sm MZ and B-1 B cell activation is the result of 
a Faslpr-induced defect in apoptotic cell clearance. 
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B.  INTRODUCTION 
 
A goal of B cell tolerance studies is to understand how tolerance is lost in 
autoimmune diseases such as SLE.  Mice of SLE-susceptible strains carry unique sets of 
susceptibility genes 1.  MRL/Faslpr mice develop a disease that closely resembles human 
SLE including the production of anti-Sm, a marker SLE antibody 2.  The MRL 
background is required for anti-Sm production 3, but the genes predisposing to 
autoimmunity have not yet been identified.  One gene that can contribute to both murine 
and human autoimmunity is the pro-apoptosis gene Fas 4 5,6. The lpr mutation of Fas 
(Faslpr) causes a loss of function 4 and is sufficient to induce SLE, but the severity is 
dependent on the background genes.  It accelerates and exacerbates the disease induced 
by the MRL background 7, but induces only a mild disease in C57BL/6 (B6) mice 7.  
Despite producing a wide spectrum of autoantibodies in B6 mice, Faslpr does not induce 
anti-Sm production in these mice 8.   
To examine how autoreactive B cells are regulated, we developed 2-12H 
transgenic (Tg) mice expressing an anti-Sm H chain transgene 9.  Both positively and 
negatively selected anti-Sm B cells co-exist in 2-12H mice, yet they are not activated to 
secrete antibody.  Anti-Sm B cells constitute ~30% of the follicular (FO) B cell subset, a 
majority of MZ B cells, and ~30% of peritoneal B-1 cells in 2-12H mice.  Regulation of 
FO anti-Sm B cells occurs by anergy and developmental arrest 9,10, but how the anti-Sm 
MZ and B-1 B cells are regulated is unknown.  We have recently determined that anti-
Sm B cells are activated and begin plasma cell (PC) differentiation, but arrest at a pre-
PC stage before becoming antibody secreting cells (ASCs) 11.  However, in 2-12H 
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MRL/Faslpr mice, anti-Sm pre-PCs overcome this block and become ASCs, producing 
elevated anti-Sm levels with complete penetrance by 2 months of age 12.   
MZ and B-1 cells are likely sources of autoantibodies in MRL/Faslpr mice, as the 
normal B-1 and MZ B cell repertoires contain a high frequency of anti-self B cells 
including anti-DNA 13,14.  MZ B cell involvement in autoantibody production has been 
documented in an Ig Tg model where these cells produce anti-ssDNA upon estrogen 
treatment 15.  Also, excess BAFF expression rescues self-reactive B cells from peripheral 
deletion and leads to autoimmunity 16,17, and interestingly induces an expansion of the 
MZ B cell subset 18 implying a role for this population.  Anti-erythrocyte B-1 cells are 
responsible for the production of the hemolytic autoantibodies in Faslpr mice 19, 
implicating a role for B-1 cells in autoantibody production.  Also, the sle2 locus of NZW 
origin contributes to autoimmunity and is responsible for, among other effects, an 
expansion of the B-1a cell population 20,21.   
We have recently demonstrated anti-Sm MZ and B-1 B cells are activated in 2-
12H Tg mice carrying a mutation of the receptor tyrosine kinase Mer (mertkkd) 22.  
mertkkd macrophages are impaired in their ability to phagocytize apoptotic cells, and 
mertkkd mice develop a mild lupus-like disease with the production of autoantibodies 
22,23
.  The anti-Sm MZ population is expanded in 2-12H/mertkkd mice, and there is a 
progressive loss of peritoneal anti-Sm B-1 cells in young adult mice, which is caused at 
least in part by B-1 cell activation and differentiation to ASCs of the mesenteric lymph 
nodes (MLN) and lamina propria (LP).  Apoptotic cells are a likely source of Sm antigen 
in vivo, as Sm is exposed on the surface of apoptotic cell blebs 22, similar to other 
nuclear antigens 24, and immunization of non-autoimmune mice results in a transient 
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anti-Sm response 22.  Thus, the increased availability of apoptotic cells caused by mertkkd 
mice could contribute to the induction of an anti-Sm response in 2-12H/ mertkkd mice, or 
mertkkd could alter the function of dendritic cells or macrophages which indirectly lead 
to defects in T cell and B cell regulation.  Since Fas has an opposing function in 
apoptosis to Mer, we sought to understand how Faslpr differs from mertkkd in the 
dysregulation of anti-Sm B cells.  In this report we show that similar to mertkkd, Faslpr 
induces the activation of anti-Sm MZ and B-1 B cells by an antigen-specific mechanism.  
This unexpected similarity can be explained by the observations that Faslpr also induces 
an increase in apoptotic cell frequency in lymphoid tissues and a defect in macrophage 
phagocytosis of apoptotic cells.  
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C.   MATERIALS AND METHODS 
  
Mice.  2-12H, 2-12H MRL/Faslpr, 2-12H/ mertkkd, and 6-1 mice have been described 
9,12,22,25,26
.  2-12H/MRL mice were generated by backcrossing 2-12H MRL/Faslpr mice 
with Fas intact MRL/Mp-+/+ (MRL) mice (Jackson Laboratory, Bar Harbor, ME) 
through two generations to eliminate the Faslpr mutation.  2-12H and 6-1 mice were 
crossed with C57BL/6 Faslpr mice (Jackson Laboratory, Bar Harbor, ME) to generate 2-
12H/Faslpr and 6-1/Faslpr mice.  Ig H chain transgenes of offspring were identified by 
PCR as previously described 9,25.  Fas and Faslpr were identified by analysis of tail 
genomic DNA using the forward primer, CAA GCC GTG CCC TAG GAA ACA CAG, 
and reverse primers, GCA GAG ATG CTA AGC AGC AGC CGG, and GTG GAG 
CTC CAA TGC AGC GTT CCT.  All animal experiments were carried out with 
institutional IACUC approval.   
 
Flow Cytometry.  The antibodies specific for IgMa (DS-1), IgMb (AF6-78), B220 (RA3-
6B2), CD11b (M1/70), CD21(7G6), CD23 (B3B4), CD43 (S7), and CD5 (53-7.3) were 
obtained from PharMingen (San Diego, CA), and were labeled with FITC, PE, APC, or 
biotin. Biotinylated Sm (Immunovision, Scottsdale AR) was used to stain for Sm 
specific B cells.  Biotinylated reagents were revealed with streptavidin-PerCP.  Cells 
were stained as described before 22,26. Liposomes encapsulating FITC and composed of 
membranes containing PtC were used as described to identify PtC-specific B cells 25,27.  
CaspACE™ FITC-VAD-FMK was purchased from Promega (Madison, WI), and cells 
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were stained according to manufacturer’s instructions.  Data were analyzed using 
WinMDI (Scripps Institute, La Jolla, CA). All data represent cells that fall within the 
lymphocyte gate determined by forward and 90° light scatter. 1-5 × 105 cells per sample 
were analyzed.  
 
Cell sorting. For cell sorting of FO, MZ and CD138+ B cells for ELISpot analysis, 
spleen cells were stained for CD19, CD21, CD23, and CD138.  The CD19+, CD21hi, 
CD23-/lo cells were sorted as MZ B cells, the CD19+, CD21low, CD23+, CD138- cells 
were sorted as FO B cells, and the CD19+, CD138+ cells sorted as pre-PCs. For cell 
sorting of peritoneal B-1 and B-2 cells for transfer, peritoneal were stained for CD19 and 
CD11b and the CD19+ CD11b+ (B-1) and CD19+ CD11b- (B-2) cells sorted.  The cells 
were sorted using a MoFlo high speed sorter (DakoCytomation, Fort Collins, CO). 
Sorted populations were >90% pure as determined by reanalysis.  
 
Mouse peritoneal cells transfer.  1x105 sorted peritoneal B-1 and B-2 cells were injected 
intraperitoneally into non-Tg recipients.  In other experiments, approximately 5x106 
peritoneal cells isolated from 2-12H Tg or 2-12H/Faslpr mice were transferred 
intraperitoneally into non-Tg wild type or non-Tg Faslpr mice.  MLN and LP ELISpot 
assays were conducted at 2 weeks post transfer.   
 
ELISAs and ELISPOTs.  Quantification of anti-Sm antibodies and total IgM in mouse 
serum was performed by ELISA as previously described 9,22,26.  A capture ELISA was 
used to measure levels of serum IL-10 levels as described previously 28. Anti-Sm and 
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IgM ELISpot assays were conducted as described previously using Sm and anti-IgM 
coated plates 22.  Small ELISpots were between 1 x10-4 to 3.2 x 10-3 mm2 and large 
ELISpots were >3.2 x 10-3 mm2.   
 
TUNEL assay.  Spleen and MLN tissues were fixed in 10% formalin, embedded in 
paraffin and sectioned. TUNEL assays were performed using ApopTag PLUS 
peroxidase In Situ Apoptosis Detection Kit (Chemicon, Temecula, CA) according to 
manufacturer’s instructions.  Methyl Green was used for counterstaining. 
 
Phagocytosis assay.  In vitro phagocytosis experiments were done as described by Scott 
et al. 23.   
 
Statistical analysis.  Statistical analysis was performed using one-tailed Student’s t test. 
A value of p<0.05 was considered significant. 
 59 
D.  RESULTS 
 
Anti-Sm antibody production in autoimmune 2-12H mice.  We previously 
demonstrated that serum anti-Sm levels were elevated in 2-12H MRL/Faslpr mice 12.  To 
investigate the contribution of Faslpr and the MRL background to anti-Sm production we 
examined mice of a mixed C57BL/6-BALB/c background (2-12H and 2-12H/Faslpr) and 
an autoimmune MRL background (2-12H MRL and 2-12H MRL/Faslpr).  Compared to 
2-12H mice, serum anti-Sm levels were significantly elevated in all 2-12H/Faslpr, 2-12H 
MRL, and 2-12H MRL/Faslpr mice examined indicating that both the MRL background 
and Faslpr induced anti-Sm production (Fig. 2.1A).  The levels were not significantly 
different between 2-12H MRL and 2-12H MRL/Faslpr mice suggesting that the MRL 
background and Faslpr were not additive.  Faslpr did not induce anti-Sm production in 
non-Tg mice, as previously demonstrated 8.  Anti-Sm ASCs of 2-12H/Faslpr and 2-12H 
MRL/Faslpr mice were demonstrated in the bone marrow (BM), spleen, MLN, and LP 
(Fig. 2.1B).   
 
Faslpr preferentially affects anti-Sm MZ B cells in the spleen.  To understand the 
effects of the MRL background and Faslpr on anti-Sm B cells, we examined their effects 
on B cell differentiation.  We observed a higher frequency and number of anti-Sm B 
cells in 2-12H MRL than 2-12H mice (41%±3 vs. 30%± 3, respectively; p=0.013) (Figs. 
2.2A and 2.2B).  This increase was against the backdrop of an overall 2-fold increase in 
the total number of splenic B cells in 2-12H MRL and non-Tg MRL mice compared to 
their non-autoimmune counterparts (Fig. 2.2B).  Thus, the MRL background 
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preferentially expanded the anti-Sm B cell subset.  This expansion was opposed by 
Faslpr , as both the frequency (16%±3 in 2-12H MRL/ Faslpr  vs. 41%±3 in 2-12H MRL 
mice; p=0.002) and number of anti-Sm B cells were reduced by half in 2-12H 
MRL/Faslpr mice (Figs. 2.2A and B).  This Faslpr-induced reduction of anti-Sm B cells in 
MRL mice did not occur in non-autoimmune 2-12H mice (30%±3 in 2-12H vs. 36%±4 
in 2-12H/Faslpr mice; p=0.114; Figs 2A and 2B).  Thus, Faslpr prevented the expansion 
of both the splenic B cell and anti-Sm B cell populations induced by the MRL 
background, but had no effect on the sizes of these populations in non-autoimmune 
mice. 
 The MRL background and Faslpr preferentially affected the anti-Sm MZ B cell 
subset.  MRL mice had an ~4-fold expansion of the MZ B cell subset compared to non-
autoimmune mice (Fig. 2.2C and 2.2D, bottom), as has been previously reported 29,30, 
but had an ~8-fold expansion of the anti-Sm MZ B cell subset (Fig. 2.2D, top).  These 
increases exceeded the ~2-fold expansion of total splenic B cell numbers (Fig. 2.2B), 
indicating a preferential effect on MZ B cells and in particular anti-Sm MZ B cells.  
Again, Faslpr opposed the expansion of the anti-Sm MZ B cell subset, as 2-12H MRL/ 
Faslpr mice had one-seventh the number of anti-Sm MZ B cells as 2-12H MRL mice 
(Fig. 2.2D).  Faslpr only affected the MRL-induced expansion of MZ B cells specific for 
Sm, since non-Tg/Faslpr and non-Tg mice did not differ in the number of MZ B cells 
(Fig. 2.2D).  Thus, the MRL background induced a preferential expansion the anti-Sm 
MZ B cell subset that was opposed by Faslpr . 
 While Faslpr opposed the expansion of the anti-Sm MZ B cell subset in 
autoimmune 2-12H MRL mice, this same mutation induced a loss of anti-Sm MZ B cells 
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in 2-12H/Faslpr mice.  2-12H and 2-12H/Faslpr mice have equal numbers of anti-Sm MZ 
B cells up to 2 months of age, but while 2-12H anti-Sm MZ numbers remained the same 
thereafter, 2-12H/ Faslpr numbers declined to background levels by 3 months of age (Fig. 
2.2C and 2.2D).  Because there was no decline in MZ B cell numbers in non-Tg Faslpr 
mice (Fig. 2.2D, bottom) and the majority of MZ B cells in 2-12H, but not non-Tg mice, 
were anti-Sm (Fig. 2.2E), we conclude that Faslpr  induces an autoantigen-specific loss of 
MZ B cells.   
 
Faslpr and the MRL background promoted bypass of the pre-PC tolerance 
checkpoint.  We previously determined that anti-Sm B cells in 2-12H mice differentiate 
to an early pre-PC stage.  Similar to PCs, these cells express intermediate levels of the 
PC marker CD138 (CD138int), have upregulated CXCR4, and have become larger and 
more granular; yet similar to B cells, they still express near normal levels of CD19, 
B220, and IgM 11.  However, PC differentiation is arrested prior to becoming ASCs.  In 
contrast, the anti-Sm B cells of autoimmune 2-12H MRL/Faslpr mice can differentiate 
beyond this checkpoint, become CD138hi, increase in size and granularity, and express 
low levels of CD19, B220, and IgM 11. Most significantly, some differentiate to ASCs 11.  
To assess the role of the MRL background and Faslpr on pre-PC differentiation we 
examined anti-Sm pre-PCs in these autoimmune mice. We found that the frequency of 
CD138int anti-Sm B cells was similar in 2-12H and 2-12H/Faslpr mice (p=0.48) (Fig. 
2.3A) and that there were no differences in size or expression of IgM, CXCR4, CD19, 
CD80 (Fig. 2.3B and data not shown).  Moreover, Faslpr did not induce an increase in 
CD138hi pre-PCs (p=0.38).  In contrast, the MRL background induced a significant 
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decrease in the frequency of CD138int anti-Sm B cells in 2-12H MRL mice (p=0.008 
versus 2-12H) and a significant increase in CD138hi anti-Sm B cells (p=0.049 versus 2-
12H).  Compared to CD138int pre-PCs, the CD138hi pre-PCs were larger, more granular, 
had higher levels of CXCR4 and lower levels of CD19, B220, and IgM (Fig. 2.3B and 
data not shown).  This phenotype was similar to that of the anti-Sm CD138hi pre-PCs of 
2-12H MRL/Faslpr mice (Fig. 2.3A and B and ref. 11).  Thus, only the MRL background 
appears to induce significant differentiation beyond the early pre-PC tolerance 
checkpoint.   
Since 2-12H/Faslpr mice generate anti-Sm ASCs (Fig. 2.1B), we sought to 
determine whether bypass of the early pre-PC checkpoint occurs inefficiently, so as not 
to alter the frequency of CD138int and CD138hi pre-PCs, yet still generate ASCs.  Thus, 
we determined the frequency of anti-Sm ASCs among CD138+ pre-PCs from both non-
autoimmune and autoimmune 2-12H mice by ELISpot analysis.  Since anti-Sm MZ B 
cells in non-autoimmune mice secrete small amounts of antibody 22, we also examined 
the frequency of ASCs among FO and MZ B cells.  The sorting criteria were as 
illustrated in Fig. 2.3C.  PCs were excluded from the sorted CD138int B cell population 
since the sorted population excluded all CD19- cells (Fig. 2.3C).  The FO and MZ B 
cells of 2-12H and 2-12H/Faslpr formed only small anti-Sm ELISpots with the highest 
frequency among MZ B cells (Fig. 2.3D).  Interestingly, 2-12H/Faslpr mice had a 
significantly lower frequency of anti-Sm ELISpots among MZ B cells than 2-12H mice, 
and anti-Sm ELISpots were undetectable among MZ and FO B cells of 2-12H 
MRL/Faslpr mice.  In contrast, large anti-Sm ELISpots were only detectable only among 
the CD138+ pre-PCs from 2-12H/Faslpr and 2-12H MRL/Faslpr mice, with the highest 
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frequency among the latter (Fig. 2.3D).  Thus, although Faslpr does not induce an 
increase in CD138hi pre-PCs, it induces some pre-PCs to become ASCs indicating 
bypass of the early pre-PC tolerance checkpoint.  Moreover, the inverse relationship 
between the numbers of small anti-Sm ELISpots of FO and MZ B cells and large anti-
Sm ELISpots of the CD138+ pre-PCs suggests that MZ and FO B cells are induced to 
differentiate to CD138int pre-PCs in autoimmune mice.  
 
Faslpr opposed the MRL-induced expansion of the B-1 cell population and induced 
anti-Sm B-1 cell activation.  Faslpr and the MRL background also affected the number 
of anti-Sm B-1 cells.  B-1 cells were identified as CD5+, CD43+, CD23-, and CD11b+ 
(Fig. 2.4A and data not shown).  As with the MZ B cell population, the MRL 
background genes induced a 1.5-2-fold expansion of both the anti-Sm B-1 cell 
population and the total B-1 cell population (Fig. 2.4B), and Faslpr opposed this increase 
(Fig. 2.4B).  However, it had no effect on the number of B-1 cells in non-autoimmune 2-
12H or non-Tg mice (Fig. 2.4B).  Also similar to anti-Sm MZ B cells, the anti-Sm B-1 
cell population underwent limited expansion in perinatal 2-12H/Faslpr and 2-12H 
MRL/Faslpr mice and declined to background numbers by 3 months of age, whereas the 
anti-Sm B-1 cell numbers were constant in 2-12H and 2-12H MRL mice.  Thus, Faslpr 
induces the loss of anti-Sm B-1 cells, but not the total number of B-1 cells, suggesting 
that like the loss of anti-Sm MZ B cells, the loss of anti-Sm B-1 cells is autoantigen 
specific.  
 We previously showed that peritoneal anti-Sm B-1 cell numbers declined in 2-
12H/ mertkkd mice after ~2 months of age and that this was due at least in part to 
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differentiation to ASCs of the MLNs and LP 22.  To determine whether a similar 
explanation accounted for the loss of peritoneal anti-Sm B-1 cells in 2-12H/Faslpr mice, 
sorted B-1 and B-2 cells from 2-12H/Faslpr mice were transferred i.p. to Faslpr recipient 
mice.  As shown in Figure 2.5A, only B-1 cell transfers generated anti-Sm ASCs in the 
MLN and LP.  Thus, Faslpr induced anti-Sm B-1 cells, but not B-2 cells, to differentiate 
to MLN and LP ASCs.  Since these data indicate that only B-1 cells are activated after 
transfer, all subsequent experiments used unsorted peritoneal cells to maximize the 
number of B-1 cells transferred.   
 To determine whether the Faslpr environment is required for activation, 2-
12H/Faslpr peritoneal cells were transferred to wt and Faslpr recipient mice.  Two weeks 
after transfer, Faslpr recipients, but not wt recipients, had an elevated level of serum anti-
Sm (Fig. 2.5B, inset) and an elevated number of anti-Sm ASCs of donor origin in the 
MLN and LP of Faslpr recipients (Fig. 2.5B).  Anti-Sm ASCs were not detected in the 
spleen or BM of either Faslpr or wt recipients.  B-1 cell activation did not require that 
they be Fas-deficient, since transfer of 2-12H peritoneal cells to Faslpr, but not wt 
recipient mice, generated serum anti-Sm and anti-Sm ASCs of donor origin (Fig. 2.5C).  
Thus, anti-Sm B-1 cells are only activated in Faslpr recipients and they need not be Fas-
deficient. 
 
B-1 cell activation by Faslpr was autoantigen specific.  That Faslpr had no effect on 
total B-1 cell numbers in non-autoimmune mice (Fig. 2.4B, lower panel) suggested that 
the loss of anti-Sm B-1 cells caused by Faslpr is antigen specific.  To further test this 
possibility we examined B-1 cells specific for phosphatidyl choline (PtC), a common 
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membrane phospholipid to which as many as 7% of B-1 cells are specific 27.  For these 
experiments we used mice with a H chain transgene that encodes anti-PtC antibodies (6-
1).  6-1 Tg mice have a high frequency of splenic and peritoneal anti-PtC B-1 cells.  
These cells were identified as CD43+, CD5+ B cells that also stained with PtC-containing 
liposomes.  Faslpr had no effect on the percentage of peritoneal anti-PtC B-1 cells (Fig. 
2.6A) or on the expansion of the anti-PtC B-1 cell population in neonatal and perinatal 
mice (Fig. 2.6B), and it did not induce a loss of PtC-specific B-1 cells (Fig. 2.6B). 
 To determine whether Faslpr increased the activation of anti-PtC B-1 cells to 
ASCs, we compared the activation of anti-PtC B-1 cells in 6-1 and 6-1/Faslpr mice by 
cell transfer.  6-1 peritoneal cells were transferred to wt and Faslpr recipient mice.  Anti-
PtC B-1 cells are normally activated in non-autoimmune mice 27, and thus, two weeks 
after transfer ASCs of donor origin were present in wt recipients (Fig. 2.6C).  However, 
the numbers of ASCs of donor origin in Faslpr mice were not significantly different from 
those in wt recipients (Fig. 2.6C).  Thus, the activation and depletion of B-1 cells in 
Faslpr mice is limited to cells of certain specificities, consistent with antigen-dependence.  
 
Faslpr mice have a high frequency of apoptotic cells in the spleen and MLNs.  The 
activation and loss of anti-Sm B-1 cells of 2-12H/Faslpr mice were remarkably similar to 
our findings with anti-Sm B-1 cells of 2-12H/mertkkd mice 22. We attributed this loss in 
mertkkd mice to an increase in availability of apoptotic cell antigens such as Sm and a 
defect in macrophage phagocytosis of apoptotic cells.  Since Fas has non-apoptotic 
functions 31,32 we sought to determine whether Faslpr mice also increased the availability 
of apoptotic cell antigens.  The frequency of apoptotic cells in wt, Faslpr, and 
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MRL/Faslpr mice was measured by flow cytometry using the fluorescence-labeled 
caspase inhibitor VAD-FMK.  Both 2 and 3 month old mice were analyzed to span the 
time frame for anti-Sm MZ and B-1 B cell loss (Figs. 2.2 and 2.4).  No difference in the 
frequency of splenic of MLN apoptotic cells were evident at 2 months, whereas at a 
higher frequency of apoptotic cells was noted at 3 months Faslpr spleens and MLNs (Fig. 
2.7A).  This was corroborated by the detection of cells with fragmented DNA by 
TUNEL assay of frozen tissue sections of 3 month old Faslpr mice (Fig. 2.7B).  In the 
spleen TUNEL+ cells were located predominantly in the extra-follicular space, whereas 
in the MLN they were located predominantly in B cell-rich follicles and in germinal 
centers.   
 
Defective phagocytosis of apoptotic cells by Faslpr macrophages.  The increase in 
apoptotic cell frequency seen in Faslpr mice could be due to a defect in their clearance by 
phagocytic cells.  Since macrophages play a key role in apoptotic cell clearance 23 we 
compared the ability of macrophages from 2 and 3 month old Faslpr and wt mice to 
phagocytize apoptotic cells in an in vitro assay.  As shown in Fig. 2.7C, both 2 and 3 
month old Faslpr macrophages were significantly less able to phagocytize apoptotic cells 
than their wt counterparts, although their defect at both ages was less severe than that of 
mertkkd macrophages.  Nevertheless, these data implicate Faslpr macrophages in the high 
frequency of apoptotic lymphocytes in Faslpr mice and in the activation of autoreactive B 
cells.   
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E.  DISCUSSION 
 
We show here that MRL, MRL/Faslpr, and Faslpr mice with the 2-12H transgene 
develop a spontaneous anti-Sm response with complete penetrance.  Our findings point 
to a central involvement of MZ and B-1 B cells in this response and suggest a link to 
defective apoptotic cell clearance in their activation.  Our comparison of anti-Sm B cells 
from 2-12H mice and B cells of diverse specificities from non-Tg mice indicates bias at 
two levels: B cell subset and antigen specificity.  Faslpr induces a loss of anti-Sm MZ 
and B-1 B cells in young adult 2-12H/Faslpr and 2-12H MRL/Faslpr mice between 2 and 
3 months of age.  Since Faslpr has no effect on non-Tg MZ and B-1 B cells (Figs. 2.2D 
and 4) or on anti-PtC B-1 cells, we conclude that the loss of anti-Sm B cells is antigen 
specific (Fig. 2.6) and not due to a general effect on the generation or maintenance of the 
MZ or B-1 B cell populations.   
The most likely explanation for the Faslpr-induced loss of anti-Sm MZ and B-1 B 
cells is that they are activated to differentiate to ASCs.  Autoantigen activation would 
account for the antigen specific depletion of anti-Sm MZ and B-1 B cells and the 
presence of ASCs in multiple lymphoid tissues (Fig. 2.1).  It would also account for the 
inverse relationship between FO and MZ ASCs and CD138int ASCs (Fig. 2.3B) since 
activated FO and MZ B cells would presumably pass through the CD138int pre-PC stage 
before differentiating to PCs.  Additionally, the activation of anti-Sm MZ and B-1 B 
cells would explain the appearance of serum anti-Sm in 2-12H MRL/Faslpr mice 
between 1 and 2 months of age 12.  Anti-Sm B-1 cell activation is confirmed by the 
transfer experiments showing that they generate MLN and LP ASCs and produce serum 
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antibody in Faslpr recipients, but not wt recipients (Fig. 2.5A).  Antigen-independent 
mechanisms may have a role in this activation, but the number of anti-PtC B-1 cells is 
the same in 6-1 and 6-1/Faslpr mice indicating that any such effect is likely to be small.  
Thus, we conclude that loss of anti-Sm B-1 cells in Faslpr mice is due to autoantigen-
specific activation and differentiation to ASCs.  The parallel loss of anti-Sm MZ B cells 
by Faslpr mice suggests that anti-Sm MZ B cells are also activated to become ASCs, 
although this remains to be confirmed.  
The inefficient bypass of the early pre-PC tolerance checkpoint induced by Faslpr 
(Fig. 3) indicates that Fas-FasL-induced cell death is not a major mechanism of 
regulation at this checkpoint.  Whether Fas-FasL interactions have a regulatory role at an 
earlier checkpoint cannot be ruled out.  The interaction of Fas on autoreactive B cells 
with FasL on helper T cells can induce cell death 33,34, but this is not always the case 35.  
Although helper T cell regulation of these B cells may occur through Fas-FasL 
interactions, the finding that Fas+ B-1 cells are activated in Faslpr hosts (Fig. 2.5) 
suggests that the primary defect leading to anti-Sm MZ and B-1 B cell activation in 
Faslpr mice lies elsewhere. 
A possible explanation for anti-Sm and B-1 cell activation in Faslpr mice is the 
defect in macrophage phagocytosis of apoptotic cells and the increase in the presence of 
apoptotic lymphocytes in lymphoid tissues (Fig. 2.7).  Apoptotic cells expose Sm and 
can induce an anti-Sm response in non-autoimmune mice 22.  A Faslpr-induced increase 
in apoptotic cells has been previously noted in the brains of MRL/Faslpr mice 36.  This 
would account for the antigen-specific effects of Faslpr and for the observation that both 
Fas-sufficient and -deficient B-1 cells are activated (Fig. 2.5).  Additionally, since anti-
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PtC antibodies do not bind apoptotic cells (unpublished data), it would explain why 
Faslpr has no effect on anti-PtC B-1 cells (Fig. 2.6).  These findings parallel our previous 
observation that anti-Sm MZ and B-1 B cells are activated in 2-12H/mertkkd mice, which 
also have a defect in apoptotic cell clearance 22.  In addition, the appearance of increased 
number of apoptotic cells in lymphoid corresponds with when anti-Sm production begins 
and when anti-Sm MZ and B-1 cells are lost, further implicating apoptotic cells as the 
driving force in the activation of Faslpr anti-Sm MZ and B-1 cells.  Interestingly, Faslpr 
mice that lack p53, a pro-apoptotic gene 37, generate lower levels of serum 
autoantibodies compared to Faslpr mice 38.  We suggest that the absence of p53 results in 
a lower frequency of apoptotic cells in Faslpr mice, accounting for the lower 
autoantibody levels.  Defective clearance of apoptotic cells is a recurring feature in 
autoimmunity and targeted impairment of apoptotic cell clearance invariably results in 
autoimmunity 23,39-41.  Defective phagocytosis of apoptotic cells is also a feature of 
human lupus 42,43.  MRL macrophages are defective in apoptotic cell clearance44 and 
thus the combination of the MRL background- and the Faslpr-induced impairment of 
apoptotic cell clearance may contribute to the more severe autoimmunity of MRL/Faslpr 
mice 42,43.  Interestingly, while the defect in macrophage phagocytosis of apoptotic cells 
is evident in Faslpr and MRL/Faslpr mice at 2 months (Fig. 2.7A), there is no apparent 
effect on the frequency of apoptotic lymphocytes relative to wt mice at 2 months (Fig. 
2.7C). Thus, either this macrophage defect is not responsible for the increase in 
apoptotic lymphocytes or that there are compensatory mechanisms for phagocytosis in 
younger mice.   
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How Faslpr induces this macrophage defect remains to be investigated.  Serum 
from lupus patients significantly inhibits efficient phagocytosis by normal human 
neutrophils 45 and thus there may be a secreted factor in Faslpr mice that diminishes 
macrophage phagocytosis of apoptotic cells.  Although incompletely characterized, Fas 
has non-apoptotic functions, such as cytokine production, induction of DC maturation 
and survival, and chemokine production 46,47 involving multiple cell types 31,32,48,49.  
Thus, Fas-FasL interactions could be necessary for the induction of efficient macrophage 
phagocytosis of apoptotic cells.  IL-10 enhances macrophage phagocytosis of apoptotic 
cells50, although there is disagreement51, but no difference in systemic IL-10 levels was 
noted (22.3 ± 0.81 pg/ml for wt mice vs. 22.9 ± 2.37 pg/ml for Faslpr mice, p=0.73).   
Our finding that B-1 cells are involved in the production of anti-Sm appears to 
contradict an earlier report 52.  This earlier study relied on reconstitution of irradiated 
recipient mice, and we find that anti-Sm B-1 cells undergo apoptosis upon encounter 
with apoptotic cells and poorly reconstitute irradiated mice after bone marrow transfer 
(unpublished observation).  Also, B-1 cells may contribute minimally to serum 
autoantibody since many anti-Sm ASCs of B-1 cell origin are located in the LP and 
likely to secrete into the intestinal lumen.  Thus, previous studies could reasonably lead 
to different conclusions. 
The activation of anti-Sm MZ and B-1 B cells in MRL and Fas-deficient mice 
adds to a growing body of evidence that MZ and B-1 B cells are involved in 
autoimmunity 13,20,22,23,30,53-56.  Both MZ and B-1 B cells are antigen-experienced cells 
that can rapidly differentiate to ASCs in response to antigen and provide protection 
against blood-bourn particulate antigens and enteric organisms 57.  These features, as 
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well as their location, may make them uniquely positioned to encounter and respond to 
apoptotic cells in the blood and lymph.  MZ B cells are potent activators of CD4+ T cells 
58
, and thus activation of MZ B cells may also contribute to disease through the 
activation of autoreactive T cells.  Understanding how autoreactive MZ and B-1 B cells 
are activated and the nature of the link to increased apoptotic cell frequency and 
defective macrophage apoptotic cell phagocytosis will be important directions for further 
investigation.  
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FIGURE 2.1 
 
 
 
 
 
 
 
Figure 2.1.  Anti-Sm antibody ASC production in autoimmune mice.  A.  Serum 
anti-Sm levels are shown for mice 2-4 months of age.  B.  The number of anti-Sm ASCs 
in the bone marrow (BM), spleen, MLN, and LP as determined by ELISPOT assay is 
shown (** P<0.01 in comparison to 2-12H mice; n ≥ 3).  
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Figure 2.2.  Anti-Sm B cell development in spleen of 2-12H Tg, 2-12H MRL, 2-
12H/Faslpr, and 2-12H MRL/Faslpr mice.   A. Anti-Sm B cells are present in the spleen 
of 2-12H Tg, 2-12H MRL, 2-12H/Faslpr, and 2-12H MRL/Faslpr mice.  All histograms 
are gated on CD19+ B cells and anti-Sm B cells are boxed.  All mice are 2-4 months of 
age.  B.  Numbers of splenic B cells and anti-Sm B cells are presented.  Means ± SEM of 
five 6-month-old mice of the indicated strain are plotted.  Asterisks indicate statistical 
significance difference (p<0.05* and 0.01**) from cell numbers of their non-
autoimmune counterparts.  Cell numbers at 3 months are not statistically different from 
those shown for 6 months (data not shown).  C.  B cell subset analysis of splenic anti-Sm 
B cells from 1-month-old and 3-month-old mice based on CD21 and CD23 expression.  
Anti-Sm B cells are gated as indicated in A.  The CD21hi, CD23lo cells are MZ B cells 
and the CD21int, CD23hi cells are FO B cells. The percent of total anti-Sm B cells for 
each subset is given.  D. Total number of anti-Sm MZ B cells (upper) and MZ B cells 
(lower) from 1 to 6 month old mice of each strain is given.  Gating for anti-Sm B cells is 
as shown in A and the gating for MZ B cell is as in C.  Mean±S.E. is plotted (n=6).  E. 
Sm staining of MZ and FO B cells is shown.  Gating on total MZ and FO B cells was 
based on CD21 and CD23 expression as indicated in B.  The shaded regions are Sm 
staining of non-Tg B cells; the solid lines are Sm staining by B cells of their Tg 
counterparts. 
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FIGURE 2.2 
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FIGURE 2.2, Continued 
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Figure 2.3.  ELISpot analysis of anti-Sm ASCs in 2-12H, 2-12H/Faslpr, and 2-
12HMRL/Faslpr mice.  A.  Spleen cells were stained for expression of CD19, CD138, 
and Sm.  The CD138-expression of CD19+, Sm+ cells is shown.  Boxes indicate the 
CD138int and CD138hi populations.  The percent of each population is provided.  Data 
are representative of 3 or more mice of each strain.  The percentages of CD138int B cells 
are: 17%±2.4% for 2-12H, 14%±3.1% for 2-12H/Faslpr, 7.0%±1.1% for 2-12H MRL, 
and 7.7%±0.50% for 2-12H MRL/Faslpr.  The percentages of CD138hi B cells are: 
0.13%±0.07% for 2-12H, 0.09%±0.01% for 2-12H/Faslpr, 1.4%±0.46% for 2-12H MRL, 
and 1.9%±0.66% for 2-12H MRL/Faslpr.  B.  Size, IgM expression, and CXCR4 
expression are shown for anti-Sm CD138int and CD138hi B cells from mice of the 
indicated strains.  The gates are illustrated in A.  Data are representative of 3 or more 
mice.  C. Spleen cells were stained for CD19, CD138, CD21, and CD23.  The gating 
scheme used to sort the FO, MZ and CD138+ cells is indicated using 2-12H spleen cells.  
The top histogram shows the identification of CD19+, CD138+ cells sorted for ELISpot 
analysis.  The CD19+ CD138- cells were further fractionated by CD21 and CD23 
expression to identify FO and MZ B cells as shown.  D. The number of small and large 
anti-Sm ELISpots was determined for each of the indicated cell populations.  The 
definition of large and small ELISpots is given in the Materials and Methods.  The 
average size of small ELISpots characteristic of MZ and FO B cells is 2 x 10-3 ± 4 x 10-4 
mm2, and the average size of the large ELISpots characteristic of CD138+ pre-PCs is 1.7 
x 10-2 ± 4 x 10-4 mm2.  Examples of the small FO/MZ-like spots and large CD138+ pre-
PC ELISpots are shown. The number of FO anti-Sm ELISpots per 105 cells in 2-12H 
and 2-12H/Faslpr mice is 23.3 ± 2.36 and 3.51 ± 2.48, respectively (p<0.001).  The 
number of MZ anti-Sm ELISpots per 105 cells in 2-12H and 2-12H/Faslpr mice is 183 ± 
19.2 and 22.5 ± 10.9, respectively  (p=0.002).  The number of CD138+ pre-PC anti-Sm 
ELISpots per 105 cells from 2-12H, 2-12H/Faslpr, and 2-12H MRL/Faslpr mice is 26.0 ± 
5.6, 1540 ± 135, and 7600 ± 265, respectively (p<0.01 for all comparisons).  ND: none 
detected.     
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FIGURE 2.3 
 
 
 
 
 
 
 
 
 
 
 78 
 
 
FIGURE 2.3, Continued 
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Figure 2.4.  Peritoneal anti-Sm B-1 cells in 2-12H Tg, 2-12H MRL, 2-12H/Faslpr, 
and 2-12H MRL/Faslpr mice.   A. Phenotypic analysis of peritoneal B cells from 2-12H 
Tg, 2-12H MRL, 2-12H/Faslpr, and 2-12H MRL/Faslpr mice.  Peritoneal cells from 1-
month-old and 3-month-old mice were stained with CD19, IgM, CD11b, and Sm.  Anti-
Sm B-1 cells are boxed.  All histograms are gated on CD19+ B cells.  B. Analysis of total 
B-1 cell numbers (upper and lower graphs) and anti-Sm B cell numbers (middle) for 
mice between 1 and 6 months of age is shown.   
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FIGURE 2.5 
 
 
 
 
 
 
 
 
 
 
Figure 2.5.  Anti-Sm B-1 cell activation in Faslpr mice after peritoneal cell transfer.  
A.  2-12H/Faslpr peritoneal cells were stained for CD19 and CD11b, and the CD19+ 
CD11b+ B-1 cells and CD19+ CD11b- B-2 cells were sorted and transferred to Faslpr 
recipient mice.  Two weeks after transfer anti-Sm ASCs in the bone marrow, spleen, 
MLN, and LP were quantified by ELISpot.  Asterisks indicate that differences (p<0.05) 
between wt and Faslpr recipients. ND: none detected.  B. Unsorted peritoneal cells from 
2-12H/Faslpr mice were transferred to wild type (wt) or Faslpr recipient mice.  ELISA 
was used to measure serum IgMa+ anti-Sm (inset) and ELISpot was used to quantify 
anti-Sm ASCs from BM, spleen, MLN, and LP.  C. The same as B except that 2-12H 
peritoneal cells were transferred to wt or Faslpr recipients.  
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FIGURE 2.6 
 
 
 
 
 
 
 
Figure 2.6.  The effect of Faslpr on PtC-specific B cells. A. Comparison of 6-1 and 6-1/ 
Faslpr peritoneal B cells for liposome binding and CD43 and CD5 expression.  
Histograms are gated on CD19+ B cells.  PtC-specific B-1 cells (CD43+ and CD5+) are 
boxed and the percent of total CD19+ B cells is indicated.  B. The number of PtC-
specific B-1 cells present in the peritoneal cavity of 6-1 and 6-1/Faslpr between 1 and 6 
months is graphed.  PtC-specific B-1 cells were gated as shown in A.  C.  Number of 
IgMa ASCs in wt and Faslpr recipient mice 2 weeks after transfer of 6-1 peritoneal cells.   
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Figure 2.7.  Apoptotic cells in wt and Faslpr mice.  A.  Flow cytometry analysis for the 
presence of apoptotic cells in the spleens and MLNs of wt and Faslpr mice by FITC-
VAD-FMK staining is shown.  Representative histograms for wt and Faslpr spleen cells 
are shown (top). Each histogram is gated on lymphocytes and the percent VAD-FMK+ is 
provided.  The graph below shows the average ± SEM of percent apoptotic lymphocytes 
in the spleen and MLN of mice at 2 months and 3 months of age (n=3).  ** indicates a 
significant difference with wt (P<0.01). B. TUNEL positive cell distributions in spleen 
and MLN of both wt and Faslpr mice.  Both low (10X) and high (40X) magnification are 
shown.  Boxes indicate the areas of higher magnification. WP: white pulp; RP: red pulp; 
GC: germinal center; F: follicle.  C. Macrophages from wt, Faslpr, MRL/Faslpr, and 
mertkkd mice were incubated with apoptotic thymocytes for 60 min and the percent of 
phagocytized thymocytes determined by fluorescent microscopy.  Controls are the 
percentage of live thymocytes (non-apoptotic) phagocytized. The graph is representative 
of four experiments and shows the average ± SEM of 3 mice per strain at both 2 months 
and 3 months of age.  * P<0.05 in comparison to wt.  
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FIGURE 2.7 
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 CHAPTER 3:  ANTI-Sm FOLLICULAR, MARGINAL 
ZONE, AND EARLY PRE-PC B CELL ACTIVATION IN 
Faslpr MICE
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A.  ABSTRACT 
 
 
Autoreactive splenic B cells specific for the Smith (Sm) ribonucleoprotein 
antigen belong to multiple subsets: follicular (FO), marginal zone (MZ), and pre-plasma 
cell (pre-PC).  However, anti-Sm B cells are not activated to become antibody secreting 
cells (ASCs) in non-autoimmune mice, but are activated in Faslpr , MRL, and 
MRL/Faslpr mice.  To identify the anti-Sm B cells activated in autoimmune mice, we 
performed adoptive transfer experiments of anti-Sm Faswt B cells into Faslpr recipient 
mice.   We find that both anti-Sm FO and MZ B cells become early pre-PCs and that 
they are blocked from activation by a B cell-extrinsic mechanism.  However, anti-Sm 
MZ and pre-PCs give rise to short-lived and immediate ASC responses, while anti-Sm 
FO B cells give rise to a delayed and long-term ASC response that is restricted to the 
spleen.  In addition, anti-Sm FO B cells undergo extensive proliferation to generate a 
memory B cell-like population in the spleen.  Thus, the activation of MZ and FO B cells 
in this autoimmune response mirrors the activation of MZ and FO B cells in response to 
foreign antigen, indicating that the activation programs inherent in B cells of each subset 
are maintained in autoimmunity.   
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B.  INTRODUCTION 
 
 The mature, splenic B cell populations in mice, consisting of follicular (FO), 
marginal zone (MZ), and pre-plasma cells (pre-PCs), have distinct phenotypes and 
functions, suggesting their regulation and potential contributions to disease may be 
different.  FO B cells are recirculating, naïve B cells that give rise to primarily T-
dependent antigens involving germinal center formation, where somatic hypermutation, 
H chain class switch, and affinity maturation occur.  The products of germinal center 
reactions are long-lived plasma cells (PCs) that localize primarily to the bone marrow 
and recirculating memory B cells[1, 2].  MZ B cells, on the other hand,  are non-
circulating antigen-experienced B cells that give rise to primarily to T-independent type 
2 (TI-2) responses[3-7]. These cells have a pre-activated phenotype and thus are able to 
rapidly differentiate to PCs upon antigen exposure[4, 8].  Upon activation they migrate 
to the T-B border where they proliferate and quickly differentiate to short-lived PCs that 
remain in the spleen[4, 8].  We have previously described an early pre-PC subset of B 
cells in mice[9].  They are defined by expression of  CD19, B220, and IgM at levels 
typical of B cells, but to also express the PC-specific marker CD138 (syndecan) at 
intermediate levels (CD138int).  Like MZ B cells, they are positively selected, but have a 
more rapid turnover rate (~3 weeks).  Intriguingly, a high frequency of pre-PCs in non-
autoimmune mice are autoreactive suggesting they could have a prominent role in 
autoantibody production in autoimmunity[9].   
The role of B cells of these subsets in autoimmunity has not been clearly 
elucidated.  Many groups have highlighted the involvement of MZ B cells, and their 
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close peritoneal counterpart, B-1 B cells, in the development of autoimmunity[10].  Our 
analysis of B cells specific for the Sm ribonucleoprotein autoantigen using the Ig H 
chain Tg mice (2-12H) has indicated that they are present in all mature B cell subsets, 
including those (MZ, B-1, and pre-PC) that are antigen selected.  FO B cells appear to be 
anergic and regulated by both intrinsic and extrinsic mechanisms.  These B cells respond 
poorly to LPS and their response to LPS is further repressed by production of IL-6, 
CD40L, and TNFα by DCs and macrophages[10-12].  In contrast, anti-Sm MZ and B-1 
cells appear to be functional, and our analysis of anti-Sm pre-PCs suggests that they are 
short-lived (~7 days), but how they are regulated has yet to be determined[9].  
Nevertheless, the presence of both positively and negatively selected anti-Sm B cells in 
non-autoimmune mice does not result in autoantibody production, indicating that 
tolerance to Sm is maintained and that even positively selected functional B cells are not 
normally activated[10, 13].  
 Tolerance to Sm is lost in 2-12H mice that carry the lpr mutation of the pro-
apoptosis gene Fas (Faslpr), or that have been backcrossed to the autoimmune MRL 
background[10].  Which B cells are activated in these mice is not clearly understood.  
Anti-Sm pre-PCs overcome the tolerance checkpoint that prevents their differentiation to 
PCs indicating that they are involved, but it is not known whether FO or MZ B cells are 
precursors to pre-PCs.  Both anti-Sm MZ and B-1 B cells decrease in number between 2 
and 3 months of age, which corresponds to the appearance of anti-Sm in the serum, 
suggesting that both subsets are activated in autoimmune mice.  Transfer of 2-12H B-1 B 
cells to Faslpr mice confirms the activation of anti-Sm B-1 B cells which are activated to 
form ASCs in the mesenteric lymph node and lamina propria of the gut[10].  Whether 
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MZ and FO B cells are also activated is not known, and nor is the nature of the response 
each cell type generates known.   
In this report we demonstrate that both FO and MZ B cells can differentiate to 
pre-PCs and that these cells are functional and blocked in their activation in non-
autoimmune mice by a pre-PC-extrinsic mechanism.  We also demonstrate that FO, MZ, 
and pre-PCs are activated in autoimmune Faslpr mice.  However, the responses generated 
by the B cells of each subset follow distinct activation programs that parallel their 
responses to foreign antigen.  Thus, the activation programs inherent to each cell type 
are not altered in responses to self-antigen. 
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C.  MATERIALS AND METHODS 
 
 
 
Mice  
Faslpr  and 2-12H Tg mice have been previously described[13-15].  The 2-12H Tg mice 
have been backcrossed 8 times to the C57BL/6 (B6) background.  The 2-12H transgene 
was identified by PCR of tail genomic DNA as previously described.  Animals were 
housed and bred in a conventional facility at the University of North Carolina at Chapel 
Hill (Chapel Hill, NC) and all animal experiments were carried out with institutional 
IACUC approval.   
 
Flow Cytometry 
Cells were stained as previously described and analyzed at the University of North 
Carolina at Chapel Hill Flow Cytometry Facility (Chapel Hill, NC) using a 
FACSCalibur (BD Biosciences) or CyAn (DakoCytomation, Denmark)[15, 16].  The 
antibodies specific for IgMa (DS-1), CD19 (1D3), B220 (RA3-6B2), CD21 (7G6), CD23 
(B3B4), and CD138 (281-2) were conjugated to FITC, PE, biotin, APC, or APC-Cy7 
(Pharmingen, San Diego, CA). For the detection of anti-Sm B cells, we biotinylated Sm 
(SMA-3000; Immunovision, Springdale, AR) as previously described.  Biotinylated 
reagents were revealed with streptavidin conjugated to either PerCP or APC 
(Pharmingen).  Data were analyzed using Summit software (DakoCytomation). All data 
represent cells that fall within the lymphocyte gate determined by forward and 90° light 
scatter. 1-5 × 105 cells per sample were analyzed. 
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Cell sorting 
2-12H Tg splenocytes were stained for B220, CD21, CD23, and CD138 as described 
above for cell sorting of FO B cells, MZ B cells and early pre-PCs for ELISpot analysis 
and adoptive transfer experiments.  MZ B cells were sorted as B220+, CD21hi, CD23-/lo 
CD138- cells, FO B cells were sorted as B220+, CD21low, CD23+, CD138- cells, and 
early pre-PCs were sorted as B220+, CD138+ cells.  The cells were sorted using a MoFlo 
high speed sorter (DakoCytomation).  Sorted populations were >90% pure as determined 
by reanalysis.  
 
CFSE labeling of sorted cells 
In denoted experiments, cells were CFSE labeled prior to adoptive transfer via 
manufacturer’s protocol (CellTrace™ CFSE Cell Proliferation Kit, Invitrogen, San 
Diego, CA).  A concentration of 10µM CFSE dye was used due to the longevity of our 
adoptive transfer experiments. 
 
B cell subset adoptive transfers 
2-12H Tg FO, MZ, and early pre-PC populations were sorted as described above.  1x106 
sorted cells in PBS were injected i.v. into either non-transgenic Faswt or Faslpr recipients.  
On days 3, 4, 12, or 30 post-transfer, cells from spleen and bone marrow were harvested 
for ELISpot and flow cytometry analysis. Donor origin cells were identifiable through 
their expression of IgMa, as they were transferred to recipients with IgMb  B cells.  
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ELISpot assay 
ELISpots were performed as previously described using plates (Millipore, Billerica, 
MA) that we coated with 10 U/well Sm Ag (Immunovision, Springdale, AR) or anti-IgM 
(Southern Biotech, Birmingham, AL)[9, 10].  Cells were resuspended in HL-1 medium 
(Cambrex) supplemented with 1% L-glutamine and 1% penicillin/streptomycin prior to 
plating.  For sorted early pre-PC ex vivo stimulations,  5x103 cells were plated per well 
and 10 ng/mL IL-4 (Peprotech, Rocky Hill, NJ), 10 µg/mL anti-CD40 (Pharmingen), 30 
µg/mL LPS (Invivogen, San Diego, CA), or 1 µg/mL CpG (Invivogen) were added to 
designated wells prior to their 72 hour incubation.  For spleen and BM samples 
harvested after adoptive transfer experiments, approximately 5x 106 cells were plated per 
well and incubated for 24 hours. Secreted 2-12H-specific anti-Sm or IgM was detected 
by using biotin-labeled anti-IgMa Ab and streptavidin-HRP (Pharmingen), while secreted 
antibodies from non-Tg mice were detected by using biotin-labeled anti-IgMb Ab and 
streptavidin-HRP (Pharmingen).  Incubation with the developing substrate 3-amino-9-
ethylcarbazole (Sigma-Aldrich, St. Louis, MO) allowed for ASC detection.  The plates 
were scanned and analyzed using the Immunospot ELISpot analyzer (Cellular 
Technology Ltd., Cleveland, OH).  
Transcription Factor Staining 
Cells were prepared as previously described before being fixed with 1.5% 
paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA)  in PBS for 10 minutes 
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at 4°C.  After fixation, cells were permeabilized with methanol for 30 minutes at 4°C.  
Cells were then stained for both surface markers and transcription factors for 1 hour at 
room temperature.  Pax-5(C20), XBP-1 (M-186), and IRF-4 (M-17) [Santa Cruz 
Biotechnology, Santa Cruz, CA] and their isotype controls were each labeled with Zenon 
technology per manufacturer’s protocol (Invitrogen, San Diego, CA).  Cells were then 
washed with RPMI 3 times for 10 minutes each before running on the CyAn 
(DakoCytomation). 
 
Statistical analysis   
The independent and paired Student’s t tests were used to evaluate significance. A value 
of p<0.05 was considered significant. 
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D.  RESULTS 
 
Anti-Sm pre-PCs are functional and regulated by extrinsic mechanisms.  We 
previously demonstrated that anti-Sm early pre-PCs from 2-12H mice are antigen-
selected, but are regulated to prevent their differentiation to ASCs[9].  As previously 
reported, neither CD138neg nor CD138int B cells from 2-12H Tg mice spontaneously 
secrete anti-Sm[9].  However, significantly more CD138int early pre-PCs than CD138neg 
B cells from non-Tg mice spontaneously secrete IgM, suggesting that the block in 
differentiation of anti-Sm CD138int pre-PCs is due to their auto specificity[9].  Several 
mechanisms may explain regulation of anti-Sm pre-PCs.  Regulation may be intrinsic, 
such as by the active mechanisms of anergy or ongoing cell death.  This is suggested by 
their short half-life relative to non-Tg pre-PCs (7 days vs. 21 days), and the higher 
frequency of anti-Sm pre-PCs staining with the caspase inhibitor VAD-FMK (17% vs. 
4%)[9].  Alternatively, regulation may be through an extrinsic mechanism such as the 
lack of an activating signal or the presence of a negative signal.  To discriminate 
between extrinsic or intrinsic regulation, we assessed the ability of 2-12H pre-PCs to be 
activated in vitro.  B cells (B220+, CD138neg) and early pre-PCs (B220+ CD138int) were 
sorted from 2-12H Tg mice and cultured in the presence or absence of various B cell 
activators.  Purities of both populations were consistently greater than 92% (Fig. 3.1A).  
Stimulation with anti-CD40 and rmIL-4 induced an increase in IgM ASC differentiation 
by 2-12H CD138int pre-PCs, which was significantly greater than the increase by 
CD138neg B cells, but comparable to that exhibited by CD138int non-Tg pre-PCs (Fig. 
3.1B, top middle).  Despite the fact that 2-12H CD138int responded to anti-CD40 and 
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rmIL-4 better than CD138neg B cells, the increase in anti-Sm ASCs was similar (Fig. 
3.1B, top middle).  Thus, anti-Sm pre-PCs are responsive to activation signals that 
mimic T cell help. 
Anti-Sm pre-PCs were also responsive to TLR agonists.  Non-Tg early pre-PCs 
were ~4 times more responsive to LPS than CD138neg B cells indicating that pre-PCs 
were more responsive to LPS than B cells (Fig. 3.1B, bottom middle).  2-12H CD138int 
and CD138neg B cells gave rise to similar frequencies of IgM ASCs.  Unlike their 
responsiveness to LPS, CD138int and CD138neg B cells are equally responsive to CpG.  
In addition, 2-12H pre-PCs gave rise to significantly higher frequencies of anti-Sm 
ASCs after LPS activation than 2-12H CD138neg B cells.  In contrast, CpG stimulation 
induced similar frequencies of IgM ASCs from CD138neg and CD138int B cells and non-
Tg and 2-12H B cell populations were not different.  However, CpG activation induced 
significantly more anti-Sm ASCs by 2-12H CD138int pre-PCs than 2-12H CD138neg B 
cells (Fig. 3.1B, bottom).  Interestingly, responsiveness to CpG by anti-Sm pre-PCs was 
much greater than to LPS or anti-CD40/rmIL-4, and a much higher proportion of the 
activated 2-12H pre-PCs were anti-Sm ASCs in response to CpG (~50%) than to LPS 
(~7%) or anti-CD40/rmIL-4 (~14%).  Thus, CpG is a potent activator of anti-Sm pre-
PCs.  Taken together, the TLR agonist and anti-CD40/IL-4 stimulations indicate that 
despite the differences in spontaneous activation, half-life, and frequency of apoptosis, 
2-12H pre-PCs and 2-12H anti-Sm pre-PCs are functional.  These data are inconsistent 
with B cell-intrinsic regulation by anergy or cell death, suggesting this block of early 
pre-PC differentiation is through a B cell-extrinsic mechanism.   
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To examine this issue in vivo, we adoptively transferred sorted 2-12H CD138int 
pre-PCs into Faswt and Faslpr mice.  2-12H/Faslpr mice develop a spontaneous anti-Sm 
response between 2 and 3 months of age[10].  Donor pre-PCs were detected at high 
frequencies (66±3% and 59±7% of number injected) by flow cytometry in Faswt 
recipient spleens at 3 and 12 days post transfer (Table 3.1).  However anti-Sm ASCs 
were not detected at either time point (Fig. 3.1C and Table 3.1).  At 30 days post- 
transfer, we detected neither donor B cells nor anti-Sm ASCs (Table 3.1), and at no time 
were donor anti-Sm ASCs or B cells detected in the bone marrow (data not shown). 
 In contrast, we observed rapid ASC differentiation by donor B cells in Faslpr 
recipients.  As in Faswt recipients, a high frequency of donor pre-PCs were detected in 
the spleen at both 3 and 12 days (70±8% and 74±3% of number injected), but unlike in 
Faswt recipients, 93% of donor cells in the spleens of Faslpr recipients were ASCs by day 
3 (Fig. 3.1C and Table 3.1).  Anti-Sm ASCs are not detectable by day 12 and 30 (Fig. 
3.1C and Table 3.1), and as with Faswt recipients, there were no detectable donor origin 
cells or donor origin ASCs in the BM at any time point (data not shown).  Thus, anti-Sm 
pre-PCs are not intrinsically defective in their ability to be activated, consistent with our 
in vitro findings.   
 
Anti-Sm FO and MZ B cells can both acquire an early pre-PC phenotype.  To 
identify the cellular precursors of anti-Sm pre-PCs, we sorted 2-12H FO 
(CD23posCD21int) and MZ (CD23negCD21hi) B cells, as illustrated in Figure 3.2A, and 
adoptively transferred them to non-Tg recipients.  After 4 days recipient splenocytes 
were analyzed by flow cytometry to assess donor cell (IgMa+) expression of the early 
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pre-PC marker CD138.  A significantly higher percentage of transferred 2-12H Tg MZ B 
cells (49±4% of injected) than FO B cells (21±3% of injected) were detected in the 
spleen (Table 3.2), and this percentage decreased somewhat at 12 days post-transfer 
(34±2% of MZ B cells injected, 15±1% of FO B cells injected) (Table 3.2).   Neither 
subset was detected 30 days-post transfer (Table 3.2).   IgMa+ donor origin cells from 
both the FO and MZ B cell subsets were heterogeneous for Sm affinity, each possessing 
both Smhi and Smlo binders (Fig. 3.2C and D).  Interestingly, all of the Smhi  donor cells 
in both FO and MZ recipient mice had acquired CD138 expression, while the Smlo B 
cells of both subtypes remained predominantly CD138neg (Fig. 3.2C and D).  Thus, both 
MZ and FO B cells can differentiate to early pre-PCs, and the ability for those of 2-12H 
origin to differentiate is dependent on the ability to bind Sm.   
 
Both anti-Sm MZ and FO B cells are activated in autoimmune mice, but follow 
different activation programs.  To determine whether anti-Sm MZ and FO B cells 
contribute to the anti-Sm response in Faslpr mice, we transferred sorted 2-12H FO and 
MZ B cells to Faswt and Faslpr mice.  At 4 and 12 days post-transfer into Faswt mice, 
neither anti-Sm FO nor anti-Sm MZ B cells became ASCs (Fig. 3.3A and 3.4A), 
although cells of each subset were detected in the spleen at 4 and 12 days post-transfer 
(Table 3.2).  After 30 days, no transferred cells from either population were detected in 
the spleen or the BM (Table 3.2 and data not shown) and no anti-Sm ASCs of donor 
origin were present in these tissues (Fig. 3.3A, 3.4A, and data not shown).  
In contrast to Faswt recipients, Faslpr recipients of 2-12H FO and MZ B cells 
developed anti-Sm ASCs.  Nearly two-thirds of transferred 2-12H Tg MZ B cells were 
detected in the spleen on day 4 , and of these, ~72% had became anti-Sm ASCs (Table 
 103 
3.2 and Fig. 3.3A).  The anti-Sm ASCs were gone by day 12, even though there was 
little change in the number of donor B cells present in the spleen at this time (Table 3.2 
and Fig. 3.3A).  As expected, transferred 2-12H MZ B cells upregulated CD138 by day 4 
and retained this expression on day 12, despite their inability to secrete antibody.  To 
assess the extent of proliferation of these cells after transfer, sorted B cells were labeled 
with CFSE before transfer.  As shown in Fig. 3B, transferred MZ B cells underwent 
extensive proliferation, as seen by a ~100-fold decrease in CFSE levels by day 4.  There 
was no further dilution of CFSE on day 12 indicating that all of the proliferation of anti-
Sm MZ B cells occurred within the first few days after transfer.  No donor-derived B 
cells were detected in the spleens or bone marrow of recipient mice on day 30 (data not 
shown).  
 Since the donor derived pre-PCs in Faslpr recipient mice were present in 
relatively equal numbers on days 4 and 12 post transfer, but were only ASCs on day 4, 
we examined the phenotype of these cells for differences in size, granularity, and 
transcriptional program that could explain for the lack of antibody secretion on day 12.  
At 4 days post-transfer of anti-Sm MZ B cells, donor-derived B cells were larger (FSC) 
and more granular (SSC) than non-transferred MZ B cells, and had a transcription 
program consistent with PC differentiation (Fig. 3.3C).  Pax5 is a B cell specific 
transcription factor that is downregulated upon PC differentiation, and XBP-1 and IRF-4 
are PC-specific transcription factors that are required for PC differentiation[17-22]. As 
shown in Fig. 3.3C, Pax5 expression was downregulated, while XBP-1 and IRF-4 levels 
were elevated compared to non-transferred MZ B cells.  At 12 days post transfer, donor 
B cells had further increased in size, but had decreased in granularity compared to non-
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transferred MZ B cells (Fig. 3.3C).  These cells remained low in PAX-5 expression and 
high in IRF-4 expression (Fig. 3.3C).  However, while about half of the donor cells 
increased XBP-1 expression, the other half decreased IRF-4 expression (Fig. 3.3C).  
Thus, with the exception of granularity and XBP-1 expression, donor-derived B cells on 
day 12 largely retained a PC-specific pattern of transcription factor expression, despite 
the fact that they are not ASCs.  Since donor cells were not present on day 30, we 
examined VAD-FMK staining to determine whether the donor B cells were undergoing 
apoptosis.  Supporting our hypothesis, a larger percentage of donor B cells were VAD-
FMK+ on day 12 than on day 4 suggesting that the lack of antibody secretion is due to 
ongoing apoptosis (data not shown).  We conclude that anti-Sm MZ B cells undergo an 
immediate burst of cell division and differentiate rapidly to pre-PCs and short-lived 
ASCs in Faslpr mice.  
Anti-Sm FO B cells exhibit a delayed ASC response when transferred to 
Faslpr mice.  Despite the presence of large numbers of donor B cells in recipient spleens 
(~56% of injected FO B cells) on day 4, no anti-Sm ASCs were detected (Table 3.2 and 
Fig. 3.4A).  However, we detected anti-Sm ASCs on day 12 in numbers ~4 times larger 
than those derived from transferred 2-12H MZ B cells on day 4 (Fig. 3.3A vs. Fig. 
3.4A).  In addition, we detected anti-Sm ASCs in the spleens on day 30, although their 
number had decreased by about half.  Donor FO B cells underwent extensive 
proliferation after transfer. At day 4, the proliferation of FO B cells resembled that for 
MZ B cells based on CFSE dilution, but in contrast to MZ B cells, which did not 
proliferate after day 4, FO B cells continued to proliferate extensively after day 4 and 
lost all CFSE.  The number of donor B cells detected in the spleen by flow cytometry 
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amounted to 1600% of that transferred (Table 3.2).  Thus, although FO B cells generated 
a larger number of anti-Sm ASCs on day 12 than MZ B cells on day 4, this represented a 
much smaller proportion of the total donor cell number (0.27% vs. 72%) (Table 3.2).  
We did not detect B cells of donor origin on day 30 post-transfer, despite the presence of 
ASCs (data not shown and Fig. 3.4A), and we did not detect anti-Sm ASCs in the bone 
marrow at any time point (data not shown).  Similar to the 2-12H MZ B cell transfers 
(Fig. 3.3B), a high frequency of  donor anti-Sm FO B cells acquired CD138 expression 
by day 4 (~77%), but only ~7% of donor B cells expressed CD138 on day 12 (Fig. 
3.4B).  This suggests that the majority of B cells generated after day 12 are likely to be 
memory B cells.   
Consistent with the initial appearance of ASCs on day 12, the donor B cells on 
day 4 were similar to non-transferred 2-12H FO B cells in size, granularity and 
transcription factor expression (Fig. 3.4C).  However, by day 12, the transferred cells 
had increased in size, decreased Pax5 expression, and increased XBP-1 and IRF-4 
expression.  Interestingly, although the majority of donor B cells have decreased Pax5 
and increased IRF-4, a small subset has even lower Pax5 and higher IRF-4 (Fig. 3.4C).  
This corresponds roughly in size to the size of the CD138int population.  Thus, the 
majority of donor B cells on day 12 had acquired a more PC-like phenotype even though 
the majority did not express CD138 and were not ASCs.  We conclude that anti-Sm FO 
B cells contribute to the anti-Sm response in Faslpr mice, but that they contribute to a 
delayed and long-term response compared to anti-Sm MZ B cells.  In addition, these 
cells give rise to a large memory-like B cell population.  This parallels the responses by 
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FO and MZ B cells to foreign antigens indicating that anti-Sm FO and MZ B cells 
follow their normal activation programs in response to self-antigens[23].  
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  E.  DISCUSSION 
 
 We directly demonstrate the activation of B cells of the three mature B cell 
subsets in the spleens of Faslpr mice; FO, MZ, and pre-PC.  This activation involves 
overcoming at least two tolerance checkpoints, B cell anergy (FO) and the early pre-PC 
checkpoint (MZ and pre-PC).  The B cells of these subsets differ in their activation 
programs and therefore make different contributions to autoimmunity, correlating with 
their functions in response to archetypal foreign antigens[23].  These data have 
implications for the development of therapeutic approaches to block activation of 
autoreactive B cells.   
 Our analysis of 2-12H anti-Sm B cells has indicated that the pre-PC stage is a 
tolerance checkpoint for anti-Sm B cells[9].  Tolerance may be due to an intrinsic 
mechanism such as anergy or an ongoing cell death program, or the B cells may be 
regulated by an extrinsic mechanism, such as by cytokine-induced repression[11, 12] or 
the absence of an essential activating signal.  The short half-life and high frequency of 
apoptosis of 2-12H pre-PCs compared to non-Tg pre-PCs supports an ongoing death 
mechanism[9].  To address these issues, we stimulated sorted pre-PCs with two TLR 
agonists, LPS and CpG and with anti-CD40 and IL-4 to mimic T cell help.  We find that 
non-Tg and 2-12H pre-PCs are activated by all stimuli essentially equally well.  This 
differs from the responsiveness of anergic 2-12H/Vκ8 FO B cells or of anergic B cells of 
multiple other autoantigen specificities[24-27].  Thus, we conclude that anti-Sm pre-PCs 
are not anergic, and therefore likely regulated by extrinsic mechanisms.  The ability of 
anti-Sm pre-PCs to become ASCs after transfer to Faslpr mice substantiates this.  The 
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mechanism of regulation could be the lack of a positive signal or the presence of a 
negative signal.  Repression by IL-6, TNFα, or CD40L secreted by DCs or macrophages 
is unlikely to be involved in pre-PC repression in the steady state[11, 12].  Although pre-
PCs are susceptible to repression by IL-6 (M.A. Kilmon and B.J. Vilen, personal 
communication), this only acts to repress activation induced by LPS or another TLR 
agonist.  In the absence of infection, pre-PCs are presumably not exposed to any of these 
cytokines.  Whatever the mechanism of activation arrest, we conclude that anti-Sm pre-
PCs are functional and poised to become ASCs. 
Interestingly, these cells are more responsive to CpG than to either LPS or anti-
CD40/IL-4, suggesting that they would be sensitive to activation by antigens that include 
CpG motifs.  Marshak-Rothstein and colleagues have demonstrated that rheumatoid 
factor B cells and anti-DNA B cells are activated by antigen that simultaneously provide 
a BCR and TLR9 (CpG) signal[28-31].  Thus, pre-PCs may be very susceptible to 
activation by self-antigens that include a CpG motif for TLR9 stimulation, and may be 
the dominate cell type activated in vivo by this mechanism.   
 The precursor cells of pre-PCs can be either FO or MZ B cells, as adoptive 
transfers indicate that essentially all transferred FO and MZ B cells become CD138int.  In 
the case of MZ B cells, they also decrease CD21 expression and increase CD23 
expression, characteristic of pre-PCs.  However, we believe that only MZ B cells 
contribute to the pre-PC population in unmanipulated mice.  First, pre-PCs are not 
present in mice that do not have a MZ B cell population, even though they have FO B 
cell populations.  For example, pre-PCs are not present in either 2-12H/Vκ8 mice, which 
generate anergic anti-Sm FO B cells, or in young anti-HEL MD4 mice (<4 mos), which 
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only have anti-HEL FO B cells (unpublished observations).  Older MD4 mice (>4 mos) 
acquire a MZ B cell population, and also acquire a pre-PC population.  Secondly, we 
show here, that anti-Sm pre-PCS exclusively generate a short-lived, immediate ASC 
response when transferred to Faslpr mice.  Even though anti-Sm FO B cells become pre-
PCs after transfer to Faslpr mice, they exclusively generate a delayed ASC response after 
transfer to Faslpr mice.  These data argue that anti-Sm FO B cells contribute little to the 
pre-PC population in 2-12H mice.  Thirdly, in Chapter 4, we demonstrate that DCs 
induce MZ B cell activation to become pre-PCs both in vivo and in vitro, but that they do 
not have this ability with FO B cells.  Thus, we consider it likely that, although anti-Sm 
B cells of both subsets can become pre-PCs, in the steady state MZ B cells are the 
primary source of pre-PCs in 2-12H mice.  
 In addition to the activation of pre-PCs in Faslpr mice, MZ and FO B cells are 
activated.  Consistent with their precursor-product relationship, the activation of MZ B 
cells closely follows that of pre-PCs.  This similarity between pre-PCs and MZ B cells is 
consistent with our evidence that anti-Sm MZ B cells are precursors to anti-Sm pre-PCs.  
Interestingly, although they are not ASCs, the pre-PCs derived from transferred MZ B 
cells are present on day 12.  This suggests that pre-PCs can cease antibody secretion, 
consistent with changes in IRF-4 expression.  The high frequency of apoptosis among 
these cells suggests that they may also be undergoing deletion.  Thus, the MZ B cell 
response parallels classic T-independent MZ B cell responses to foreign antigen[23].   
In contrast to MZ B cells and pre-PCs, FO B cells generate a delayed, but long-
lived ASC response.  Anti-Sm ASCs are detected on day 12 and are still detected on day 
30.  Surprisingly, the response was exclusive to the spleen, as no ASCs were detected at 
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any time in the bone marrow, the normal site of long-lived ASCs[2, 32, 33].  
Accompanying ASC differentiation of FO B cells is extensive proliferation and the 
generation of a CD138neg B cell population.  These cells may be memory B cells of 
germinal center origin.  However, their transcription factor profile is more characteristic 
of PCs than memory B cells, particularly the low Pax5 expression[20, 21, 34, 35], and 
they are not present in the spleen on day 30, as would be expected of long-lived memory 
B cells.  In future experiments it will be important to determine what these cells are.   
Thus, anti-Sm FO B cells generate a long-lived response, typical of T-dependent 
responses by FO B cells specific for foreign antigens[23]. However, this differs from 
foreign antigen responses in at least two regards; absence of bone marrow involvement 
and disappearance of the putative memory B cell population.  
 These data suggest that two anti-Sm responses occur simultaneously in 
autoimmune mice.  The first is from MZ B cells that differentiate to pre-PCs and then 
short-lived ASCs.  By continual replacement of MZ B cells and exposure to self-antigen, 
this response could provide a persistent supply of short-lived, anti-Sm ASCs.  However, 
as these ASCs would not be GC products and are unlikely to have undergone affinity 
maturation, they would produce only low-affinity, anti-Sm IgM antibodies that are likely 
to be non-pathogenic.  The second response is from anti-Sm FO B cells that differentiate 
into long-lived, anti-Sm ASCs.  They may form germinal centers and thus, the ASCs 
would be somatically mutated and more likely to produce high affinity, pathogenic IgG 
antibodies.  Interestingly, analysis of anti-Sm hybridomas from MRL/Faslpr mice 
supports our two response theory as we have identified both heavily somatically mutated 
IgG hybridomas, as well as clonal populations of IgM hybridomas that are unmutated.  
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Unmated and clonally-related IgM hybridomas are rare among hybridomas specific for 
foreign antigens.  Since the ASCs of FO B cell origin are likely to have the greatest 
impact on disease, a better understanding of this response and its differences from 
responses to foreign antigens will be important to design therapeutic approaches to 
interfere with FO B cell activation.   
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Figure 3.1. Anti-Sm pre-PCs are functional and regulated by extrinsic mechanisms.  
A.  Sort scheme and post-sort purities depicting the CD138neg and CD138 int populations 
isolated for experiments shown in B and C.  Cells are gated on lymphocytes and sorted 
by a MoFlo cell sorter. Percentages on representative post-sort purity histograms show 
cell frequencies falling into their respective gates, with sort purities >93%.  B.  IgM and 
anti-Sm ASCs formed from sorted Non-Tg and 2-12H CD138neg and CD138 int 
populations were detected 72 hours after plating.  Cells were cultured with media alone 
(top panel), 10µg/mL anti-CD40 and 10ng/mL IL-4 (top middle panel), 30µg/mL LPS 
(bottom middle panel), and 1µg/mL CpG (bottom panel).  Each circle represents cells 
sorted from one mouse, and significant differences are indicated on each graph.  C.  
Donor-origin anti-Sm ASCs were detected by ELISpot assay 3 or 12 days post-transfer 
to Faswt or Faslpr recipients, as indicated.  The asterisk (*) represents significance 
(p<0.001) as compared to background spots (n=at least 3 per recipient group). 
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FIGURE 3.1 
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FIGURE 3.1, Continued 
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FIGURE 3.1, Continued 
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TABLE 3.1 
 
 
 
 
Table 3.1.  Donor cell detection and ASC secretion in the spleen after 2-12H early 
pre-PC transfers.  Transferred cells were assessed in recipient mice at the designated 
time points by flow cytometry (% detected in spleen) and ELISpots (% of detected cells 
that are ASCs).  Donor cells were identified through IgMa antibodies for both flow 
cytometry and ELISpot assays, as recipient B cells were all IgMb.  Numbers shown are 
percentages ± standard error and n=at least 3 per recipient group. 
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Figure 3.2.  Anti-Sm follicular (FO) and marginal zone (MZ) B cells can both 
acquire an early pre-PC phenotype.  A.  Sort scheme and post-sort purities depicting 
the FO (B220+, CD21low, CD23+) and MZ (B220+, CD21hi, CD23-/lo) populations 
isolated for adoptive transfer experiments in Figures 3.2-3.4.   Cells are gated on 
lymphocytes and the above parameters and excluded CD138-expressing cells, and were 
sorted by a MoFlo cell sorter. Percentages on representative post-sort purity histograms 
show cell frequencies falling into their respective gates, with sort purities >94%.  B.  
Representative histogram of a Faswt mouse that did not receive any IgMa cells, showing 
background levels of IgMa staining.  Cells are gated on lymphocytes only.  C and D.  
Cell surface staining of Faswt recipient splenocytes that received 2-12H FO (C) or 2-12H 
MZ (D) B cells 4 days prior.  Percentages shown are of total B cells (despite showing the 
B cell negative population for comparison) and representative histograms are displayed. 
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FIGURE 3.2 
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Figure 3.3.  Anti-Sm MZ are activated in autoimmune mice to induce a rapid, 
short-lived ASC response.  A.  Donor-origin anti-Sm ASCs were detected by ELISpot 
assay 4 or 12 days post-transfer to Faswt or Faslpr recipients, as indicated.  Day 30 data 
was not displayed, as no ASCs were detected.  The asterisk (*) represents significance 
(p<0.001) as compared to background spots (n=at least 3 per recipient group).  Error 
bars indicate standard error.  B.  Cell surface staining of Faslpr control splenocytes (top 
row, left column) and Faslpr 2-12H MZ transfer recipients on days 4 (middle) and 12 
(bottom) post-transfer.  As described before, all transferred MZ B cells were CD138neg 
(top row, middle column) and were now CFSE-labeled prior to transfer (top row, right 
column). While all histograms are gated on lymphocytes, the histograms in the middle 
and right columns (for day 4 and 12 stains) are further gated on the donor-origin (IgMa+ ) 
cells only, as depicted in the left columns.  Percentages displayed indicate percentage of 
B cells (left column) and percentage of donor-origin cells (middle column).  C.  FSC, 
SSC, and transcription factor expression by non-transferred 2-12H MZ B cells (shaded) 
and 2-12H MZ B cells transferred to Faslpr mice(black line). Representative histograms 
are shown (n=3). 
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FIGURE 3.3 
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FIGURE 3.3, Continued 
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Figure 3.4.  FO B cells are activated in autoimmune mice to induce a delayed, long-
lived ASC response.  A.  Donor-origin anti-Sm ASCs were detected by ELISpot assay 
4, 12, or 30 days post-transfer to Faswt or Faslpr recipients, as indicated.  The asterisk (*) 
represents significance (p<0.001) as compared to background spots (n=at least 3 per 
recipient group).  Error bars indicate standard error.  B.  Cell surface staining of Faslpr 
control splenocytes (top row, left column) and Faslpr 2-12H FO transfer recipients on 
days 4 (middle) and 12 (bottom) post-transfer.  As described before, all transferred FO B 
cells were CD138neg (top row, middle column) and were now CFSE-labeled prior to 
transfer (top row, right column). While all histograms are gated on lymphocytes, the 
histograms in the middle and right columns (for day 4 and 12 stains) are further gated on 
the donor-origin (IgMa+ ) cells only, as depicted in the left columns.  Percentages 
displayed indicate percentage of B cells (left column) and percentage of donor-origin 
cells (middle column).  C.  FSC, SSC, and transcription factor expression by non-
transferred 2-12H FO B cells (shaded) and 2-12H FO B cells transferred to Faslpr 
mice(black line). Representative histograms are shown.  
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FIGURE 3.4 
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FIGURE 3.4, Continued 
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TABLE 3.2 
 
 
 
 
 
 
Table 3.2.  Donor cell detection and ASC secretion in the spleen after 2-12H MZ 
and FO transfers.  Transferred cells were assessed in recipient mice at the designated 
time points by flow cytometry (% detected in spleen) and ELISpots (% of detected cells 
that are ASCs).  Donor cells were identified through IgMa antibodies for both flow 
cytometry and ELISpot assays, as recipient B cells were all IgMb.  Numbers shown are 
percentages ± standard error and n=at least 3 per recipient group. 
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CHAPTER 4:  DENDRITIC CELL ACTIVATION OF  
ANTI-Sm MARGINAL ZONE B CELLS
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A.  ABSTRACT 
 
Anti-Smith (Sm) B cells are positively selected into the marginal zone (MZ) B 
cell subset, but whereas their differentiation to plasma cells (PCs) is blocked in non-
autoimmune mice, they bypass this block in autoimmune mice.  Dendritic cells (DCs) 
can activate MZ B cells specific for a foreign antigen, and, since they efficiently 
phagocytize apoptotic cells, are a potential source of Sm antigen. We therefore tested 
whether DCs can activate of anti-Sm MZ B cells.  Using anti-Sm Tg mice (2-12H), we 
demonstrate that immature bone marrow-derived (BMDCs) and ex vivo DCs that have 
phagocytized apoptotic cells induce anti-Sm MZ B cell differentiation to PCs in vivo and 
in vitro.  DCs activate MZ B cells to become non-secreting pre-PCs, but require T cells 
to induce pre-PC to PC differentiation.  B cell activation is antigen-specific, cell contact-
dependent, and dependent on IL-1β, CD40L, and BAFF production.  Interestingly, TNF-
α treatment of BMDCs abrogates the response.  T cell help is non-specific, as 2-12H, 
non-Tg, and OVA TCR Tg T cells are equally effective.  BMDCs from autoimmune 
Fas-deficient mice (Faslpr) are able to activate anti-Sm MZ B cells independent of 
apoptotic cell phagocytosis and regardless of TNF-α treatment.  Restriction to the 
immature DC stage prevents concomitant T cell activation and limiting the B cell 
response to being short-lived in non-autoimmune mice.  In contrast, the lack of 
restriction of autoimmune Faslpr DCs may result in concomitant cognate T cell 
activation, potentially resulting in a long-lived T cell-dependent response.  These data 
suggest a possible mechanism for long-lived anti-self responses in SLE.  
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B.  INTRODUCTION 
 
 Dendritic cells (DCs) are professional antigen presenting cells that provide a 
crucial link between innate and acquired immunity, as they are able to both initiate and 
dictate immune responses[1].  DCs perform a variety of functions at different stages of 
an immune response, and their abilities are largely dependent upon their activation 
status.  Immature DCs have not upregulated co-stimulatory molecules, and thus, are 
unable to induce T cell activation, yet, importantly, immature DCs are very efficient at 
phagocytosis[2-5].  On the other hand, mature DCs are defined by co-stimulatory 
molecule upregulation and pro-inflammatory cytokine secretion, and therefore are able 
to activate T cells and initiate an adaptive immune response[4-9].  Further complexity in 
the interplay between DCs and acquired immune responses comes from the fact that 
there are many different DC subsets that are also phenotypically and functionally 
distinct. 
 While DC-mediated T cell activation has garnered much focus over the years, 
recent studies have revealed direct DC interactions with B cells.  DCs have been shown 
to play a role in Ig class-switch, B cell activation, and B cell antibody production[10, 
11].  Germain and colleagues demonstrated through 2-photon intravital imaging that 
antigen-bearing DCs that come in direct contact with B cells results in B cell Ca2+ 
signaling, antigen acquisition, and extrafollicular accumulation[12].  Kearney and 
colleagues demonstrated DC involvement in response to a TI-2 antigen by showing that 
blood DCs transport bacteria to the MZ where they activate marginal zone (MZ) B 
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cells[13].  They also showed that this activation is dependent on BAFF[13].  Moreover, 
Vilen and colleagues showed a DC-mediated repression of anergic, autoreactive B cells 
that requires direct cell contact and secretion of the cytokines IL-6 and TNFα[14, 15].  
Thus, a picture is emerging of DCs having a direct role in B cell activations. 
 In addition, DCs also have a role in the development of autoimmunity both in 
mice and human diseases, including systemic lupus erythematosus (SLE).  Vilen and 
colleagues have recently demonstrated that DCs from lupus-prone MRL/Faslpr mice are 
defective in IL-6 mediated repression of autoreactive B cells, suggesting that the loss of 
this tolerance mechanism may contribute to disease in these mice[16].  Additionally, 
CD4+ T cells in lupus-prone MRL/Faslpr were shown to be activated by B cells and DCs 
in a fixed-light chain transgenic mouse model[17].  One of the critical factors secreted 
by DCs for B cell activation and survival is B cell activating factor (BAFF).  BAFF 
over-production is associated with autoimmunity in mice, as transgenic mice with excess 
BAFF, or mice that receive recombinant BAFF, have increased mature B cell numbers 
and develop autoantibodies[18-22].  BAFF over-expression is also a characteristic of 
human SLE[23, 24]. Thus, DCs are able to directly activate B cells and this cellular 
relationship may be dysregulated in autoimmune diseases. 
 The ability of immature DCs to phagocytize apoptotic cells (ACs) suggests they 
may be a source of antigen for the regulation and activation of autoreactive B cells in 
SLE.  Several SLE-associated antigens, including DNA, histones, La, Ro, and Sm have 
been shown to localize on the outer surface of ACs[25, 26].  We and others have 
demonstrated a transient anti-DNA and anti-Sm response after AC immunization of non-
autoimmune mice, indicating that ACs can activate some autoreactive B cells[26].  
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Therefore efficient AC ingestion by phagocytes may be crucial to the maintenance of 
tolerance.  Indeed, defects in AC clearance can result in the development of 
autoimmunity[27].   
 To investigate autoreactive B cell regulation, we developed 2-12H transgenic 
mice expressing an anti-Sm heavy chain transgene[28].  Sm is a component of a 
ribonucleoprotein complex involved in RNA splicing and the development of 
pathogenic, anti-Sm autoantibodies is unique to SLE.  2-12H B cells are both positively 
and negatively selected, yet they are not activated to spontaneously secrete autoantibody 
in these non-autoimmune mice[28].  Three distinct, mature anti-Sm B cell subsets exist 
in the murine 2-12H spleen: follicular (FO), marginal zone (MZ), and pre-plasma cell 
(PC) B cells[28].  Anti-Sm FO B cells are anergic, while anti-Sm MZ B cells are 
positively selected and functionally responsive to TLR and AC stimulation[27, 28].  The 
anti-Sm pre-PCs are also positively selected and activated, yet they fail to terminally 
differentiate into PCs, suggesting the presence of a tolerance checkpoint at this stage 
[29].  The presence of functional anti-Sm MZ B cells and the demonstrated ability of 
DCs to both phagocytose ACs and induce MZ B cell activation raises the possibility that 
DCs could be involved in the activation of anti-Sm MZ B cells.  Indeed we have shown 
that MZ B cells are progressively lost early in the development of SLE, coincident with 
the appearance of serum anti-Sm and anti-Sm ASCs in the spleen[27].  
 We show here that immature apoptotic cell-pulsed DCs activate anti-Sm B cells 
in an antigen-specific, T cell-dependent manner.  Anti-Sm MZ B cells are primarily 
responsible for this loss of tolerance, as they are depleted upon in vivo AC-pulsed DC 
immunization and become antibody secreting cells (ASCs) upon in vitro co-culture.  We 
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show that this mechanism requires IL-1β, BAFF, and CD40L, and that DC maturation 
abrogates it.  Interestingly, DCs derived from autoimmune-prone mice deficient in Fas 
(Faslpr) activate anti-Sm MZ B cells regardless of AC-pulsing and maturation status, 
revealing a mechanism by which tolerance may be lost in autoimmunity.  The restricted 
ability of immature, non-autoimmune DCs to activate anti-Sm MZ B cells after AC 
phagocytosis is likely to prevent concomitant T cell activation and to induce only a 
short-lived B cell response.  In contrast, the loss of these restrictions by Faslpr DCs is 
likely to allow concomitant T cell activation, resulting in long-lived, T cell-dependent 
responses.  These data not only demonstrate a new role for immature DCs that have 
ingested ACs but also provide a possible mechanism for long-lived, anti-self responses 
in SLE.   
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C.  MATERIALS AND METHODS 
 
Mice  
C57BL/6 and Faslpr mice were used to harvest bone marrow (BM) from which dendritic 
cells (DCs) were derived.  2-12H Tg mice have been previously described, yet the 2-12H 
Tg mice have now been backcrossed 8 times to the C57BL/6 background[28].  The 2-
12H transgene was identified by PCR of tail genomic DNA as previously described[28].  
Tg(IghelMD4)4Ccg (MD4 mice), Tg(TcraTcrb)426Cbn (OT-II mice), and Tnfsf13b 
(BAFFko mice) mice used are previously described.  Animals were housed and bred in a 
conventional facility at the University of North Carolina at Chapel Hill (Chapel Hill, 
NC) and all animal experiments were carried out with institutional IACUC approval.   
 
Apoptotic cells (ACs)  
Apoptotic cells were prepared as described by Mevorach et al. with slight modification. 
Briefly, thymocytes were prepared from young mice (4–6 wks) and irradiated at 600 
rads[30]. The irradiated thymocytes were then cultured overnight, washed, and either (a) 
added to DC cultures at a ratio of 10 ACs: 1 DC or (b) injected into 2-12H mice (1-10 x 
107). 
 
Bone marrow-derived dendritic cell (BMDC) cultures 
Bone marrow was harvested from femurs and tibias of C57BL/6, Faslpr, or BAFFko 
mice, depending on the experiment.  Single-cell suspensions were RBC lysed and 
cultured in 6-well ultra low attachment plates (Corning, Lowell, MA) in the presence of 
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10ng/mL GM-CSF (Peprotech, Rocky Hill, NJ) and 10ng/mL IL-4 (Peprotech) for 5 
days.  The immature BMDCs at day 5 (CD11c+ , CD86lo , I-Alo ) were incubated with 
10X more ACs for 24 hours for designated treatments only. Non-ingested apoptotic cells 
were removed prior to injections or cultures via Lympholyte M density cell separation 
medium per manufacturer’s protocol (Cedarlane, Canada).  Additionally, for TNF-α 
treated groups, 10ng/mL TNF-α (Peprotech) was added for 24 hours after AC pulsing. 
 
 In vivo CD4 and CD8 T cell depletion  
Animals were depleted simultaneously of CD4+ and CD8+ cells by i.p. injection of 500 
µg of anti-CD4 (GK1.5 hybridoma) and 500 µg of anti-CD8 (2.43 hybridoma).  
Antibodies were injected on days -4 and -1 before dendritic cell transfers (Day 0) into 2-
12H Tg mice. Control mice received PBS as a control. The depletion efficiency was 
validated by flow cytometry analysis of splenocytes using anti-CD4-FITC (Pharmingen, 
San Diego, CA) and anti-CD8-PE (Pharmingen).  97% of the relevant cell subsets were 
depleted. 
 
BMDC transfers to recipient mice 
After BMDCs were ready for use and had undergone necessary treatments as described 
above, cells were washed 3X with PBS before intravenous injection of 1x106 
BMDCs/mouse.  Spleens and BM (data not shown) were harvested for ELISpot and flow 
cytometry analysis after 6 days. 
 
Phagocytosis assay 
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BMDCs derived from either C57BL/6 or Faslpr mice, as outlined above, were assessed 
for apoptotic cell ingestion as  previously described[27, 31]. 
 
B cell and CD4+ T cell purifications 
Splenic CD19+  B cells and CD4+  T cells were individually isolated from 2-12H spleen, 
unless otherwise noted (Fig. 4C), by negative selection per the manufacturer’s protocol 
to a purity >97% (Stem Cell Technologies, Canada).  Cells were washed 3X prior to use 
in the co-culture systems.  
 
Anti-Sm ELISpot assay 
Anti-Sm ELISpots were performed as previously described using plates (Millipore, 
Billerica, MA) which we coated with 10 U/well Sm Ag (Immunovision, Springdale, 
AR)[27, 29].  Cells were resuspended in HL-1 medium (Cambrex) supplemented with 
1% L-glutamine and 1% penicillin/streptomycin prior to plating.  For analysis of 
splenocytes 6 days after BMDC injections, 5x105 cells were plated per well and serially 
diluted across the plate before incubating for 24 hours.  For the in vitro co-culture 
system, approximately 4.5x 104  purified B cells, 4.5x103 purified CD4+ T cells, and 
4.5x103 DCs were plated per well after optimizing the response as detailed in Figure 4A.  
T cells were purified from 2-12H splenocytes, unless otherwise noted (Fig. 4C).  Co-
culture experiments were incubated for 72 hours before detection of secretion.  One 
exception is in the sorted B cell populations in vitro co-culture experiment where 1x104 
B cells were plated per well due to smaller B cell yields, with the identical 10 fold-less 
number of T cells and DCs, and incubated for 72 hours.   Secreted anti-Sm was detected 
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by using biotin-labeled anti-IgMa Ab and streptavidin-HRP (Pharmingen), followed with 
the developing substrate 3-amino-9-ethylcarbazole (Sigma-Aldrich, St. Louis, MO). The 
plates were scanned and analyzed using the Immunospot ELISpot analyzer (Cellular 
Technology Ltd., Cleveland, OH ).  
BAFF ELISpot 
The BAFF ELISpot was adapted from the ELISA protocol developed by Apotech 
(Switzerland). 1x105 BMDCs were plated on ELISpot plates coated with monoclonal 
BAFF (5A8, Apotech) to assess spontaneous BAFF secretion, while the same cell 
numbers as outlined above were used to measure BAFF secretion in the co-culture 
environment.  Secreted BAFF  was detected by using biotinylated monoclonal BAFF 
antibody (1C9, Apotech) and streptavidin-HRP (Pharmingen), followed with the 
developing substrate 3-amino-9-ethylcarbazole (Sigma-Aldrich). The plates were 
scanned and analyzed using the Immunospot ELISpot analyzer (Cellular Technology 
Ltd.).  
 
Flow Cytometry 
Cells were stained as previously described and analyzed at the University of North 
Carolina at Chapel Hill Flow Cytometry Facility (Chapel Hill, NC) using a 
FACSCalibur (BD Biosciences) or CyAn (DakoCytomation, Denmark).  The antibodies 
specific for CD80 (16-10A1), CD86 (GL-1), I-Ab (25-9-17), CD40 (3/23), CD19 (1D3), 
B220 (RA3-6B2), CD21(7G6), CD23 (B3B4), CD138 (281-2), CD11c (HL3), CD11b 
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(M1/70), and Gr.1(Gr-1) were conjugated to FITC, PE, biotin, APC, or APC-Cy7 
(Pharmingen). For the detection of anti-Sm B cells, we biotinylated Sm (SMA-3000; 
Immunovision) as previously described.  Biotinylated reagents were revealed with 
streptavidin conjugated to either PerCP or APC (Pharmingen).  Data were analyzed 
using Summit software (DakoCytomation). All data represent cells that fall within the 
lymphocyte gate determined by forward and 90° light scatter. 1-5 × 105 cells per sample 
were analyzed. 
 
Cell sorting 
For B cells, 2-12H Tg splenocytes were stained for B220, CD21, CD23, and CD138 as 
described above for cell sorting of each subset for ELISpot co-culture experiments.  MZ 
B cells are B220+, CD21hi, CD23-/lo CD138- cells, FO B cells are B220+, CD21low, 
CD23+, CD138- cells, and early pre-PCs are B220+, CD138+ cells.  For ex vivo DCs, 
C57BL/6 or Faslpr splenocytes were stained for CD11c, CD11b, Gr.1, and B220 for cell 
sorting of each subset for ELISpot co-culture experiments.  Myeloid (My)  DCs are 
CD11c+ , CD11b+ ,  lymphoid (Ly) DCs are CD11c+ , CD11b- , Gr.1- , B220- , and 
plasmacytoid DCs (PDC) are CD11c+ , CD11b- , Gr.1+ , B220+.   The cells were sorted 
using a MoFlo high speed sorter (DakoCytomation).  Sorted populations were >90% 
pure as determined by reanalysis.  
 
In vitro co-culture reagents 
The following is a list of neutralizing antibody concentrations and add-back reagent 
concentrations for co-culture ELISpot experiments:  10 µg/mL anti-CD40L 
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(Pharmingen),  2.5 µg/mL  anti-IL-1β (R&D Systems, Minneapolis, MN), 10 µg/mL  
TACI-Ig (R&D Systems), 200 ng/mL huBAFF(Peprotech), and 10pg/mL-100ng/mL 
mIL-1β (R&D). 
 
Statistical analysis   
The independent and paired Student’s t tests were used to evaluate significance. A value 
of p<0.05 was considered significant. 
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D.  RESULTS 
 
Apoptotic cell (AC)-pulsed BMDCs induce anti-Sm antibody secreting cell (ASC) 
formation in vivo.  We previously demonstrated that AC immunization of 2-12H Tg 
mice induces a transient anti-Sm autoantibody response[30].  The mechanism by which 
this occurs, however, had not been investigated.  The decline in the number of MZ B 
cells in response to AC immunization suggested that MZ B cells were activated by 
apoptotic cells (unpublished observation).  Since MZ B cells can be activated by DCs 
bearing antigen, we investigated whether DCs are involved in the activation of AC-
specific B cells.  BMDCs were grown in GM-CSF and IL-4 for 5 days, cultured for an 
additional 24 hrs with or without apoptotic thymocytes, and iv injected into 2-12H mice.  
As shown in Fig. 1A, AC-pulsed BMDCs induced a significant increase in the number 
of splenic anti-Sm ASCs by day 6.  In  contrast, non-pulsed BMDCs did not induce anti-
Sm ASCs.  ACs were separated from the BMDCs before iv injection by passage over a 
lympholyte column, but to control for the possibility that B cell activation was the result 
of non-phagocytized ACs, we gave mice a dose of ACs equivalent to either 1x or 10x the 
amount used to pulse a dose of BMDCs.  As shown in Fig 1A, ACs induced significantly 
fewer anti-Sm ASCs than AC-pulsed DCs.  Thus, uptake by BMDCs enhances the 
ability of ACs to activate anti-Sm B cells.  Flow cytometry indicated that both AC-
pulsed and unpulsed BMDCs expressed low levels of CD80, CD86, and MHCII, 
consistent with an immature phenotype (Fig. 1B).  AC-pulsed BMDCs treated for 24 hrs 
with TNF-α before injection induced DC maturation (Fig. 1B) but ablated anti-Sm ASC 
differentiation (Fig. 1A).  BMDC-induced B cell activation appeared to be antigen-
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specific, since AC-pulsed BMDCs did not induce anti-HEL ASCs when injected into 
anti-HEL MD4 mice, although BMDCs induced a robust anti-HEL ASC response when 
pulsed with HEL (Fig. 1C).  Thus, we conclude that immature, but not mature, AC-
pulsed BMDCs induce anti-Sm B cell activation in non-autoimmune mice by an antigen-
specific mechanism.   
Since AC phagocytosis induces tolerogenic DCs [3, 5], and since 2-12H mice 
lack functional anti-Sm T cells[32], we expected that anti-Sm ASC formation was T cell 
independent.  To confirm this, 2-12H recipient mice were depleted of both CD4 and 
CD8 T cells by anti-CD4 and anti-CD8 treatment prior to BMDC transfer.  Recipient 
mice had fewer than 1% T cells in their spleens after treatment (data not shown).  
However, contrary to expectation, T cell depletion ablated the anti-Sm response induced 
by AC-pulsed BMDCs (Fig. 1D).  Thus, the anti-Sm ASC response induced by 
immature AC-pulsed BMDCs is T cell dependent.   
 
AC-pulsed BMDCs affect B cell activation at two stages.  To identify the B cells 
activated by AC-pulsed BMDCs, we examined the splenic B cell compartments in 2-
12H Tg mice 6 days-post transfer for changes in subset size and B cell phenotype.  We 
observed no changes in the total number of splenic anti-Sm FO B cells (2.9 x 107 ± 1 x 
106) in response to BMDC treatment (Fig. 2A).  However, there was an ~50% decrease 
in both frequency (p<0.01) and number (p<0.001) of anti-Sm MZ B cells in response to 
the AC-pulsed BMDCs, but not in response to unpulsed BMDCs or TNF-α activated 
BMDCs (Fig. 2B).  In addition, we observed a significant increase in the frequency 
(p<0.001) and number (p<0.001) of anti-Sm early pre-PCs in response to AC-pulsed 
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BMDCs, but not in response to unpulsed BMDCs or TNF-α treated BMDCs (Fig. 2C).  
Differentiation beyond the tolerance checkpoint at the early pre-PC stage was evident by 
the increase in cytoplasmic IgM in pre-PCs in mice that received AC-pulsed BMDCs, 
but not any of the other treatments (Fig. 2E).  Anti-Sm MZ B cells rapidly differentiate 
into early pre-PCs upon transfer to Faslpr mice (Chapter 3), which supports our current 
findings linking these two splenic subsets.  Thus, AC-pulsed BMDCs induce 
differentiation of anti-Sm MZ B cells to pre-PCs.  They also act at a second stage in 
overcoming the tolerance checkpoint at the pre-PC to ASC transition, since anti-Sm pre-
PCs from non-autoimmune mice are not ASCs [29].   
To determine where in the activation pathway T cells are required, we analyzed 
the changes in B cell subsets in T cell depleted 2-12H mice after transfer of AC-pulsed 
BMDCs.  As shown in Fig. 2D, the loss of MZ B cells and the increase in pre-PC 
numbers occurred in the absence of T cells.  However, unlike T cell-sufficient mice 
treated with AC-pulsed BMDCs, the anti-Sm pre-PCs in T cell-deficient mice treated 
with AC-pulsed BMDCs exhibited no increase in cytoplasmic IgM (Fig. 2E).  Thus, 
BMDCs induce the activation of anti-Sm MZ B cells to become pre-PCs, but T cells are 
required for bypass of the early pre-PC tolerance checkpoint.   
 
Fas-deficient BMDC activation of anti-Sm B cells is not limited by ingestion of ACs 
or to the immature stage.  Since tolerance to Sm is lost in 2-12H/Faslpr mice[27], we 
determined whether Faswt and Faslpr BMDCs differed in their ability to activate anti-Sm 
B cells.  As shown in Fig. 3A, unlike with Faswt BMDCs, the ability of Faslpr BMDCs to 
activate anti-Sm B cells was not limited by AC-pulsing or to the immature DC stage. 
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Unpulsed Faslpr BMDCs and TNF-α treated Faslpr BMDCs induced anti-Sm ASC 
formation, although the greatest response was by AC-pulsed Faslpr BMDCs.  This 
difference between Faswt and Faslpr BMDCs was not due to a difference in maturation 
stage, as analysis of co-stimulatory molecule expression confirms that, like Faswt 
BMDCs, AC-pulsed Faslpr BMDCs had an immature phenotype, and that treatment with 
TNF-α induced a mature phenotype (Fig. 3B).  Neither were Faswt and Faslpr BMDCs 
different in their ability to phagocytize ACs, as shown using an in vitro phagocytosis 
assay (Fig. 3C).   
 
In vitro activation of anti-Sm B cells by BMDCs recapitulates in vivo activation.  To 
further investigate the mechanism of anti-Sm B cell activation by AC-pulsed BMDCs, 
we developed an in vitro B cell activation assay.  AC-pulsed Faswt BMDCs induced a 
modest increase in anti-Sm ASC in vitro, which could be titrated to background levels 
with increasing B:DC ratios (Fig. 4A).  However, there was no difference between AC-
pulsed and unpulsed BMDCs in their ability to induce anti-Sm ASCs.  In contrast, there 
was a dramatic induction of anti-Sm ASCs in the presence of 2-12H T cells.  This 
increase was dependent on AC-pulsing and was abrogated by TNF-α treatment of the 
BMDCs (Fig. 4A).   
 Faslpr BMDCs induce anti-Sm ASCs in vitro, and, as seen in vivo (Fig. 3A), their 
ability to activate anti-Sm B cells is independent of AC pulsing and occurs after TNF-α 
treatment (Fig. 4B).  Thus, the in vitro activation of anti-Sm B cells by Faswt and Faslpr 
BMDCs recapitulates their ability to activate anti-Sm B cells in vivo.   
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 To further delineate the role of T cells in anti-Sm B cell activation, we performed 
the in vitro activation of anti-Sm B cells using T cells from different sources.  Non-Tg T 
cells and 2-12H T cells were equally able to activate anti-Sm B cells.  Moreover, OVA-
specific T cells from OT-II TCR Tg mice were as effective as 2-12H T cells (Fig. 4C).  
Since T cells specific for Sm should be rare in non-Tg mice and rarer still in OVA TCR 
Tg mice, we conclude that the contribution of T cells to the activation of anti-Sm B cells 
is independent of their antigen specificity, and that cognate T cell help is not required.   
 
BMDCs activate only anti-Sm MZ B cells in vitro.  To determine the identity of the B 
cells activated by AC-pulsed DCs, we sorted FO, MZ, and pre-PCs from 2-12H spleens 
and cultured them with T cells and BMDCs.  As shown in Fig. 5A, anti-Sm MZ B cells 
differentiated to ASCs, but not FO B cells or pre-PCs.  In addition, only MZ B cells 
were induced to become ASCs  by Faslpr BMDCs (Fig. 5B).  Thus, the ability of DCs to 
induce an anti-Sm response is limited to the MZ B cell subset. 
 
Ex vivo DCs can activate anti-Sm B cells.  To determine whether splenic DC subsets 
can activate anti-Sm B cells, we sorted myeloid (CD11b+, CD11c+), lymphoid (CD11b-, 
CD11c+, Gr.1-, B220- ), and plasmacytoid (CD11b-, CD11c+, Gr.1+, B220+) DCs from 
Faswt and Faslpr mice (Fig. 5C, left) and used them to activate anti-Sm B cells in vitro.  
As shown in Fig. 5D, AC-pulsed myeloid and lymphoid DCs from Faswt mice induced 
anti-Sm ASCs, while their non-pulsed counterparts did not.  Moreover, myeloid and 
lymphoid DC subsets from Faslpr mice also induced anti-Sm ASCs (Fig. 5C, right), and 
in line with our findings with Faslpr BMDCs, activation did not require AC-pulsing and 
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occurred after TNF-α treatment (Fig. 5C, right).  One notable difference between ex vivo 
Faswt DCs and BMDCs is that TNF-α treatment does not abrogate anti-Sm B cell 
activation by myeloid Faswt DCs, as it does with Faswt BMDCs (Fig. 1), and in this way, 
they resemble Faslpr DCs.  Neither Faswt nor Faslpr plasmacytoid DC subsets induced 
anti-Sm ASCs (Fig. 5C, right).  Thus, ex vivo myeloid and lymphoid splenic DCs can 
activate anti-Sm B cells.   
 
Cell contact is required for optimal anti-Sm B cell activation by AC-pulsed 
BMDCs. To identify whether the anti-Sm MZ B cell activation required cell contact, we 
performed transwell assays.  Cells were cultured at the same ratios used above with the 
B cells consistently in the lower chamber.  Cells were cultured as depicted in Fig. 6A for 
3 days before ELISpot analysis.  As shown in Fig. 6A, co-culture of any of the two cell 
types with one another, for both Faswt and Faslpr BMDCs, slightly increases anti-Sm 
ASC formation.  However,  the most efficient anti-Sm ASC response is generated when 
B cells, T cells, and AC-pulsed BMDCs are all cultured together.  Thus, contact by B, T, 
and DCs is required for optimal anti-Sm ASC formation.  
 
Cytokines are involved in anti-Sm ASC formation by AC-pulsed BMDC.  To 
identify the cytokines required for anti-Sm ASC formation, we added cytokine-specific 
inhibitory antibodies to the anti-Sm B cell activation cultures.  A significant reduction in 
anti-Sm ASCs by Faswt and Faslpr BMDCs was noted after neutralization of CD40L, and 
interleukin (IL)-1β (Fig. 6B).  Neutralization of multiple other cytokines (IL-2, IL-4, IL-
5, IL-6, IL-21, GM-CSF, and IFN-γ) had no effect on ASC formation (data not shown).  
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 The role of BAFF was tested using BAFF-deficient BMDCs. As shown in Fig. 
6C, BAFF-deficient BMDCs were unable to induce anti-Sm ASCs.  Since BAFF-
deficient Faslpr DCs are not available, we neutralized BAFF with a decoy receptor 
(TACI-Ig).  BAFF neutralization reduced activation by Faslpr DCs, but seemingly had no 
effect on activation by Faswt BMDCs (Fig. 6C).  One explanation for the inability of 
TACI-Ig to block activation by Faswt DCs despite the inability of BAFF-deficient Faswt 
DCs to activate anti-Sm B cells, is that Faswt DCs secrete more BAFF than do Faslpr 
DCs.  To test this, we activated BMDCs as before and used them in a BAFF ELISpot 
assay to determine the frequency of BAFF-secreting BMDCs.  Fig. 6D shows that a 
higher frequency of Faswt BMDCs secrete BAFF when co-cultured with T and B cells 
than when cultured alone, and the frequency was highest after AC-pulsing.  The effect of 
AC-pulsing on BAFF production, however, was lost after TNF-α activation.  Thus, AC-
pulsing induces BAFF-secretion by BMDCs and TNF-α blocks BAFF secretion 
providing a possible explanation for why AC-pulsing is required for anti-Sm ASC 
formation and why this function is lost after TNF-α treatment.   
 Similar to Faswt BMDCs, the frequency of BAFF-secreting Faslpr BMDCs was 
increased by co-culturing with T and B cells, but in contrast to Faswt BMDCs, AC-
pulsing had no effect on the frequency of BAFF-secreting Faslpr BMDCs (Fig. 6D).  
Thus, Faslpr DCs are defective in AC-induced BAFF secretion, resulting in lower BAFF 
levels and providing an explanation for the inhibition by TACI-Ig.  Moreover, this result 
suggests that another factor(s) is required for activation of anti-Sm B cells by Faslpr 
BMDCs. 
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Exogenous BAFF and IL-1β can replace AC-pulsing of DCs.  To determine whether 
IL-1β and BAFF are sufficient to replace AC-pulsing or DCs altogether, we added these 
cytokines with or without unpulsed BMDCs to cultured 2-12H B and T cells.  Both IL-
1β and BAFF induced anti-Sm ASCs in cultures of B and T cells, and in combination the 
effects of IL-1β and BAFF were additive (Fig. 7, first bar in each group).  However, in 
the absence of DCs, activation is significantly suboptimal (Fig. 7).  The addition of 
either cytokine to cultures of B, T, and unpulsed BMDCs increased the frequency of 
anti-Sm ASCs, and the combination of the two cytokines induced the frequency of anti-
Sm ASCs to be equal to that induced by AC-pulsed BMDCs (Fig. 7, second bar in each 
group).  Thus, BAFF and IL-1β, in the presence of unpulsed BMDCs, are sufficient to 
replace AC-pulsing of BMDCs.  The addition of IL-1β and BAFF (or both) to cultures 
containing B, T and AC-pulsed BMDCs increases the frequency of anti-Sm ASCs still 
further (data not shown).   
Unpulsed Faslpr BMDCs alone are more potent in the activation of anti-Sm B 
cells than Faswt BMDCs (Fig. 7, third bar in each group), as seen before (Fig. 1), but 
exogenously added IL-1β and BAFF increase this activation significantly.  Significantly, 
BAFF alone induces a much greater ASC response by Faslpr BMDCs than by Faswt 
BMDCs, indicating that BAFF has a more potent effect on activation of anti-Sm B cells 
by Faslpr BMDCs than on activation by Faswt BMDCs.  
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E.  DISCUSSION 
 
 We show here that AC-pulsed DCs can activate anti-Sm MZ B cells.  This 
activation is T cell-dependent, cell contact-dependent, and cytokine-dependent.  
Activation is antigen specific since AC-pulsed DCs do not activate anti-HEL B cells 
after transfer to MD4 mice.  Antigen specificity likely comes from phagocytized 
apoptotic cells, as apoptotic cells expose many nuclear antigens targeted in lupus 
including Sm[25, 30].  Moreover, Sm is present on the surface of immature DCs and is 
increased after apoptotic cell phagocytosis (D. Gutches and B. Vilen, personal 
communication).  DCs are separated from free apoptotic cells before i.v. injection or in 
vitro culture, arguing against the possibility that free apoptotic cells are responsible for 
anti-Sm B cell activation.  In addition, i.v. injection of 10-times the number of ACs used 
to pulse a dose of DCs is not sufficient to induce an equal anti-Sm response in vivo.  
These data establish that DCs can induce the activation of autoreactive MZ B cells 
specific for antigens exposed on the surface of apoptotic cells.   
 It is surprising that anti-Sm B cell activation is T cell dependent, since MZ B 
cells are commonly associated with T-independent responses and since apoptotic cell 
phagocytosis induces tolerogenic DCs[3-5, 33-36].  Tolerogenic DCs induce antigen-
specific T cells to undergo a proliferative burst before undergoing apoptosis[5].  
Tolerogenic DCs have an immature phenotype characterized by low expression of co-
activation molecules, CD80, CD86, CD40, and MHCII, which we confirm to be the case 
with the DCs used in the activation of anti-Sm B cells[5].  Thus, we consider it unlikely 
that DCs present antigens via MHCII to T cells to provide cognate T cell help for B cell 
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activation.  Corroborating this conclusion are the observations that 2-12H, non-Tg, and 
OVA-specific T cells are equally able to activate anti-Sm B cells.  Further, TNF-α 
activation of DCs following apoptotic cell phagocytosis results in the abrogation of the 
anti-Sm B cell response in vivo and in vitro, indicating that DCs expressing of high 
levels of MHCII and other co-stimulatory molecules are unable to activate anti-Sm B 
cells, opposite of that expected for cognate T cell help.  How T cells contribute to anti-
Sm MZ B cell activation has yet to be determined, but, as discussed below, one 
possibility is that activated T cells provide FasL and CD40L to DCs or B cells.   
The B cells targeted for activation by AC-pulsed DCs are MZ B cells.  We 
observed no activation of FO B cells, although we cannot exclude the possibility that 
they require more time for activation.  MZ B cells are depleted and pre-PCs are 
expanded in vivo after AC-pulsed DC injection, but not when mice are given DCs that 
do not induce anti-Sm B cell activation.  In addition, only sorted MZ B cells are 
activated in vitro.  We have established that anti-Sm MZ B cells can become pre-PCs in 
vivo (manuscript in preparation), and in the in vitro activation cultures used here, MZ B 
cells become CD138int (data not shown), a defining characteristic of pre-PCs.  FO B cells 
may be intrinsically refractory from activation by DCs for lack of a critical receptor for 
DC-mediated activation.  Alternatively, the inability of anti-Sm FO B cells to be 
activated may be because these cells are anergic [37] and intrinsically refractory to 
activation.  In contrast, our analysis of 2-12H anti-Sm MZ B cells suggests that they are 
functional.  Anti-Sm pre-PCs are not activated directly even though they too appear to be 
functional [29] and are largely derived from MZ B cells (manuscript in preparation).  
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Perhaps the interaction of AC-pulsed DCs with anti-Sm MZ B cells provides a critical 
signal for induced pre-PCs to respond to additional signals required for ASC formation.   
Our findings indicate that AC-pulsed DCs act at two stages in B cell activation.  
The first is at the MZ B cell stage to induce differentiation to the pre-PC stage.  This is 
evident by the in vivo decrease in MZ B cell numbers and increase in pre-PC numbers 
after AC-pulsed DC injection, and by the pre-PC differentiation by MZ B cells in vitro 
(data not shown).  We suggest that this stage of activation is T-independent since T cell 
depleted 2-12H mice undergo this stage of activation after AC-pulsed DC injection.  The 
presence of Ag on the surface of DCs is likely crucial, but whether additional signals are 
provided by the DC is unknown.  The second stage of activation is at the pre-PC to ASC 
transition.  This step is T-cell dependent, as seen from that lack of ASC differentiation in 
vivo in T cell depleted mice, and breaches the tolerance checkpoint that blocks activation 
in non-autoimmune mice.  Since T cells are required for inducing a high frequency of 
BAFF-producing DCs (Fig. 6), we speculate that BAFF is required for the pre-PC to PC 
transition.  These results parallel the activation of MZ B cells by foreign antigens 
captured by DCs[13].  In addition, this two-step activation program of anti-Sm MZ B 
cells by DCs is reminiscent of a study by Banchereau and colleagues that demonstrates 
how human plasmacytoid DCs (pDCs) mediate plasma cell differentiation through there 
production of interferonα/β (IFNα/β) and IL-6[38, 39].  Their study shows that IFNα/β 
generates activated pre-PCs, but does not induce them to become ASCs, and that IL-6 is 
required for ASC differentiation[39].   
Our findings indicate a requirement for IL-1β secretion by DCs for the activation 
of anti-Sm MZ B cells.  IL-1β secretion may be induced by Fas-FasL or CD40-CD40L  
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interactions between DCs and activated T cells, which express elevated levels of FasL 
and CD40L[9, 40-43].  IL-1β induces, in an autocrine fashion, DC activation and 
cytokine secretion[42].  Apoptotic cell phagocytosis likely blocks IL-1β−induced 
upregulation of co-stimulatory molecules, but may induce the secretion of other 
cytokines such as BAFF.  We are not clear whether we have identified all of the 
cytokines involved in the activation of these B cells.  However, add-back experiments 
indicate that we have likely identified the principal cytokines, since the addition of IL-1β 
and BAFF to DCs that have not been pulsed with apoptotic cells generate a response that 
is equivalent to that induced by AC-pulsed DCs alone.   
These data expand our understanding of how B cells are involved in the 
regulation of autoreactive B cell activation.  Vilen and colleagues recently demonstrated 
that DCs repress the activation of anergic FO B cells by LPS[14, 15].  IL-6 and TNF-α 
produced by activated LPS-activated DCs repress the ability of these B cells in vitro.  
Thus, responses to LPS-producing bacteria that lead to DC activation and could lead to 
polyclonal activation of autoreactive B cells cannot occur.  Our findings indicate that 
DCs can induce the activation of functional anti-Sm B cells.  However, this ability is 
restricted to the immature DC stage and is restricted to MZ B cells.  Non-specific 
polyclonal activation by LPS-producing bacteria cannot occur, because this would result 
in DC maturation.  An important consequence of anti-Sm MZ B cell activation by only 
immature DCs is that concomitant T cell activation will not occur[5].  This block in T 
cell activation would prevent the formation of germinal centers, which can occur with 
MZ B cells that receive cognate T cell help, and consequently, the production of a long-
lived, affinity matured anti-Sm response.  We predict that injection of apoptotic cells 
 153 
into 2-12H mice, which generates a short-lived response, activates anti-Sm MZ B cells 
after the apoptotic cells are captured by DCs[30].  Marginal zone DCs are a likely DC 
subset to be involved, since they are excellent at capturing apoptotic cells in vivo.  
Consistent with this, we see a depletion of MZ B cells in 2-12H mice after injection of 
apoptotic cells (unpublished observation).   
The restricted ability of DCs to activate anti-Sm B cells is lost in DCs from Faslpr 
mice.  DCs no longer require apoptotic cell phagocytosis, and maturation with TNF-α 
does not abrogate the ability to activate anti-Sm MZ B cells.  It should be noted that, as 
with Faswt DCs, optimal activation occurs with AC-pulsed Faslpr DCs.  Thus, Fas 
signaling plays a critical role in the proper regulation of autoreactive B cells.  We 
suggest that Fas signals provide a negative signal to DCs that apoptotic cell phagocytosis 
overcomes.  Faslpr DCs do not acquire the ability to activate non-MZ B cells and thus the 
target B cells for DC-mediated activation are unchanged.  However, we have 
demonstrated that FO B cells are activated in Faslpr mice (manuscript in preparation) 
and whether DCs indirectly induce anti-Sm FO B cell activation cannot be excluded.   
A critical question that remains to be resolved is how Fas signals regulate DC-
mediated activation of anti-Sm B cells.  Fas signals induce DC activation and IL-1β 
secretion[9, 41, 44].  IL-1β induces upregulation of co-stimulatory molecules and 
cytokine secretion, and we have shown that IL-1β secretion is required for the ability of 
Faslpr DCs to activate anti-Sm B cells.  Thus, we deduce that Faslpr DCs secrete IL-1β 
despite the absence of Fas.  Other signals are likely involved, such as from CD40 
binding to CD40L on T cells.  Constitutively high BAFF secretion could explain the loss 
of regulation, but we find no evidence to support this.  The frequency of BAFF secreting 
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Faslpr DCs is quite similar to that of Faswt DCs.  The one exception is that AC-pulsed 
Faslpr DCs do not increase to the very high levels seen with AC-pulsed Faswt DCs.  
Thus, the ability of Faslpr DCs to constitutively activate anti-Sm B cells is unlikely 
related to BAFF secretion.  However, cell surface BAFF is increased on DCs given 
apoptotic cells[45] and thus, it is possible that surface BAFF is upregulated to higher 
levels on Faslpr DCs than on Faswt DCs, regardless of whether they have phagocytized 
apoptotic cells or been treated with TNF-α.   
Regardless of the mechanism, the constitutive ability of Faslpr DCs to activate 
anti-Sm B cells provides new insights into autoantibody production.  Faslpr DCs are able 
to constitutively activate anti-Sm B cells, as they do not require increased apoptotic cell 
loads, and more importantly, activation will occur even after they become mature.  
Consequently, concomitant anti-Sm B and T cell activation could occur.  MZ B cells can 
form germinal centers when appropriate T cell help is available[46], and thus, rather than 
generate short-lived responses, as with Faswt DCs, Faslpr DCs could generate long-lived 
responses that are accompanied by affinity maturation, H chain class switch, memory B 
cell formation, and long-lived bone marrow plasma cells.  This would be a 
fundamentally different response from that in Faswt mice, since decreased apoptotic cell 
loads cannot turn off the response, and high affinity IgG autoantibodies that are more 
likely to be pathogenic will be formed.   
In summary, we have shown that anti-Sm B cells are activated in vivo and in 
vitro by immature DCs by a BAFF-dependent mechanism.  In non-autoimmune mice, 
activation is dependent on apoptotic cell phagocytosis and an immature DC phenotype.  
In addition, activation is limited to MZ B cells.  These restrictions prevent the 
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concomitant activation of anti-Sm T cells, thereby limiting the scope of the response to 
being short-lived and self-limiting.  In contrast, in Faslpr autoimmune mice, anti-Sm MZ 
B cell activation is not restricted.  It occurs in the absence of apoptotic cell phagocytosis 
and regardless of the DC maturation stage.  Consequently, concomitant anti-Sm B and T 
cells will likely occur, generating a germinal center reaction and long-lived memory and 
plasma cells that produce pathogenic, high affinity IgG autoantibodies.  Thus, these data 
identify a new mechanism for autoreactive B cell activation and provides additional 
evidence that DC-B cell interactions are critical in this process.   
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Figure 4.1.  Apoptotic cell (AC)-pulsed BMDCs induce anti-Sm antibody secreting 
cell (ASC) formation in vivo.  A,D.  Splenic anti-Sm ASCs detected by ELISpot assay 
6 days post-transfer of ACs or each BMDC group (see Materials and Methods section) 
into (A) 2-12H mice (n=at least 16 per group) or (D) T cell-depleted 2-12H mice (n=4 
per group).  The asterisk (*) denotes significance of that group over background and 
over all of the other injection groups. Error bars indicate standard error.  B.  Overlays of 
cell surface activation marker staining comparing AC-pulsed (open) and un-pulsed 
(shaded) BMDCs.  Representative histograms are displayed.  C.  Splenic anti-HEL ASCs 
detected by ELISpot assay 6 days post-transfer of ACs or each BMDC group (see 
Materials and Methods section) into HEL-transgenic MD4 mice.  The asterisk (*) 
denotes significance of that group over background and over all of the other injection 
groups. Error bars indicate standard error.  n=5 per group.   
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FIGURE 4.1 
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Figure 4.2.  AC-pulsed BMDCs affect B cell activation at two stages.  A, B, C.  Anti-
Sm B cell population frequencies (left) and absolute numbers (right) as detected by flow 
cytometry 6 days post-transfer of each BMDC group into 2-12H mice.  The anti-Sm FO 
subset (CD23+CD21int) is displayed in A, the anti-Sm MZ subset (CD23lo/int CD21hi) is 
displayed in B, and the anti-Sm early pre-PC subset (CD19+CD138int).  All histograms 
are gated on lymphocytes and Sm and those displayed in A and B are gated on CD19+ 
cells.  The percentages represent the percentage of anti-Sm B cells.  The asterisk (*) 
denotes significance (p<0.001).  D.  Anti-Sm MZ B cell (left) and early pre-PC (right) 
absolute numbers as detected by flow cytometry 6 days post-transfer of each BMDC 
group into T cell-depleted mice.  The asterisk (*) denotes significance (p<0.001).  E.  
Overlay of anti-Sm early pre-PC intracellular IgM levels as detected by flow cytometry.  
Cells are gated on lymphocytes, CD19, Sm, and CD138.  Representative samples show 
intracellular IgM levels of early pre-PCs after PBS was injected into 2-12H mice 
(shaded), AC-pulsed BMDCs were injected into T cell-depleted 2-12H mice (black line), 
and AC-pulsed BMDCs were injected into 2-12H mice (dotted-line).  n=4 per group   
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FIGURE 4.2 
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FIGURE 4.2, Continued 
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Figure 4.3.  Fas-deficient BMDC activation of anti-Sm B cells is not limited by 
ingestion of ACs or to the immature stage.  A.  Splenic anti-Sm ASCs detected by 
ELISpot assay 6 days post-transfer of ACs or each BMDC group (see Materials and 
Methods section) into 2-12H mice (n=4 per group).  B6 BMDC injections (black bars) 
are shown for comparison to the Faslpr BMDC injections (checkered bars).  Significant 
differences between B6 and Faslpr BMDC injections are denoted with p values.  Error 
bars indicate standard error.  B.  Overlays of cell surface activation marker staining 
comparing AC-pulsed (open) and un-pulsed (shaded) Faslpr BMDCs.  Representative 
histograms are displayed.  C.  BMDCs from B6 and Faslpr mice were incubated with 
apoptotic thymocytes for 60 min and the percent of phagocytized thymocytes determined 
by fluorescent microscopy.  The graph is representative of two experiments and shows 
the average ± SEM of 3 mice per strain. 
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FIGURE 4.3 
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Figure 4.4.  In vitro activation of anti-Sm B cells by BMDCs recapitulates in vivo 
activation.  A.  Anti-Sm ASCs were detected by ELISpot assay after 72 hours of 
culture, as described in Materials and Methods.  Varying ratios of B cells:T cells:DCs 
were used to initially optimize the assay, as shown below the graph, and all subsequent 
in vitro experiments used the cell numbers outlined in Materials and Methods.  Fold 
increase in anti-Sm secretion, compared to 2-12H B cells cultured alone, is displayed 
and un-pulsed (open bars) and AC-pulsed (black bars) BMDC treatments are compared.  
B.  In vitro assay performed as in 4.4A with the addition of Faslpr BMDCs; un-pulsed 
(gray) and AC-pulsed (checkered) Faslpr BMDCs are each displayed.  C.  Anti-Sm ASCs 
were detected by ELISpot assay to compare the efficacy of 2-12H, Non-Tg, and OT-II 
TCR Tg T cells in this assay.  T cells of each mouse strain were individually purified as 
outlined in Materials and Methods and cultured with either B cells only (open bars) or B 
cells and AC-pulsed B6 BMDCs.  The asterisk (*) denotes significance (p<0.001) and 
n=3 per T cell strain. 
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FIGURE 4.4 
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Figure 4.5.  Cell sorting of splenic B cell and splenic DC populations demonstrates 
the primary responding subsets involved in anti-Sm B cell activation by BMDCs in 
vitro.  A and B.  FO (B220+CD23+CD21int), MZ (B220+CD23low/intCD21hi), and early 
pre-PC (B220+CD138int) B cells were sorted from 2-12H spleens and put into culture for 
ELISpot analysis as described above for 2-12H bulk populations.  Each subset was 
cultured with 10-fold less 2-12H T cells and 10-fold less of each B6 (A) and Faslpr (B) 
BMDC treatment.  The asterisk (*) denotes significance (p<0.001). n=3 per B cell 
subset.  C.  Splenic myeloid (CD11b+, CD11c+), lymphoid (CD11b-, CD11c+, Gr.1-, 
B220- ), and plasmacytoid (CD11b-, CD11c+, Gr.1+, B220+)  DCs were sorted from 
C57BL/6 and  Faslpr spleens and put into culture with 2-12H T cells and bulk 2-12H B 
cells for ELISpot analysis as described above for BMDC cultures.  The gates used to sort 
myeloid (My), lymphoid (Ly), and plasmacytoid (PDC) DCs are outlined on the top and 
anti-Sm ASCs created after 72 hours are displayed on the bottom.  n=5. 
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FIGURE 4.5 
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FIGURE 4.5, Continued 
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Figure 4.6.  Both cell contact and secreted cytokines are required for optimal anti-
Sm B cell activation by AC-pulsed BMDCs.  A.  Anti-Sm ASCs were detected by 
ELISpot after transwell cultures, as described in Materials and Methods.  Labels beneath 
the graph indicate the localization of each cell type that correlates to that particular 
amount of secretors, with B cells consistently on the bottom closest to the ELISpot 
capture membrane.  Cultures were performed with un-pulsed (open bars) and AC-pulsed 
(black bars) BMDCs from C57BL/6 DCs (top graph) and Faslpr mice (bottom graph).  B.  
In vitro ELISpot assay was performed as above, yet neutralizing anti-CD40L (10 µg/mL) 
and anti-IL-1β (2.5 µg/mL)  were individually added at the start of culture, as indicated.  
All DC cultures exhibited significant (p<0.001) reduction in anti-Sm ASC production in 
response to both neutralizing antibodies.  C.  Anti-Sm ELISpot assays altering BAFF 
production were performed as described   BAFFko BMDCs replaced the B6 BMDCs in 
the middle columns while TACI-Ig (10 µg/mL ), a BAFF agonist, was added to the 
cultures represented by the right columns.  The asterisk (*) denotes significance 
(p<0.001) in comparison to the same treatment of control in vitro cultures, shown by left 
columns. (n=3)  D.  A BAFF ELISpot assay was adapted from the BAFF ELISA 
developed by Apotech, as detailed in Materials and Methods.  BAFF-secreting C57BL/6 
and Faslpr BMDCs were detected after 72 hrs.  Spontaneous BAFF secretion was 
assessed, as well as BAFF secretion of BMDCs in response to co-cultures with 2-12H B 
cells and T cells.  All BMDC treatments induced significantly more (p<0.001) BAFF-
secretors when co-cultured with B and T cells than individually, the highest of which in 
response to AC-pulsed C57BL/6 BMDCs. 
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FIGURE 4.6 
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FIGURE 4.6, Continued 
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FIGURE 4.7 
 
 
 
 
Figure 4.7.  Exogenous BAFF and IL-1β can replace AC-pulsing in anti-Sm ASC 
induction by BMDCs.  An in vitro ELISpot assay was performed as above with 
C57BL/6 and Faslpr un-pulsed BMDCs to determine whether exogenous BAFF, IL-1β, 
or both can mimic the AC-pulsing BMDC-induced anti-Sm response.  Recombinant 
murine IL-1β (100ng/mL), human recombinant BAFF (200 ng/mL), or both were added 
at the start of culture and anti-Sm ELISpots were performed after 72 hrs.  The asterisk 
(*) denotes a significant increase in anti-Sm ASCs when B6 BMDCs were cultured with 
both cytokines, as compared to no added cytokines.  Importantly, this number of ASCs 
correlates with the number of anti-Sm ASCs induced by AC-pulsed BMDCs. 
 172 
F. REFERENCES 
 
1. Banchereau, J. and R.M. Steinman, Dendritic cells and the control of immunity. 
Nature, 1998. 392(6673): p. 245-52. 
2. Rutella, S., S. Danese, and G. Leone, Tolerogenic dendritic cells: cytokine 
modulation comes of age. Blood, 2006. 108(5): p. 1435-40. 
3. Stuart, L.M., et al., Inhibitory effects of apoptotic cell ingestion upon endotoxin-
driven myeloid dendritic cell maturation. J Immunol, 2002. 168(4): p. 1627-35. 
4. Steinman, R.M., et al., The induction of tolerance by dendritic cells that have 
captured apoptotic cells. J Exp Med, 2000. 191(3): p. 411-6. 
5. Steinman, R.M., D. Hawiger, and M.C. Nussenzweig, Tolerogenic dendritic 
cells. Annu Rev Immunol, 2003. 21: p. 685-711. 
6. Sparwasser, T., et al., Bacterial CpG-DNA activates dendritic cells in vivo: T 
helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J 
Immunol, 2000. 30(12): p. 3591-7. 
7. Boule, M.W., et al., Toll-like receptor 9-dependent and -independent dendritic 
cell activation by chromatin-immunoglobulin G complexes. J Exp Med, 2004. 
199(12): p. 1631-40. 
8. Kalergis, A.M. and J.V. Ravetch, Inducing tumor immunity through the selective 
engagement of activating Fcgamma receptors on dendritic cells. J Exp Med, 
2002. 195(12): p. 1653-9. 
9. Guo, Z., et al., Fas ligation induces IL-1beta-dependent maturation and IL-
1beta-independent survival of dendritic cells: different roles of ERK and NF-
kappaB signaling pathways. Blood, 2003. 102(13): p. 4441-7. 
10. Gerloni, M., D. Lo, and M. Zanetti, DNA immunization in relB-deficient mice 
discloses a role for dendritic cells in IgM-->IgG1 switch in vivo. Eur J Immunol, 
1998. 28(2): p. 516-24. 
11. MacPherson, G., N. Kushnir, and M. Wykes, Dendritic cells, B cells and the 
regulation of antibody synthesis. Immunol Rev, 1999. 172: p. 325-34. 
12. Qi, H., et al., Extrafollicular activation of lymph node B cells by antigen-bearing 
dendritic cells. Science, 2006. 312(5780): p. 1672-6. 
13. Balazs, M., et al., Blood dendritic cells interact with splenic marginal zone B 
cells to initiate T-independent immune responses. Immunity, 2002. 17(3): p. 341-
52. 
 173 
14. Kilmon, M.A., et al., Low-affinity, Smith antigen-specific B cells are tolerized by 
dendritic cells and macrophages. J Immunol, 2005. 175(1): p. 37-41. 
15. Kilmon, M.A., et al., Macrophages prevent the differentiation of autoreactive B 
cells by secreting CD40 ligand and IL-6. Blood, 2007. 
16. Gilbert, M.R., et al., Dendritic cells from lupus-prone mice are defective in 
repressing immunoglobulin secretion. J Immunol, 2007. 178(8): p. 4803-10. 
17. Beaudette-Zlatanova, B.C., et al., B cells and dendritic cells from V kappa 8 light 
chain transgenic mice activate MRL-lpr/gld CD4+ T cells. J Immunol, 2006. 
177(1): p. 45-52. 
18. Gross, J.A., et al., TACI and BCMA are receptors for a TNF homologue 
implicated in B-cell autoimmune disease. Nature, 2000. 404(6781): p. 995-9. 
19. Khare, S.D., et al., Severe B cell hyperplasia and autoimmune disease in TALL-1 
transgenic mice. Proc Natl Acad Sci U S A, 2000. 97(7): p. 3370-5. 
20. Mackay, F., et al., Mice transgenic for BAFF develop lymphocytic disorders 
along with autoimmune manifestations. J Exp Med, 1999. 190(11): p. 1697-710. 
21. Parry, T.J., et al., Pharmacokinetics and immunological effects of exogenously 
administered recombinant human B lymphocyte stimulator (BLyS) in mice. J 
Pharmacol Exp Ther, 2001. 296(2): p. 396-404. 
22. Moore, P.A., et al., BLyS: member of the tumor necrosis factor family and B 
lymphocyte stimulator. Science, 1999. 285(5425): p. 260-3. 
23. Zhang, X., et al., BAFF supports human B cell differentiation in the lymphoid 
follicles through distinct receptors. Int Immunol, 2005. 17(6): p. 779-88. 
24. Cheema, G.S., et al., Elevated serum B lymphocyte stimulator levels in patients 
with systemic immune-based rheumatic diseases. Arthritis Rheum, 2001. 44(6): 
p. 1313-9. 
25. Qian, Y., et al., Lupus-specific antiribonucleoprotein B cell tolerance in 
nonautoimmune mice is maintained by differentiation to B-1 and governed by B 
cell receptor signaling thresholds. J Immunol, 2001. 166(4): p. 2412-9. 
26. Qian, Y., H. Wang, and S.H. Clarke, Impaired clearance of apoptotic cells 
induces the activation of autoreactive anti-Sm marginal zone and B-1 B cells, in 
J Immunol. 2003. 
27. Qian, Y., et al., Autoreactive MZ and B-1 B-cell activation by Faslpr is 
coincident with an increased frequency of apoptotic lymphocytes and a defect in 
macrophage clearance. Blood, 2006. 108(3): p. 974-82. 
 174 
28. Santulli-Marotto, S., et al., Autoreactive B cell regulation: peripheral induction 
of developmental arrest by lupus-associated autoantigens. Immunity, 1998. 8(2): 
p. 209-19. 
29. Culton, D.A., et al., Early preplasma cells define a tolerance checkpoint for 
autoreactive B cells. J Immunol, 2006. 176(2): p. 790-802. 
30. Qian, Y., H. Wang, and S.H. Clarke, Impaired clearance of apoptotic cells 
induces the activation of autoreactive anti-Sm marginal zone and B-1 B cells. J 
Immunol, 2004. 172(1): p. 625-35. 
31. Scott, R.S., et al., Phagocytosis and clearance of apoptotic cells is mediated by 
MER. Nature, 2001. 411(6834): p. 207-11. 
32. Yan, J. and M.J. Mamula, Autoreactive T cells revealed in the normal repertoire: 
escape from negative selection and peripheral tolerance. J Immunol, 2002. 
168(7): p. 3188-94. 
33. Martin, F. and J.F. Kearney, B-cell subsets and the mature preimmune repertoire. 
Marginal zone and B1 B cells as part of a "natural immune memory". Immunol 
Rev, 2000. 175: p. 70-9. 
34. Lopes-Carvalho, T., J. Foote, and J.F. Kearney, Marginal zone B cells in 
lymphocyte activation and regulation. Curr Opin Immunol, 2005. 17(3): p. 244-
50. 
35. Cyster, J.G., B cells on the front line. Nat Immunol, 2000. 1(1): p. 9-10. 
36. Martin, F., A.M. Oliver, and J.F. Kearney, Marginal zone and B1 B cells unite in 
the early response against T-independent blood-borne particulate antigens. 
Immunity, 2001. 14(5): p. 617-29. 
37. Borrero, M. and S.H. Clarke, Low-affinity anti-Smith antigen B cells are 
regulated by anergy as opposed to developmental arrest or differentiation to B-1. 
J Immunol, 2002. 168(1): p. 13-21. 
38. Jego, G., et al., Dendritic cells control B cell growth and differentiation. Curr Dir 
Autoimmun, 2005. 8: p. 124-39. 
39. Jego, G., et al., Plasmacytoid dendritic cells induce plasma cell differentiation 
through type I interferon and interleukin 6. Immunity, 2003. 19(2): p. 225-34. 
40. Wesa, A. and A. Galy, Increased production of pro-inflammatory cytokines and 
enhanced T cell responses after activation of human dendritic cells with IL-1 and 
CD40 ligand. BMC Immunol, 2002. 3: p. 14. 
41. Ashany, D., et al., Dendritic cells are resistant to apoptosis through the Fas 
(CD95/APO-1) pathway. J Immunol, 1999. 163(10): p. 5303-11. 
 175 
42. Luft, T., et al., IL-1 beta enhances CD40 ligand-mediated cytokine secretion by 
human dendritic cells (DC): a mechanism for T cell-independent DC activation. 
J Immunol, 2002. 168(2): p. 713-22. 
43. Companjen, A.R., et al., CD40 ligation-induced cytokine production in human 
skin explants is partly mediated via IL-1. Int Immunol, 2002. 14(6): p. 669-76. 
44. Ma, Y., et al., Fas ligation on macrophages enhances IL-1R1-Toll-like receptor 4 
signaling and promotes chronic inflammation. Nat Immunol, 2004. 5(4): p. 380-
7. 
45. Diaz-de-Durana, Y., et al., TACI-BLyS signaling via B-cell-dendritic cell 
cooperation is required for naive CD8+ T-cell priming in vivo. Blood, 2006. 
107(2): p. 594-601. 
46. Song, H. and J. Cerny, Functional heterogeneity of marginal zone B cells 
revealed by their ability to generate both early antibody-forming cells and 
germinal centers with hypermutation and memory in response to a T-dependent 
antigen. J Exp Med, 2003. 198(12): p. 1923-35. 
 
CHAPTER 5:  CONCLUSIONS AND FUTURE 
DIRECTIONS
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 Understanding how autoreactive B cells are regulated and how these mechanisms 
are compromised in autoimmunity is important for treatment of autoimmune diseases.  
With this goal in mind, I have focused my studies throughout my graduate school 
training on elucidating how autoreactive B cell tolerance is lost.  Particularly, I have 
concentrated on autoreactive B cells specific for an anti-nuclear antigen, Smith (Sm), 
which is unique for and diagnostic of systemic lupus erythematosus, or SLE.  The pro-
apoptosis gene Fas has been implicated in both human and murine autoimmune diseases, 
and thus Faslpr mice, which possess a mutation in this gene, were the predominant 
murine strain on which I concentrated.  The data presented in my dissertation focuses on  
mechanisms of anti-Sm B cell activation in mice, which has important implications for 
understanding human SLE initiation and progression.  While my studies have offered 
insight into basic B cell activation and plasma cell (PC) differentiation, they have more 
importantly contributed to the understanding of these processes in autoreactive B cells.   
 
 In Chapter 2, I demonstrate that tolerance to Sm is lost in 2-12H mice with 
autoimmune backgrounds or susceptibility genes.  Faslpr mice, which do not typically 
develop an anti-Sm response, acquired elevated anti-Sm titers and developed anti-Sm 
ASCs in the bone marrow, spleen, mesenteric lymph node and lamina propria.  I 
demonstrate that B-1 B cells are activated to produce ASCs in the mesenteric lymph 
node and lamina propria and that the early pre-PC tolerance checkpoint is bypassed.  
Moreover, marginal zone (MZ) B cell numbers, like B-1 B cell numbers, decrease, 
concurrent with an increase in serum anti-Sm, suggesting that anti-Sm MZ B cells are 
also activated.  The activation of anti-Sm MZ and B-1 B cells in Fas-deficient mice adds 
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to a growing body of evidence that MZ and B-1 B cells are involved in autoimmunity.  
Understanding what mechanisms are inducing the activation of these anti-Sm B cell 
subsets, as well as determining whether other subsets are involved in this Faslpr-induced 
anti-Sm response, are important questions that I have begun to address in the latter two 
chapters of my dissertation. 
 Coincident with the activation of these anti-Sm subsets in 2-12H/Faslpr mice, we 
demonstrate a macrophage defect in AC ingestion and subsequent accumulation of Sm-
bearing ACs in the spleen and lymph nodes of Faslpr mice.  Defective clearance of ACs 
is a recurring feature in autoimmunity and targeted impairment of AC clearance 
invariably results in autoimmunity.  Defective phagocytosis of ACs is also a feature of 
human lupus.  We believe this defect and increase in antigenic load may be contributing 
factors to the activation of anti-Sm B cells and the development of disease.  How Faslpr 
induces this macrophage defect remains to be investigated.  Serum from lupus patients 
significantly inhibits efficient phagocytosis by normal human neutrophils and thus there 
may be a secreted factor in Faslpr mice that diminishes macrophage phagocytosis of 
ACs.  Although incompletely characterized, Fas has non-apoptotic functions, such as 
cytokine production, induction of DC maturation and survival, and chemokine 
production involving multiple cell types, thus there are many mechanisms by which this 
macrophage defect could be induced, warranting further investigation. 
  
 In, Chapter 3 I directly demonstrate the involvement of B cells of the follicular, 
(FO), MZ, and early pre-PC subsets in the anti-Sm response in Faslpr mice.  Through 
adoptive transfer experiments of 2-12H splenic B cells into Faswt and Faslpr recipients, I 
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identify that both anti-Sm FO and MZ B cells can become early pre-PCs and that all 
three subsets are activated in Faslpr mice.  However, the anti-Sm subsets undergo distinct 
activation programs, thus each making different contributions to disease.  Anti-Sm pre-
PCs, which are functional, generate an immediate, short-lived anti-Sm ASC response 
that is limited to the spleen.    I show that anti-Sm MZ B cells undergo an immediate 
burst of cell division and differentiate rapidly to pre-PCs and short-lived ASCs in Faslpr 
mice.  Anti-Sm FO B cells also contribute to the anti-Sm response in Faslpr mice, 
however they contribute to a delayed and long-term response compared to anti-Sm MZ 
B cells. 
 While these anti-Sm FO and MZ B cell responses in Faslpr mice parallel the 
responses by FO and MZ B cells to foreign antigens, there is much more to be learned 
about autoreactive B cell activation.  The rapid differentiation and short-lived ASC 
formation from anti-Sm MZ B cells suggests an extrafollicular, most likely T cell-
independent response, which is consistent with the paradigm of MZ responses to blood-
bourne pathogens.  I propose FO B cells, which exhibit a delayed, long-lived ASC 
response in these Faslpr transfers, may undergo germinal center reactions, requiring T 
cell-help, in response to self-antigens.  Current efforts are focusing on acquiring 
immunohistochemistry images of the spleen to identify where the transferred cells are 
localizing throughout their responses, perhaps providing a glimpse at whether these anti-
Sm subsets are extrafollicular and/or forming germinal center foci.  To corroborate and 
strengthen those findings, anti-Sm FO, MZ, and early pre-PC B cell transfers should be 
performed into T cell-depleted Faslpr recipients to fully understand the T cell 
requirements for each of these responses.  Understanding the nature of the response 
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elicited by each anti-Sm subset is of utmost importance.  These data provide provoking 
insights into subset-specific activation programs of autoreactive B cells. 
 
 In Chapter 4, I describe a role for DCs in anti-Sm B cell activation.  
Dendritic cells (DCs) can activate MZ B cells that are specific for a foreign antigen, and, 
since they efficiently phagocytize apoptotic cells, a source of Sm antigen, I investigated 
whether DCs can activate anti-Sm MZ B cells.  I demonstrate a role for immature, AC-
pulsed DCs in activating anti-Sm MZ B cells in a T cell-dependent manner.  In these 
AC-pulsed DC studies, anti-Sm MZ B cells differentiate into early pre-PCs 
(corroborating my findings in Chapter 3) in the absence of T cells.  However, I 
demonstrate that T cells are required for the subsequent early pre-PC activation and ASC 
formation, as intracellular IgM is not upregulated in the early pre-PC population and 
anti-Sm ASCs are not formed in response to AC-pulsed DC injections into T cell-
depleted 2-12H mice.  Interestingly, this response is abrogated when DCs are pre-treated 
with TNF-α, suggesting non-autoimmune DCs possess a regulatory mechanism that 
prevents autoreactive B cell activation in a proinflammatory environment.  We also 
demonstrate IL-1β and BAFF are both required for this MZ B cell activation. 
Faslpr DCs, on the other hand, activate anti-Sm MZ B cells regardless of 
maturation and AC phagocytosis, suggesting they are unrestricted in their anti-Sm B cell 
activation.  We propose non-autoimmune, immature AC-pulsed DCs are able to induce 
controlled, short-lived anti-Sm secretion under appropriate environmental conditions.  
We suggest Faslpr autoimmune-prone DCs, on the other hand, elicit concomitant T cell 
activation as they are not restricted in their activation potential, thus promoting chronic, 
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long-lived B cell responses.  These studies provide another mechanism by which anti-
Sm B cells are activated in disease, as we hypothesize the Faslpr DCs are contributing to 
the induction of chronic, long-lived B cell responses.   
Current and future efforts are focusing on elucidating the mechanism through 
which this anti-Sm MZ B cell activation is occurring.  While we have identified several 
important mediators, many questions remain to be resolved, the most important of which 
is how Fas signals regulate DC-mediated activation of anti-Sm B cells.  We have shown 
AC-pulsing is necessary for this DC-mediated anti-Sm MZ B cell activation, suggesting 
a BCR signal and/or TLR signal may be involved, although AC ingestion is most likely 
affecting DC function as well.  Moreover, we demonstrate that CD40 and Fas signals are 
also a requirement and propose that one or both of these pathways are involved in the 
DCs’ production of another necessary component, IL-1β.  IL-1β, known to work in an 
autocrine fashion and induce production of downstream effectors in DCs, including 
BAFF, is integral and may dictate BAFF secretion, providing a potential link between 
these identified players.  Deciphering how CD40L, IL-1β, BAFF, and Fas are 
interconnected and working in concert to induce anti-Sm  B cell activation and how this 
is dysregulated in autoimmunity will contribute greatly to the autoimmunity field.  As 
over-production of BAFF and mutations in Fas have each been associated with SLE 
patients, understanding how these factors induce autoreactive B cell activation will 
provide much insight into some components of this complex, systemic disease.  In 
addition, while we believe we have identified the primary players, we can not exclude 
that there are other mediators involved in this response.  These data identify a new 
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mechanism for autoreactive B cell activation and provide additional evidence that DC-B 
cell interactions are critical in this process.  
APPENDIX 1: EARLY PRE-PLASMA CELLS DEFINE 
A TOLERANCE CHECKPOINT FOR AUTOREACTIVE B 
CELLS 
 
 
This research was originally published in Journal of Immunology. 
Culton DA, O’Conner BP, Conway KL, Diz R, Rutan J, Vilen BJ, and Clarke SH.  Early 
pre-plasma cells define a tolerance checkpoint for autoreactive B cells.  Journal of 
Immunology.  2006;  176: 790-802. 
© 2006 The American Association of Immunologists, Inc.
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A  ABSTRACT 
 
 Ab-secreting plasma cells (PCs) are the effectors of humoral immunity. In this 
study, we describe regulation of autoreactive B cells specific for the ribonucleoprotein 
Smith (Sm) at an early pre-PC stage. These cells are defined by the expression of the PC 
marker CD138 and normal levels of CD19 and B220. They are present at a high 
frequency in normal mouse spleen and bone marrow, are Ag dependent, and are located 
predominantly along the T cell-B cell border and near bridging channels. Anti-Sm pre-
PCs also occur at a high frequency in nonautoimmune mice and show additional 
phenotypic characteristics of PC differentiation. However, while some of these pre-PCs 
are Ab-secreting cells, those specific for Sm are not, indicating regulation. Consistent 
with this, anti-Sm pre-PCs have a higher turnover rate and higher frequency of cell death 
than those that do not bind Sm. Regulation of anti-Sm pre-PCs occurs upstream of the 
transcriptional repressor, B lymphocyte-induced maturation protein-1, expression. 
Regulation at this stage is overcome in autoimmune MRL/lpr mice and is accompanied 
by an altered B lymphocyte stimulator receptor profile. These data reveal a new B cell 
tolerance checkpoint that is overcome in autoimmunity. 
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B. INTRODUCTION 
 Humoral immune responses to foreign Ag involve differentiation of mature B 
cells to Ab-secreting cells (ASCs) or plasma cells (PCs) (1). Responses to both T-
independent (TI) and T-dependent (TD) Ags result in the formation of short-lived PCs 
and TD Ags give rise to long-lived PCs that derive from germinal centers (2, 3). 
Numerous changes are associated with PC differentiation, including the loss of surface 
IgM, CD19, and MHC class II, the production of secretory IgM, and the up-regulation of 
the PC marker CD138 (syndecan-1) (1). Recently, PCs have been found to up-regulate 
the B lymphocyte stimulator (BlyS) receptor, B cell maturation Ag (BCMA), and 
chemokine receptor CXCR4, which are necessary for PC survival and homing to the 
bone marrow (BM), respectively (4, 5, 6, 7, 8, 9, 10, 11).  
 PC differentiation is largely controlled by the transcriptional repressor B 
lymphocyte-induced maturation protein-1 (Blimp-1) (12). Direct targets of Blimp-1 
repression are c-myc, Pax5 (encoding B cell-specific activator protein), MHC CIITA, 
SpiB, and Id3 (12, 13). Blimp-1 is also important for induction of X box-binding protein 
1 (XBP-1), the only other transcription factor required for PC differentiation (14, 15). 
Thus, Blimp-1 plays a critical role in PC differentiation by inducing cell cycle arrest, 
induction of Ig secretion, and inhibition of germinal center function (12).  
 The cellular differentiation of B cells to PCs has not been completely elucidated, 
but recently several intermediate stages of PC differentiation have been described (6, 7, 
14, 16, 17, 18). These intermediates differ in function and phenotype exhibiting 
characteristics of mature B cells and PCs (B220low, CD19+, surface Iglow, CD138+, high 
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intracellular Ig+, and Ig secretion). It is not clear how the different intermediates relate to 
one another and whether they all exist on a single differentiative pathway.  
 Multiple mechanisms of B cell regulation, including central deletion, receptor 
editing, peripheral deletion, and anergy (19, 20, 21, 22, 23, 24, 25, 26, 27, 28), block 
anti-self B cell differentiation to ASCs thereby preventing autoimmunity. Several of 
these mechanisms regulate B cells specific for Smith (Sm), a ribonucleoprotein uniquely 
targeted in systemic lupus erythematosus (SLE). In transgenic (Tg) mice that posses an 
anti-Sm H chain rearrangement (2-12H), anti-Sm B cells comprise 30–50% of peripheral 
B cells and are present as transitional, follicular (FO), and marginal zone (MZ) B cells in 
the spleen and as B-1 cells in the peritoneum (29, 30). Despite the large number of anti-
Sm B cells, serum anti-Sm in 2-12H Tg mice is no different from non-Tg mice indicating 
that tolerance is maintained and PC differentiation prohibited (29). Anti-Sm B cells are 
regulated by developmental arrest, anergy, and ignorance after differentiation to MZ and 
B-1 B cells (29, 30, 31, 32). In this study, we describe a new regulatory checkpoint that 
occurs after activation at an early pre-PC stage. Regulation of autoreactive B cells at a 
pre-PC stage prompts new considerations regarding the fundamentals of B cell activation 
and early PC differentiation in the context of autoimmunity and tolerance. 
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C.  MATERIALS AND METHODS 
Mice  
2-12H Tg, 2-12H Tg MRL/lpr, MD4 and MD4 x ML5 mice have been previously 
described (24, 29, 33) and were housed and bred in a conventional facility at the 
University of North Carolina (Chapel Hill, NC). Screening of 2-12H mice for the 
transgene was performed by PCR analysis of tail genomic DNA as previously described 
(29). All mice were 2–8 mo of age at the time of analysis. MD4 and MD4 x ML5 mice 
were the gift of P. Oliver (National Jewish Medical and Research Center, Denver, CO) 
and K. Hippen (University of Minnesota Medical School, Minneapolis, MN).  
Flow cytometry  
Single-cell suspensions of splenocytes were prepared and RBCs were lysed using an 
RBC lysis solution (1 M Tris, 0.15 M ammonium chloride, and 0.1 M EDTA). All 
staining was done in RPMI 1640 medium (HyClone) containing 3.0% bovine calf serum 
(HyClone) as described (30). FcRs were blocked with mAb 2.4G2 for 20 min at 4°C. 
Cells were analyzed at the University of North Carolina Flow Cytometry Facility 
(Chapel Hill, NC) using a FACSCalibur (BD Biosciences). The Abs specific for CD19 
(1D3), CD138 (281-2), IgM (II/41), B220 (RA3-6B2), CD21 (7G6), CD23 (B3B4), 
CD80 (16-10A1), CXCR4 (2B11), and CXCR5 (2G8) were obtained from BD 
Pharmingen and were labeled with FITC, PE, allophycocyanin, biotin, or Alexa 647. For 
the detection of apoptotic cells, CaspACE FITC-VAD-FMK was used as described by 
the manufacturer (Promega). For the identification of anti-Sm B cells, we used Sm 
(SMA-3000; Immunovision) that was biotinylated in our laboratory as described 
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previously (29). For the detection of biotinylated probes we used streptavidin-FITC, 
streptavidin-PerCP (BD Pharmingen), or streptavidin-allophycocyanin (BD 
Pharmingen). Data were analyzed using Summit software (DakoCytomation). All data 
represent cells that fell within the lymphocyte gate determined by forward and 90° light 
scatter. One to 5 x 105 cells per sample were analyzed. All contour plots are 5% 
probability.  
Immunohistochemistry  
Freshly isolated spleens were embedded in Tissue-Tek OCT (Sakura Finetek) and frozen 
in 2-methyl-butane and liquid nitrogen. Six-micrometer spleen sections were prepared 
and fixed for 5 min in acetone:MeOH at –20°C before staining. Sections were blocked 
for 1 h with Superblock Blocking buffer in PBS (1:1 ratio) containing 2.4G2 anti-Fc
R Ab. Slides were rinsed and stained at room temperature for 2 h with anti-CD138-PE, 
IgM-Alexa 350 (Molecular Probes), anti-CD3-allophycocyanin (BD Pharmingen), anti-
CD11b-biotin, and anti-CD11c-biotin (eBioscience) diluted in blocking buffer. CD11b 
and CD11c staining was revealed by streptavidin Alexa 488 (Molecular Probes). Stained 
slides were rinsed with PBS and coverslips mounted in FluorSave mounting media 
(Calbiochem). Analysis was performed using a digital deconvolusion microscope 
(Intelligent Imaging Innovations (3I)). Images were collected and analyzed using 
Slidebook software (3I).  
IC IgM detection  
Cell surface proteins were stained as described above. During the staining of cell surface 
proteins, surface Ig was blocked using unlabeled anti-IgM (II/41; BD Pharmingen) at 2 
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µg/106 cells for 20 min at 4°C. After washing with RPMI 1640, cells were washed once 
with PBS and fixed with 1% paraformaldehyde in PBS (200 µl/106 cells for 10 min at 
4°C). After fixation, cells were permeabilized with saponin buffer (0.05% in PBS 
containing 0.5% BSA) using 100 µl/106 cells for 30 min at 4°C. Cells were then stained 
with anti-IgM-FITC (II/41; BD Pharmingen) in saponin buffer using 50 µl/106 cells at a 
previously determined optimal concentration for 30 min at 4°C. Cells were washed twice 
with saponin buffer and once with RPMI 1640 before analysis in RPMI 1640 as 
described above.  
Cell sorting  
For cell-sorting experiments, spleen cells were stained with Ab as described for each 
experiment and sorted on a MoFlo high-speed sorter (DakoCytomation). Sorted 
populations were >90% pure as determined by reanalysis.  
Ex vivo ELISPOT  
ELISPOT was performed as previously described (30) using ImmunoSpot Mid Plates 
(Cellular Technology) were coated with 10 U/well Sm Ag (Immunovision), anti-IgM 
(Southern Biotechnology Associates), or anti-Ig (Southern Biotechnology Associates). 
Sorted cells were resuspended in HL-1 medium (BioWhittaker) supplemented with 1% L-
glutamine and 1% penicillin/streptomycin; 1 x 105 cells were added to each well and 1/2 
serial dilutions were made across the plate. Spots were detected using biotin-labeled anti-
IgMa or IgMb Ab (BD Pharmingen), streptavidin-HRP (BD Pharmingen), or anti-IgG 
HRP (Southern Biotechnology Associates) and developed with 3-amino-9-
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ethylcarbazole (Sigma-Aldrich) in 3-amino-9-ethylcarbazole buffer. The plates were 
scanned and analyzed using an ELISPOT Analyzer (Cellular Technology).  
BrdU incorporation  
Mice were given 0.5 mg/ml BrdU (Sigma-Aldrich) with 1 mg/ml dextrose in their 
drinking water continuously for 1 wk and spleens cells were prepared for flow cytometry 
as described above. Staining for BrdU was done as described by Allman et al. (34) using 
anti-BrdU-FITC (BD Biosciences).  
Cell cycle analysis  
Cells were stained with CD19-allophycocyanin, CD138-PE, and Sm and were sorted as 
described above. The cells were then fixed with 70% ethanol and stained with a buffer 
containing 100 µg/ml propidium iodide and 250 µg/ml RNase A (Boehringer 
Mannheim) overnight at 4°C. The DNA content was analyzed by FACSCalibur, as 
described above.  
Real time RT-PCR  
CD138–, CD138int, and CD138high CD19+ B cells were positively selected to a purity of 
>90% via FACS sorting using Ab combinations against 2-12Tg BCR, CD138, and 
CD19. Total RNA was isolated from the purified cell samples by the TRIzol method 
(Invitrogen Life Technologies) followed by a DNase-I treatment step. One microgram of 
DNA-free RNA was reverse-transcribed to cDNA using Moloney murine leukemia virus 
reverse transcriptase (Invitrogen Life Technologies). Real-time PCR was performed with 
the Absolute SYBR Green Mix (ABgene) on an ABI Prism 7900HT sequence detection 
system (Applied Biosystems). Amplification conditions were as follows: 50°C for 2 min, 
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95°C for 15 min, followed by 40 cycles of 95°C for 15 s, 56°C for 30 s, and 72°C for 15 
s. Real-time primers were designed using Primer3 software, with a specified amplicon 
length between 100 and 250 bp. Primers for the control gene mouse actin were as 
follows: forward, 5'-AGGGCTATGCTCTCCCTCAC-3' and reverse, 5'-
CTCTCAGCTGTGGTGGTGAA-3'. Other primers used were as follows: BCMA, 
forward, 5'-ATCTTCTTGGGGCTGACCTT-3' and reverse, 5'-
CTTTGAGGCTGGTCCTTCAG-3'; B cell-activating factor receptor (BAFF-R), 
forward, 5'-CCCCAGACACTTCAGAAGGA-3' and reverse, 5'-
AGGTAGGAGCTGAGGCATGA-3'; transmembrane activator and calcium modulator 
and cyclophilin ligand interactor (TACI), forward, 5'-GTGTGGCCACTTCTGTGAGA-
3' and reverse, 5'-CTGGTGCCTTCCTGAGTTGT-3'; Blimp-1, forward, 5'-
TGTTGGATCTTCTCTTGGAAAA-3' and reverse, 5'-
GTGTAAAGTAGACTGCCTTGA3'; CD138, forward, 5'-
CTCACTAGGCTCCCACTTGC-3' and reverse 5'- ATGCAAGAAACCCTTTGCAC-3'. 
Relative expression of RNA was determined via: relative expression = 2–(CT) x 1000, 
where CT = (cycle threshold (CT) gene of interest) – (CT -actin in experimental sample) 
– (CT gene of interest – CT -actin in a no-template control sample). Statistical p values 
were determined via a two-tailed paired t test. Real-time SYBR-green dissociation 
curves show one species of amplicon for each primer combination (data not shown). 
Agarose gels (1.5%) show a single PCR product of the appropriate size (data not shown).  
Statistical analysis  
The paired Student’s t test and the independent Student’s t test were used to assess the 
significance of the observed differences. A value of p < 0.05 was considered significant.  
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D.  RESULTS 
Anti-Sm B cells are present at a CD138int B cell stage  
 We have previously shown that immunization of 2-12H mice with apoptotic cells 
or small nuclear ribonucleoproteins induces an anti-Sm response and anti-Sm B cells are 
activated upon transfer to mice deficient in clearance of apoptotic cells (29, 30). To 
understand the activation of anti-Sm B cells, we looked for the presence of pre-PCs and 
PCs in the spleens of 2-12H and 2-12H MRL/lpr mice using CD138 as a marker (1, 5, 6, 
7, 14, 16, 17, 18). Few CD19–/low, CD138+ PCs were present in the spleens of non-Tg and 
2-12H mice. However, a population of B cells expressing intermediate levels of CD138 
(CD138int), and normal levels of CD19 and B220, was observed (Fig. 1A, and data not 
shown). They are distinct from pre-PCs described previously that have high levels of 
CD138 and low levels of CD19 and B220 (6, 7, 14, 18). The CD138int B cells comprise 
20% of the anti-Sm CD19+ cells in 2-12H mice and 20% of non-Sm binding B cells from 
2-12H and non-Tg mice (Fig. 1B). Most were CD23+ and CD21int similar to FO B cells, 
although a small subset were CD23low and CD21high similar to MZ B cells (Fig. 1C). 
Thus, a large fraction of normal mouse B cells express the PC marker CD138. 
Interestingly, autoreactive B cells are enriched in the CD138int population of non-Tg 
mice; 20% and 13% CD138int and CD138– non-Tg B cells, respectively, were anti-Sm, a 
nearly 2-fold enrichment in the CD138int population (Fig. 1D and Table I). Thus, 
autoreactive B cells of normal mice are enriched in the CD138int population and a 
substantial fraction of CD138int cells are autoreactive. CD138int B cells were also present 
in the BM (Fig. 1, E and F). Twenty-five to 30% of mature (IgD+ and/or CD23+) B cells 
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were CD138int, and in 2-12H mice this population included anti-Sm B cells. Thus, 
significant numbers of CD138int B cells are present in the BM and spleen.  
 To determine whether Ag stimulation is required for anti-Sm CD138int B cell 
differentiation, we compared the expression levels of activation markers on CD138– and 
CD138int B cells. Both flow cytometry and light microscopy of Wright-Giemsa-stained 
cells indicated that the CD138int or CD138– B cells of non-Tg did not differ in size or 
granularity (Fig. 1C, first column, and data not shown). However, the anti-Sm CD138int 
B cells from 2-12H mice were significantly larger and more granular by flow cytometry, 
and had significantly lower surface IgM levels than CD138– B cells (Fig. 1C). In 
addition, chemokine receptor expression levels were different; CXCR4 was significantly 
increased and CXCR5 was significantly decreased on anti-Sm CD138int compared with 
CD138– B cells (Fig. 1C). The differences in CD80 expression were not significant, 
although the pattern of expression was different (Fig. 1C). In contrast to the phenotypic 
differences between anti-Sm CD138– and CD138int B cells of 2-12H mice, CD138– and 
CD138int B cells of non-Tg mice differed only in IgM and CXCR5 expression levels 
(Fig. 1C). No differences were seen in CD86, MHC class II, peanut agglutinin (PNA), 
and GL7 expression between CD138– and CD138int B cells from mice of either strain 
(data not shown). Thus, the differences between the anti-Sm CD138– and CD138int B 
cells of 2-12H mice suggest that the latter have encountered Ag, consistent with a model 
in which they have begun PC differentiation.  
 To more definitively address the requirement for Ag, we determined whether Ag 
was required for the development of CD138int B cells specific for hen egg lysozyme 
(HEL). As shown in Fig. 1, B and G, there was a significantly (p = 0.0002) higher 
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frequency of anti-HEL CD138int B cells in the presence of Ag (10%; MD4 x ML5 mice) 
than in the absence of Ag (MD4 only mice; 0.70%). CD138 staining is unlikely to be 
artifactual; real-time PCR shows that CD138 mRNA expression was higher in sorted 
CD138int cells than CD138– cells (Fig. 1E), and the CD138int B cells were significantly 
larger and more granular (p < 0.01) than CD138– B cells (Fig. 1E). Anti-HEL B cells 
were transitional, FO, and MZ in similar proportions in the presence or absence of HEL 
(data not shown) indicating that changes in subset distribution caused by the presence of 
Ag cannot explain the increase in CD138int B cell frequency. To assess whether a BCR 
signal is similarly required for CD138int B cell differentiation in non-Tg mice, we 
generated mice with low levels of CD19 (CD19+/–), a positive regulator of BCR 
signaling. As shown in Fig. 1B, there was a significant decrease in the frequency of 
CD138int B cells suggesting the requirement for a BCR signal. Thus, CD138int B cell 
differentiation is Ag dependent, and self-Ag can induce autoreactive B cells to 
differentiate to the CD138int stage in nonautoimmune mice.  
Pre-PCs are located in follicles primarily near bridging channels and the T cell areas  
 Activated B cells typically migrate within follicles (9) and we therefore 
determined the location of CD138int B cells in the spleen by immunohistochemistry. 
Because multiple cell types express CD138, sections were stained for CD138 and for 
CD3, CD11b, CD11c, and IgM to discriminate B cells from T cells, macrophages, and 
dendritic cells (DCs). In non-Tg and 2-12H mice, CD138int B cells were located 
primarily in follicles (Fig. 2, A and B), and were rare in the MZ and red pulp. Within the 
follicle, the CD138int B cells were generally clustered, and were more likely to be found 
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near the border with the T cell-rich periarteriolar lymphoid sheath (PALS) and bridging 
channels. In addition, the CD138int B cells proximal to the PALS border and bridging 
channels tended to stain more intensely for CD138 than those located more distally. 
Location in these areas allowed for proximity of some CD138int B cells to T cells and 
DCs. These data suggest that CD138int B cells migrate toward the T cell region and 
bridging channels. This is similar to migration induced by TI Ags (35). 
Anti-Sm B cells are regulated at the CD138int B cell stage  
 To further test the possibility that CD138int B cells were pre-PCs, they were 
examined for intracellular IgM (IC IgM) and Ab secretion (6, 16, 17). In both 2-12H and 
non-Tg mice a higher frequency of CD138int than CD138– B cells were IC IgMhigh (Fig. 
3, A and B) suggestive of PC differentiation. Moreover, a higher frequency of CD138int 
than CD138– B cells of non-Tg mice secreted Ab (IgM or IgG) according to an 
ELISPOT assay (Fig. 3C). Although CD138int B cells constitute a minority of the B cell 
population, they contribute 8-fold more IgM and IgG ASCs than CD138– B cells (Table 
II). Similarly, a higher frequency of CD138int than CD138– B cells of 2-12H mice were 
ASCs, although the difference was considerably smaller than in non-Tg mice. The 
frequency of IgM ASCs from non-Tg and 2-12H mice was low among CD138int B cells 
(<1%) (Fig. 3C), but this is consistent with the low frequency IC IgMhigh B cells (<3%) 
(Fig. 3B) and with their early pre-PC phenotype. Most significantly, there was no 
difference between 2-12H CD138int and CD138– B cells in the frequency of anti-Sm-
secreting cells (Fig. 3C and Table II). There was also no difference in the number anti-
HEL CD138– and CD138int ASCs from anti-HEL mice (data not shown). Because anti-
Sm ASCs were largely absent, we presumed that the IgM ASCs among CD138int B cells 
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of 2-12H mice had either a low affinity for Sm or did not bind Sm. The low frequency of 
IgM ASCs from 2-12H mice is seemingly at odds with the high frequency of splenic B 
cells falling outside of the Sm-binding gate (Fig. 1A). However, many 2-12H B cells 
show weak staining with Sm (Fig. 1A) and are likely to have low affinity anti-Sm BCRs. 
As a result, they too may be subject to regulation resulting in the low frequency of IgM 
ASCs observed. Thus, while some non-Sm CD138int B cells had become ASCs, 
consistent with their early pre-PC phenotype, the autoreactive anti-Sm and anti-HEL 
CD138int B cells had not.  
Anti-Sm CD138int B cells are not regulated in autoimmune 2-12H Tg MRL/lpr mice  
 To determine how anti-Sm CD138int B cells were regulated differently in 
autoimmune mice, we examined 2-12H MRL/lpr mice. Both Sm binding and non-Sm 
binding CD138int B cells were present in the spleens of 2-12H MRL/lpr mice (Fig. 4, A 
and B), but they were present at a lower frequency than in nonautoimmune mice (Fig. 1, 
A and B). As with nonautoimmune mice, a large fraction of CD138int B cells from non-
Tg MRL/lpr mice were anti-Sm (Fig. 4C), and the anti-Sm B cells were enriched (3-fold) 
in this population relative to the CD138– population (35 vs 11%; Fig. 4C and Table I). 
Compared with CD138– B cells, anti-Sm CD138int B cells had lower IgM levels, 
increased CXCR4, and decreased CXCR5 levels, and most had high levels of CD80 (Fig. 
4D). These expression differences were more pronounced than those in nonautoimmune 
mice (compare Fig. 4D with 1C). There was no difference in PNA or GL-7 expression 
(data not shown). Similar results were observed with non-Sm binding CD138– and 
CD138int B cells (data not shown). As in nonautoimmune mice, some CD138int B cells 
were IC IgMhigh and ASCs, but the frequencies in both MRL/lpr and 2-12H MRL/lpr 
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mice (IC IgMhigh: 10–30%; ASCs: 1.5–2.0%) were higher than in their nonautoimmune 
counterparts (IC IgMhigh: 2–3%, ASCs: <1%) (Fig. 4, E and F). Most significantly, the 
frequency of anti-Sm ASCs among CD138int B cells of 2-12H MRL/lpr mice was higher 
than among anti-Sm CD138– B cells (p < 0.05; Fig. 4F). The average number of anti-Sm 
ASCs among CD138int from 2-12 MRL/lpr was 4129 ± 1557 per 106 B cells (range: 0–
12,687/106; n = 11; Fig. 4F), but was 155 ± 54 per 106 B cells in 2-12H mice (range:0–
196; n = 8; p = 0.045; Fig. 4C). Thus, the anti-Sm CD138int cells of MRL/lpr mice 
showed a more activated and differentiated phenotype than those of nonautoimmune 
mice, with a higher frequency having become ASCs.  
 Anti-Sm B cells of MRL/lpr mice had also differentiated to a CD138high stage in 
both MRL/lpr and 2-12H MRL/lpr mice. These cells were also CD19low and B220low 
(Fig. 4, A and B, and data not shown), and in 2-12H MRL/lpr mice this population 
included anti-Sm B cells (Fig. 4, A and B). Their frequency was significantly higher in 2-
12H MRL/lpr mice than in 2-12H mice where they were barely detectable (0.66 ± 0.13% 
and 0.13 ± 0.025%, respectively; p = 0.0084; see legend to Fig. 4A). Their phenotype 
resembled that of the late pre-PCs described previously (6, 14). Consistent with a later 
stage of differentiation, the anti-Sm CD138– and CD138high B cells were generally more 
different in the expression levels of IgM, CD80, CXCR4, and CXCR5 than were anti-Sm 
CD138– and CD138int B cells, although not all differences were statistically significant, 
owing in part to greater heterogeneity in expression levels between mice (Fig. 4D). 
CD138high B cells did not show increased expression of either PNA or GL-7. A higher 
proportion of CD138high than CD138int B cells were IC IgMhigh and ASCs (Fig. 4, E and 
F). The frequency of anti-Sm ASCs among CD138high B cells was also higher than 
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among CD138– B cells (Fig. 4, E and F). This frequency is lower than the frequency of 
IgM ASCs consistent with the fact that not all B cells are anti-Sm. The CD138int and 
CD138high B cells contributed 10–20 times the number of IgM and IgG ASCs, and 3 
times the number of anti-Sm ASCs, as CD138– B cells (Table II). Based on a postsort 
analysis, <1% of the CD138int ASCs could be attributed to contaminating CD138high B 
cells and even fewer could be due to contaminating CD138+CD19– PCs (data not 
shown). Thus, anti-Sm CD138int pre-PCs of MRL/lpr mice differentiated to CD138high 
pre-PCs and PCs.  
 Immunohistochemistry analysis indicated that the distribution of CD138+ B cells 
in MRL/lpr is similar to that in nonautoimmune mice. However, there are significant 
architectural differences in the white pulp of MRL/lpr mice compared with 
nonautoimmune mice. A MZ region rich in B cells surrounded the follicle and PALS 
(Fig. 2, C and D). B cells were also located in a follicle that is often separated from the 
MZ by an infiltration of T cells into the marginal sinus (Fig. 2, C and D). Staining with 
PNA did not reveal germinal centers (data not shown). Despite these differences, as in 
nonautoimmune mice, CD138+ B cells were located primarily in the follicle and were 
rare in the encircling MZ and in the red pulp. In the follicles, B cells staining brightly and 
weakly for CD138 were evident, consistent with the flow cytometry analysis. Thus, the 
CD138+ B cells of MRL/lpr mice are located primarily in follicles.  
Anti-Sm CD138int B cells progress toward apoptosis  
 To understand the regulation of anti-Sm CD138int B cells in nonautoimmune 
mice, we examined cell cycle, half-life, and cell death. The absence of anti-Sm ASCs 
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among CD138int B cells of 2-12H Tg mice could be due to their elimination before 
becoming competent to secrete Ab. A BrdU incorporation assay indicated that anti-Sm 
CD138int B cells of nonautoimmune mice incorporated BrdU more rapidly than 
nonautoreactive CD138int B cells (Fig. 5A). Moreover, few anti-Sm and non-Sm 
CD138int B cells were in cycle (Fig. 5B). Cell division was unlikely to occur before 
expression of CD138 because <1% of CD138– B cells were in cycle (data not shown). 
Thus, in the absence of proliferation of anti-Sm CD138– and CD138int B cells, the BrdU 
incorporation rate would reflect the 50% turnover rate of the cells, estimated to be 7 days 
for anti-Sm CD138int B cells and 21 days for non-Sm binding CD138int B cells from 
nonautoimmune mice. Consistent with this difference in turnover rate, a high frequency 
(17%) of anti-Sm CD138int B cells were undergoing apoptosis, based on staining with the 
caspase inhibitor VAD-FMK (Fig. 5C). In contrast, only 4% of non-Sm CD138int B cells 
were apoptotic. Some anti-Sm CD138– B cells may be eliminated before they reach the 
CD138int stage, because a high frequency of these cells were VAD-FMK+ (12%) (Fig. 
5C). These data indicate that anti-Sm CD38int B cells of nonautoimmune mice do not 
enter cell cycle and have a rapid turnover rate at least partly due to cell death, while the 
non-Sm CD138int B cells also do not enter cell cycle but have a relatively long turnover 
rate. 
 An analysis of anti-Sm CD138int B cells of MRL/lpr mice showed evidence of 
both entry into cell cycle and apoptosis. The anti-Sm CD138int B cells of MRL/lpr mice 
had a comparable BrdU incorporation rate to those in nonautoimmune mice (Fig. 5A). 
This rate was similar to those of their non-Sm binding counterparts (Fig. 5A). This high 
incorporation rate for anti-Sm CD138int B cells was likely due to cell division in the 
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spleen, because 3% of anti-Sm and 7% of non-Sm CD138int B cells were in cycle (Fig. 
5B). This proliferation precluded an estimation of half-life. Also, a high frequency of 
anti-Sm CD138int B cells in 2-12H MRL/lpr was VAD-FMK+ (22%). Thus, some anti-
Sm B cells undergo apoptosis after they reach the CD138int stage (Fig. 5C), as they do in 
nonautoimmune mice, while others must continue differentiation to the CD138high and 
PC stages.  
Autoreactive CD138int B cell regulation and Blimp-1 transcription  
 To understand the molecular basis of CD138int B cell regulation, we examined 
Blimp-1 mRNA expression by real-time PCR. Blimp-1 mRNA levels were significantly 
higher in nonautoreactive CD138int B cells than CD138– B cells of nonautoimmune mice 
(Fig. 6), consistent with the observation that some CD138int B cells were IC IgMhigh and 
were ASCs (Fig. 4C). However, anti-Sm CD138int B cells of nonautoimmune mice, 
which were not ASCs, did not have elevated Blimp-1 mRNA levels (Fig. 6). Thus, 
regulation occurred upstream of Blimp-1 transcription. Blimp-1 mRNA levels were 
significantly elevated in anti-Sm CD138int B cells of MRL/lpr mice, and higher still in 
the anti-Sm CD138high pre-PCs (Fig. 6) consistent with the progressive increase in 
frequency of cells that were IC IgMhigh and ASCs. Interestingly, Blimp-1 levels were 
higher in anti-HEL CD138int B cells than anti-HEL CD138– B cells. Because the anti-
HEL CD138int B cells were not ASCs (data not shown), these data indicate that 
regulation occurred downstream of Blimp-1 expression. Thus, regulation of autoreactive 
CD138int B cells can occur before or after Blimp-1 expression. 
Differential BlyS receptor expression in CD138int B cells  
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 BlyS receptors affect the longevity of pre-PCs (35, 36) and thus could influence 
the life span of anti-Sm CD138int B cells. Using real-time PCR, we determined the 
relative mRNA expression levels in CD138int and CD138– B cells of the three BlyS 
receptors, BAFF-R, TACI, and BCMA. As shown in Fig. 7, CD138int B cells from non-
Tg mice had not up-regulated BAFF-R mRNA, but had up-regulated TACI mRNA, a 
negative regulator of cell survival, and BCMA mRNA, a prosurvival receptor for pre-
PCs. Interestingly, the anti-Sm CD138int B cells of 2-12H mice had up-regulated BAFF-
R and TACI mRNA, but had not up-regulated BCMA mRNA, while anti-Sm CD138int B 
cells from MRL/lpr mice had up-regulated BAFF-R, TACI, and BCMA mRNAs, and to 
a much higher level than in nonautoimmune mice. Thus, BCMA mRNA up-regulation 
correlates with anti-Sm CD138int B cell differentiation to ASCs, suggesting a role for 
BCMA in their regulation. 
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E.  DISCUSSION 
 In this study, we describe an early pre-PC population of B cells in the BM and 
spleen of normal mice. They are defined by the expression of intermediate levels of 
CD138, but normal levels of CD19 and B220. Some are IC IgMhigh and ASCs. These 
pre-PCs do not correspond to any other recognized B cell population; based on CD21 
and CD23 staining, most resemble FO B cells and some MZ B cells, but the large 
majority of FO and MZ B cells are CD138–. Autoreactive B cells appear to be enriched 
in this population and a large fraction of them are autoreactive. In nonautoimmune 2-
12H mice a large anti-Sm CD138int population is present, but these cells exhibit a more 
differentiated phenotype than the non-Sm-binding CD138int B cells of non-Tg mice. 
These data suggest that autoreactive B cells in normal mice have been activated and have 
begun differentiation toward the PC stage.  
 A number of findings suggest that the activation of CD138int B cells is Ag driven. 
This includes the cell surface phenotype and increase in size and granularity relative to 
CD138– B cells, the lower frequency of CD138int B cells in CD19+/– than CD19+/+ mice, 
and the near absence of anti-HEL CD138int B cells in mice that lack HEL. In addition, 
the location of CD138int pre-PCs primarily in the follicles proximal to the PALS and 
bridging channels is suggestive of the B cell migration induced by Ag activation (9). 
This possible migration is consistent with the chemokine receptor expression changes 
observed. These data argue that CD138int B cell differentiation is Ag dependent.  
 The Ags responsible for CD138int B cell differentiation in normal mice are 
unknown. The analysis of anti-HEL mice and the fact that a large proportion (20%) of 
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CD138int B cells of non-Tg mice are anti-Sm argues that self-Ags are involved. In fact, 
the bulk of these cells may be specific for self-Ags and therefore there may be continual 
pressure to generate CD138int B cells because of the ubiquitous presence of Ag. The 
distribution of these cells near bridging channels is suggestive of activation by TI Ags, 
which would be consistent with self-Ag involvement (35). It remains unresolved whether 
foreign Ags are involved. The autoantibodies produced by these cells may have a normal 
physiological role and their differentiation to the brink of PC differentiation would 
ensure a rapid response. Our previous finding that anti-Sm B cells are selected into the 
MZ and B-1 subsets (30, 31) reinforces the idea of a physiological role for anti-Sm B 
cells. For the anti-Sm CD138int B cells, the activating Ag may be Sm itself. Sm is 
exposed on apoptotic cells and immunization with apoptotic cells and soluble Sm 
induces an anti-Sm response (30). In addition, mice defective in apoptotic cell clearance 
develop chronically high titers of anti-Sm (30). Thus, the high rate of lymphocyte 
turnover by apoptosis in the spleen may provide a continuous source of Ag to drive 
CD138int B cell differentiation.  
 Important questions regarding the CD138int population in non-Tg mice are yet to 
be answered. For example, why do CD138int B cells of non-Tg mice and the anti-Sm 
CD138int B cells of 2-12H mice differ in phenotype (size, granularity, and surface IgM 
and chemokine receptor expression), and why are there so few CD138high B cells in non-
Tg mice, given the large number of CD138int B cells? There are several possible 
explanations. 1) Many may be autoreactive and regulated to prevent further 
differentiation. That 20% of non-Tg CD138int B cells are anti-Sm supports this 
possibility. 2) They may serve as a reservoir of cells capable of rapid PC differentiation 
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upon encounter with foreign or self-Ags. Along these lines, an interesting possibility is 
that these cells can move back and forth between the CD138– and CD138int populations. 
Fujita et al. (37) have demonstrated that the PC transcription program can be reversed 
and that PCs can reacquire a B cell transcription program and a B cell phenotype. Thus, 
the CD138– and CD138int populations may exist in dynamic equilibrium controlled by 
fluctuations in self-Ag concentration. 3) Non-Tg CD138int B cells may in general have 
low affinity BCRs for their cognate Ag or are exposed to Ag at concentrations 
suboptimal for driving differentiation to the CD138high stage. This may result in 
increased CD138 expression, but not the other changes seen in 2-12H mice. The 2-12H 
and MD4 x ML5 (anti-HEL/HEL) mice may reveal a more extreme phenotype because 
of a high affinity of their BCRs for self-Ag. 4) CD138int B cells from non-Tg mice may 
also exit the spleen and complete their differentiation to PCs elsewhere, although 
whether these cells can exit the spleen is unknown. CD138int B cells are present in the 
bone marrow and may derive from splenic B cells, although it cannot be excluded that 
they arise in situ from newly developed B cells or from recirculating mature CD138– B 
cells.  
 The pre-PCs described here appear to precede in differentiation the previously 
described PC intermediates. PC differentiation involves multiple intermediates whose 
relationship to each other is ill-defined. There are likely to be multiple pathways for PC 
differentiation, dictated by several factors, not the least of which is whether the Ag is TI 
or TD. Several groups have begun to unravel this complexity. Underhill et al. (6), using 
P- and E-selectin-deficient mice, have proposed a stepwise scheme of PC differentiation. 
According to this scheme, activated B cells progressively acquire increasing levels of 
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CD138 and decreasing levels of B220 to finally arrive at B220– PCs, which are either 
CD138int or CD138high. Based on this scheme, the CD138int population we have 
described would likely precede the earliest (CD138high) population identified by 
Underhill et al. (6).  
 There are also similarities between the CD138int B cells we have described and 
pre-PCs induced by TD and TI stimulation. Murine mammary tumor virus immunization 
generates CD138int and CD138high cells (7). They too have up-regulated CXCR4 and 
down-regulated CXCR5. Likewise, TI stimulation with LPS induces CD138int/high B cells 
that retain surface IgM. A more comprehensive comparison will be required to 
understand how these populations are related. Unfortunately, these comparisons provide 
little insight into the nature of the Ag responsible for the CD138int B cells in 
unimmunized mice. The CD138int cells in nonautoimmune mice are GL7– (data not 
shown) and the immunohistochemistry analysis indicates that they are not in germinal 
centers (Fig. 2), pointing to activation by TI Ags.  
 Our data demonstrate that the CD138int B cell stage is a checkpoint for the 
regulation of autoreactive B cells. A higher frequency of CD138int B cells from both non-
Tg and 2-12H mice are IC IgMhigh cells than are their CD138– counterparts, but only the 
non-Sm binding CD138int B cells become ASCs. The up-regulation of Blimp-1 by non-
Sm, but not anti-Sm, CD138int B cells would account for this (12, 13). We also find that 
these cells have not up-regulated XBP-1 or down-regulated PAX-5 (H. Wang, and S. H. 
Clarke, manuscript in preparation). The up-regulation of XBP-1 and down-regulation of 
PAX-5 are important to PC differentiation (15, 38). A CD138int population is present in 
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mice lacking Blimp-1 (14), confirming that Blimp-1 is not required for CD138int B cell 
differentiation. However, Blimp-1 transcription is up-regulated by anti-HEL B cells (Fig. 
5) despite the fact that they do not progress to the ASC stage (data not shown). Thus, a 
block in PC differentiation can occur at different molecular checkpoints in 
differentiation. That anti-Sm and anti-HEL B cells differ in this regard suggests that the 
self-Ag-induced signals control the molecular checkpoint.  
 Why anti-Sm CD138int B cells fail to up-regulate Blimp-1 is unknown. Bcl-6 
represses Blimp-1 transcription, and strong BCR signals can repress Bcl-6, thereby 
allowing Blimp-1 transcription (39, 40). This model is presented in the context of a 
germinal center reaction, for which there is no evidence in 2-12H Tg mice, and how 
Blimp-1 transcription is up-regulated in a TI response is not known. A signal necessary 
for Blimp-1 transcription, such as a T cell- or DC-derived signal (35, 36), may be 
lacking, or anti-Sm CD138int B cells may receive a signal that blocks Blimp-1 
transcription. For example, anti-Sm pre-PCs may be susceptible to IL-6-mediated 
repression by DCs, as described for anergic anti-Sm B cells (41), or to repression by 
regulatory T cells (42). Alternatively, continuous BCR stimulation may lead to BCR 
desensitization (43) or sustained ERK phosphorylation (44), either of which might block 
Blimp-1 transcription. Finally, autoreactive CD138int B cells may be eliminated before 
Blimp-1 up-regulation, consistent with the rapid turnover rate and high frequency of 
apoptosis among anti-Sm CD138int B cells in nonautoimmune mice.  
 The subset origin of CD138int B cells has yet to be determined. The CD23 and 
CD21 expression by anti-Sm and non-Sm CD138int B cells (Fig. 1C) and their location 
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primarily in follicles (Fig. 2) suggests that in nonautoimmune mice most derive from FO 
B cells. However, because CD23 and CD21 expression levels are altered by activation 
and MZ B cells migrate toward the PALS upon activation (35), these findings do not 
exclude or include B cells of any subset as direct precursors. Interestingly, the presence 
of these cells in MD4 x ML5 mice (Fig. 1G) indicates that the same BCR that mediates 
anergy also mediates CD138int B cell differentiation. One interpretation of this is that 
anergic B cells can be activated to become CD138int pre-PCs, but a more interesting 
possibility is that immature or transitional B cells differentiate to either an anergic FO B 
cell or a CD138int pre-PC depending on the signal they receive. The difference in signal 
may be the strength of the BCR signal, or the transduction of another signal, such as 
through a TLR or from DCs (45). The latter hypothesis is attractive because it does not 
require the activation of anergic B cells.  
 Comparison of the BlyS receptor expression patterns in Sm- and non-Sm-binding 
CD138int B cells may provide clues to the regulation of anti-Sm CD138int B cells. BlyS 
and its receptors BAFF-R, TACI, and BCMA are key players in B cell development and 
regulation (46) and have different functions (4, 47, 48). They also differ in ability to bind 
BlyS and the related cytokine a proliferation-inducing ligand (APRIL); BlyS binds all 
three receptors, while APRIL binds only TACI and BCMA. It is intriguing that BCMA 
expression is up-regulated by CD138int B cells of non-Tg mice and by anti-Sm CD138int 
B cells of MRL/lpr mice, but not by those of 2-12H Tg mice. Because BCMA is critical 
for long-term PC survival in part by up-regulating the antiapoptotic gene Mcl-1 (4), 
BCMA expression could account for the shortened half-life of anti-Sm CD138int B cells 
in nonautoimmune mice and survival and continued differentiation in MRL/lpr mice.  
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High TACI levels on anti-Sm CD138int B cells could also contribute to their short half-
life. TACI is a negative regulator of BlyS signaling, and TACI-deficient mice develop an 
SLE-like disease, suggesting that TACI has a role in negative selection of autoreactive B 
cells (48). To our knowledge, this is the first example of TACI up-regulation by 
autoreactive B cells. TACI, in the absence of BCMA, may provide a predominantly 
negative BlyS signal. Although BAFF-R is also up-regulated on anti-Sm CD138int B 
cells, which could deliver a survival signal (49), non-Tg CD138int B cells have a long 
half-life in the absence of BAFF-R up-regulation, suggesting that it is not required. 
Interestingly, APRIL could provide an unopposed negative signal to anti-Sm CD138int B 
cells, because it binds TACI, but not the BAFF-R. In this model, anti-Sm CD138int B 
cells of 2-12H MRL/lpr mice would receive signals through both TACI and BCMA, 
which may be sufficient to prolong survival. This speculation highlights the need to 
understand how BlyS receptor signals are integrated and whether BlyS and APRIL are 
involved in regulation.  
 Anti-Sm B cells from MRL/lpr mice overcome the CD138int tolerance 
checkpoint. Many have differentiated to the more PC-like CD138high stage and have 
become ASCs. The CD138high B cells have lower levels of IgM and other cell surface 
molecules and increased granularity and size compared with CD138int B cells (Fig. 4). 
They are similar to late pre-PCs described previously (6, 14). In addition, CD138int and 
CD138high B cells have progressively increased Blimp-1 expression and increased XBP-1 
expression and decreased PAX-5 expression (Fig. 6 and H. Wang and S. H. Clarke, 
manuscript in preparation). The immunohistochemistry analysis suggests that CD138int B 
cells of MRL/lpr mice are located predominantly in follicles, as they are in 
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nonautoimmune mice. There is no evidence that they are formed in germinal centers. 
However, it is possible that many are formed in a TI response, as we speculate for 
nonautoimmune mice, while a few are activated in a TD response and in germinal 
centers. The numbers of the cells activated in germinal centers may be too few for 
detection by the methods used here. Anti-Sm T cells are present in 2-12H MRL/lpr mice 
(50), and thus T cell-derived signals, whether in germinal centers or not, may be 
involved in driving differentiation of anti-Sm CD138int B cells to become ASCs. 
Consistent with this, nonautoimmune anti-Sm CD138int B cells can be induced in vitro to 
become ASCs by anti-CD40 + IL-4 stimulation (data not shown). Other signals may also 
be important to overcoming tolerance at this checkpoint. Increased levels of serum BlyS 
have been described in autoimmune NZBWF1 and MRL/lpr mice (51), and in SLE 
patients (52), and thus BlyS could be important to CD138int B cell survival and 
differentiation due to increased BCMA expression. Increased levels of apoptotic cells (a 
source of Sm Ag) (53, 54), different cytokine profiles (10), and DC activation could also 
contribute to overcoming this checkpoint in MRL/lpr mice. Fluctuations in any of these 
factors could affect the rate of ASC differentiation and explain the considerable 
variability in anti-Sm ASC numbers among CD138int B cells in 2-12 MRL/lpr mice. 
Precisely how the early pre-PC checkpoint is overcome in MRL/lpr mice will be an 
important area for further investigation.  
 Regulation at an early pre-PC stage prompts new considerations of how B cell 
tolerance is lost. The anti-Sm CD138int cells in 2-12H mice have been activated and 
appear to be on the verge of becoming ASCs. The conditions under which these cells can 
be activated in vivo have yet to be determined. The expression of Blimp-1 and BlyS 
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receptors are potentially critical factors in maintaining these cells at the CD138int stage in 
normal mice. Thus, there may be an important interface between anti-self BCR 
stimulation, BlyS/APRIL signaling, and Blimp-1 transcription in determining an 
appropriate balance between tolerance and activation. Understanding the molecular 
mechanism of how Blimp-1 and BlyS receptors are regulated in autoreactive B cells may 
identify new targets for therapeutic intervention in autoimmune diseases. 
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FIGURE A1.1. CD138int cells are present at a high frequency in the spleens and BM 
of non-Tg and 2-12H mice. A, CD138 expression by splenic B cells. Top row, CD19 
and CD138 staining of total splenic lymphocytes in non-Tg and 2-12H littermates as 
determined by forward scatter (FSC) and side scatter (SSC). The right histogram is a 
representative isotype (IgG2a, ) control stain (1.19 ± 0.25% (n = 4) falling within the 
CD19+, CD138+ quadrant). Middle row, Shown are histograms for IgM and Sm staining 
of CD19+ B cells from non-Tg and 2-12H mice. The indicated gate is that for the Sm+ 
population analyzed in the bottom row. Bottom row, Shown is the CD138 expression of 
gated Sm+ and Sm– B cells from 2-12H mice and total B cells from non-Tg mice. The 
percentage of CD19+ B cells that are CD138int is provided. B, Frequency of 
CD19+CD138int B cells among CD19+ B cells. Each symbol represents a single mouse 
and a horizontal line marks the mean. Absolute numbers of CD138int B cells are 5.48 x 
106± 1.16 x 106 (n = 8) for 2-12H anti-Sm, 8.19 x 106± 1.77 x 106 (n = 8) for 2-12H non-
Sm, and 2.37 x 107± 6.47 x 106 (n = 6) for non-Tg mice, 4.91 x 106± (Figure legend 
continues) 4.66 x 105 (n = 4) for CD19+/– mice, 2.7 x 105± 1.63 x 105 (n = 8) in MD4 
mice, and 1.20 x 106± 4.76 x 105 (n = 11) in MD4 x ML5 mice. C, Activation marker 
expression by CD19+ CD138– B cells (shaded) and CD19+ CD138int (black line) from 
non-Tg and 2-12H mice. Representative histograms are shown. Values of p are given for 
the differences between the CD138int and CD138– cells. D, Sm binding by CD138int B 
cells. Histograms are gated on CD138int B cells from the indicated mice as illustrated in 
A (upper right quadrant of top row). The percentage of anti-Sm CD138int B cells is 
provided. The average percentage for non-Tg and 2-12H mice is given in Table I. E, 
CD138 expression by BM B cells. Top row, Histograms are gated on CD19+ cells to 
identify the recirculating IgD+CD23+ B cells. Middle row, Sm binding by gated IgD+ 
CD23+ B cells. Bottom row, CD138 expression by the indicated B cell subsets. The 
percentage of gated B cells that are CD138+ is given. F, Frequency of CD138int B cells 
among the recirculating IgD+CD23+ B cells of the BM. Each symbol represents a single 
mouse and a horizontal line marks the mean. G, CD19+ CD138int B cells are absent in 
anti-HEL MD4 mice, but present in anti-HEL/HEL MD4 x ML5 mice. Frequency of 
CD138int B cells is given as percent of CD19+ B cells. The FSC and SSC for CD138– 
(shaded) and CD138int (solid line) B cells are shown along with the p values for the 
differences in mean fluorescence intensities. The gating for CD138int cells is indicated in 
the top histograms. The CD138– B cells were all CD19+ cells that fell outside the 
CD138int gate. Lower graph shows real-time PCR results for CD138 expression using 
sorted CD138– and CD138int B cells from MD4 and MD4 x ML5 mice. 
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FIGURE A1.2. Immunofluorescence analysis of nonautoimmune and autoimmune 
mice. Spleens were sectioned and stained with anti-CD138 and anti-IgM, anti-CD3, anti-
CD11b, and anti-CD11c to identify B cells, T cells, macrophages, and DCs, respectively. 
A, Non-Tg: A representative follicle at x10 magnification is shown in panel 1. B cells 
are blue, CD138 is red, and macrophages/DCs are green. The locations and 
corresponding photos for the higher magnifications (x40) are indicated. Panels 2 and 4 
are stained identically to A1, but in panels 3 and 5, T cells are blue and B cells are not 
shown. White carets identify examples of CD138+ B cells. Panels 2 and 3 show a 
clustering of CD138int B cells near a bridging channel (BC). Note that the CD138+ B 
cells are more frequent near the PALS and bridging channel. Panels 4 and 5 show an 
area of the follicle away from the bridging channel in which CD138+ B cells are 
infrequent. B, 2-12H: Panels 1–3 are as described for the corresponding photos in A. 
Panels 4–6 are higher magnification (x64) of the indicated areas indicated in panel 2. 
Panels 4 and 6 show B cells (blue), but not T cells; panels 5 and 7 show T cells (blue), 
but not B cells. Panels 2–6 show an area near a bridging channel. Note the greater 
concentration of CD138+ B cells near the PALS and bridging channel. White carets 
identify representative CD138+ B cells. The yellow carrot shows an example of a T cell 
near a cluster of CD138+ B cells. C, MRL/lpr: Panels 1 and 2 show a representative 
follicle at x10 magnification. Panel 1 shows B cells (blue), macrophages/DCs (green), 
and T cells (red). In this view, T cells have infiltrated into the marginal sinus. Panel 2 
shows the same follicle with B cells (blue), macrophages/DCs (green), and CD138 (red). 
Note that many T cells are CD138+. Panels 3 and 4 show the MZ area (x40 
magnification), and panels 5 and 6 show a follicle (x40 magnification). Panels 3 and 5 
show B cells (blue) but not T cells; panels 4 and 6 show T cells (blue), but not B cells. 
D, 2-12H MRL/lpr. Same as C. Panels 3 and 4 show the follicle; panels 5 and 6 show 
the MZ. 
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FIGURE A1.3. A subset of CD138int B cells are IC IgMhigh and secrete Ab, but anti-
Sm CD138int B cells do not secrete Ab. A, Surface and IC IgM on non-Tg CD138– and 
CD138int B cells. Nonpermeabilized and isotype controls do not show IC IgM staining 
(top row). CD138– and CD138int B cells were gated as indicated (bottom row; left 
histogram) and the percentage of IC IgM+ B cells that are IC IgMhigh determined (second 
row; middle and right histograms) and displayed in B. The bottom and top gates indicate 
the IC IgMlow and IC IgMhigh populations, respectively. B, The frequency of IC IgMhigh 
cells among CD138– and CD138int B cells from non-Tg and 2-12H mice. The horizontal 
line marks the mean frequency. C, The number of ASCs per 106 sorted CD138– or 
CD138int B cells detected by ELISPOT. IgM and IgG ELISPOT assays were used for 
analysis of non-Tg mice, and IgM and anti-Sm ELISPOT assays were used for analysis 
of 2-12H mice. The total number of ASCs per spleen is presented in Table II. 
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FIGURE A1.4. Anti-Sm CD138int B cells are ASCs in autoimmune mice. A, 
CD19+CD138int and CD19+CD138high B cells are present in non-Tg MRL/lpr mice and 
as anti-Sm and non-Sm B cells in 2-12H MRL/lpr mice. T cells from MRL/lpr mice 
express CD138 and have been excluded from the histograms of the top row by anti-CD3 
staining and gating on the CD3-negative cells. The histograms of the middle row are 
gated on CD19+ lymphocytes, and the bottom row on the indicated Sm-binding or non-
Sm-binding populations. B, Frequency of CD19+CD138int and CD19lowCD138high B cells 
as a percentage of CD19+ B cells. Each symbol represents a single mouse, and the 
horizontal line marks the mean frequency. The number of CD19+CD138int B cells is as 
follows: 9.48 x 106± 3.55 x 106 for non-Tg MRL/lpr (frequency: 6.8 ± 2.5% of CD19+ B 
cells); 2.12 x 106± 1.49 x 106 for 2-12H MRL/lpr anti-Sm (frequency: 3.0 ± 2.1% of 
CD19+ B cells); and 2.67 x 106± 1.31 x 106 for 2-12H MRL/lpr non-Sm (frequency: 3.8 
± 1.8% of CD19+ B cells). The number of CD19lowCD138high cells are as follows: 1.46 x 
106± 8.46 x 105 for non-Tg MRL/lpr (frequency: 1.04 ± 0.174% of CD19+ B cells); 1.48 
x 105± 1.20 x 105 for 2-12H MRL/lpr anti-Sm (frequency: 0.66 ± 0.130% of CD19+ B 
cells); and 4.27 x 105± 3.52 x 105 for 2-12H MRL/lpr non-Sm (frequency: 0.900 ± 
0.180% of CD19+ B cells). The number and frequency of CD138int from 2-12H 
nonautoimmune mice is given in Fig. 1. The number of anti-Sm CD138high B cells in 2-
12H mice is 4.24 x 104± 8.33 x 103 (frequency: 0.127 ± 0.0249% of CD19+ B cells). The 
number of CD138high B cells in nonautoimmune non-Tg mice is 2.92 x 105± 5.78 x 104 
(frequency: 0.23 ± 0.047% of CD19+ B cells) (using gates (Figure legend continues) 
identical to those used for 2-12H mice). The frequency of anti-Sm CD138high B cells in 
2-12H and 2-12H MRL/lpr mice differs significantly (p = 0.0084). C, Sm binding by 
CD138int B cells. Histograms are gated on CD138int B cells from the indicated mice as 
illustrated in A (upper right quadrant of top row). The percentage of anti-Sm CD138int B 
cells is provided. The average percentage for non-Tg and 2-12H mice is given in Table I. 
D, FSC, SSC, and activation marker expression for CD19+CD138– (shaded), 
CD19+CD138int (thin black line), and CD19lowCD138high (thick black line) B cells from 
2-12H Tg MRL/lpr mice. Representative histograms are shown. Anti-IgM levels on T 
cells are shown as a negative control for IgM expression in the first panel. The p values 
for the differences between CD138– and CD138int (top value) and between CD138int and 
CD138high (bottom value) are given. E, The frequency of IC IgMhigh cells among CD138–
, CD138int, and CD138high B cells from non-Tg and 2-12H Tg MRL/lpr mice. The 
horizontal line marks the mean frequency. The p values for the relevant comparisons are 
shown. F, ASCs among 106 sorted CD138–, CD138int, and CD138high B cells from non-
Tg MRL/lpr and 2-12H MRL/lpr mice. *, Statistical significance from CD138– B cells (p 
< 0.05). The ELISPOT assays were as described for Fig. 1. Note that the scale is 
different from that for Fig. 3C. 
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FIGURE A1.5. Anti-Sm CD138int B cells have a high turnover rate and a high 
frequency are undergoing apoptosis. A, Seven-day BrdU incorporation by CD138– ( ) 
and CD138int ( ) B cells from non-Tg, 2-12H, and 2-12H MRL/lpr mice (n = 4). Error 
bars indicate SD. On the right are representative histograms to illustrate the gatings used 
to measure the frequency CD138– and CD138int populations that have incorporated 
BrdU. B, Cell cycle analysis of CD138int B cells based on propidium iodide (PI) 
incorporation. The frequency of PI+ cells in the G2/S gate is shown for each population. 
Representative of two independent experiments using cells pooled from three mice. C, 
Detection of early apoptosis using VAD-FMK staining of CD138– ( ) and CD138int ( ) 
B cells in non-Tg, 2-12H, and 2-12H MRL/lpr mice (n = 6). Error bars indicate SD. On 
the right are representative histograms illustrating the gates for VAD-FMK and CD138 
staining used to generate the frequency of apoptotic cells. Values of p are for the 
comparison between the indicated CD138int populations. 
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FIGURE A1.6 
 
FIGURE A1.6. Blimp-1 mRNA is up-regulated in CD138int B cells that secrete Ab. 
Shown are Blimp-1 mRNA levels from sorted CD138– ( ) and CD138int ( ) B cells 
from non-Tg mice and sorted anti-Sm CD138– and CD138int B cells from 2-12H and 2-
12H MRL/lpr mice. The right panel shows Blimp-1 mRNA levels in CD138int ( ) and 
CD138high ( ) B cells in 2-12H MRL/lpr. In the lower graph are relative Blimp-1 levels 
from sorted CD138– and CD138int B cells from MD4 and MD4 x ML5 mice. Data are 
representative of two independent experiments using pooled mice. Values of p are 
shown for the indicated comparisons. 
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FIGURE A1.7 
 
FIGURE A1.7. Differential expression of BAFF-R, TACI, and BCMA on anti-Sm 
and non-Tg CD138int B cells. BAFF-R, TACI, and BCMA mRNA levels in CD138– ( ) 
and CD138int ( ) non-Tg B cells and anti-Sm B cells from 2-12H and 2-12H MRL/lpr 
mice. Data are representative of two independent experiments using pooled mice. Values 
of p are shown for the indicated comparisons. 
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A.  ABSTRACT 
 EBV is associated with systemic lupus erythematosus (SLE), but how it might 
contribute to the etiology is not clear. Since EBV-encoded latent membrane protein 2A 
(LMP2A) interferes with normal B cell differentiation and function, we sought to 
determine its effect on B cell tolerance. Mice transgenic for both LMP2A and the Ig 
transgene 2-12H specific for the ribonucleoprotein Smith (Sm), a target of the immune 
system in SLE, develop a spontaneous anti-Sm response. LMP2A allows anti-Sm B cells 
to overcome the regulatory checkpoint at the early preplasma cell stage by a self-Ag-
dependent mechanism. LMP2A induces a heightened sensitivity to TLR ligand 
stimulation, resulting in increased proliferation or Ab-secreting cell differentiation or 
both. Thus, we propose a model whereby LMP2A induces hypersensitivity to TLR 
stimulation, leading to activation of anti-Sm B cells through the BCR/TLR pathway. 
These data further implicate TLRs in the etiology of SLE and suggest a mechanistic link 
between EBV infection and SLE. 
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B.  INTRODUCTION 
 Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder 
characterized by the production of autoantibodies and multiorgan inflammatory damage. 
Both genetic and environmental factors contribute to the etiology of SLE, but a clear 
understanding of how these factors contribute to disease is still lacking. Among the 
environmental risk factors, EBV is the most closely associated with SLE. SLE patients 
have higher titers of anti-EBV Abs than control populations (1, 2, 3, 4), and EBV 
infection is more common among juvenile and adult SLE patients than among control 
populations (5, 6). Some cases of SLE appear to directly result from acute EBV infection 
(4, 7) or reactivation of EBV (8). In addition, SLE patients have a 40-fold higher EBV 
viral load in peripheral blood leukocytes than control populations due to poor cytotoxic T 
cell (CTL) responses (9) and a higher frequency of infected B cells (10).  
 Experimental studies support a role for EBV in the induction of SLE. EBV 
induces infectious mononucleosis causing B cell activation and autoantibody production 
(11). Some Abs elicited by EBV cross-react with nuclear Ags, suggesting that antigenic 
mimicry is involved in the appearance of certain autoantibodies (12, 13, 14). This 
possibility is strengthened by the observation that EBV-encoded protein, EBNA-1, 
contains linear epitopes similar to those of common self-antigenic targets in SLE, the 
B/B' and D peptides of ribonucleoprotein Smith (Sm) (15) and the Ro protein (16). 
Moreover, animal immunizations with plasmids for in vivo expression of EBNA-1 
peptides cross-reactive with Sm and Ro elicit anti-Sm and anti-Ro responses that are 
characterized by epitope spreading. The spreading involves other regions of the 
autoantigen, as well as additional nuclear Ags, including dsDNA, and is associated with 
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the development of clinical symptoms of SLE (16, 17, 18). Thus, EBV Ags could induce 
anti-nuclear Abs in SLE, providing a basis for EBV as an etiologic factor.   
 EBV exists as a lifelong latent B cell infection in >90% of the world’s 
population. The latent membrane protein (LMP) 2A plays a critical role in regulating 
viral latency by mimicking a constitutively activated BCR (19). The cytoplasmic domain 
of LMP2A contains ITAMs, the same signaling domains found in BCR subunits Ig  and 
Ig . This allows LMP2A to recruit the protein tyrosine kinases Lyn and Syk, 
sequestering them from the BCR and thereby inhibiting BCR signal transduction (20, 
21). It also activates the PI3K/Akt pathway, which enhances survival by increasing Bcl-
xL expression (19). A LMP2A transgene interferes with B cell development by permitting 
B cells that lack a BCR to leave the bone marrow and migrate to the spleen (22), 
indicating that it provides survival signals independent of the BCR.   
 The effects of LMP2A on B cell development and activation raise the possibility 
that it affects the regulation of autoreactive B cells. Recently, LMP2A expression has 
been shown to affect anergy induction (23). In this report, we sought to determine 
whether LMP2A affects the regulation of B cells specific for an Ag characteristically 
targeted in SLE. We have investigated the regulation of anti-Sm B cells in mice 
transgenic (Tg) for an anti-Sm H chain, 2-12H (24, 25). 2-12H Tg mice develop a high 
frequency of anti-Sm B cells, some of which are negatively regulated by developmental 
arrest and anergy (24). Other anti-Sm B cells are activated in 2-12H mice and begin 
plasma cell (PC) differentiation, but arrest at an early pre-PC stage (26). Differentiative 
arrest occurs before the up-regulation of the transcription factor B lymphocyte 
maturation protein 1 (Blimp-1), which is required for PC differentiation (27). However, 
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these anti-Sm pre-PCs differentiate to Ab-secreting PCs on the autoimmune MRL/lpr 
background (26). Thus, in 2-12H mice, anti-Sm B cell regulation occurs at multiple 
checkpoints and both before and after activation.      
 Since LMP2A affects BCR signaling and B cell differentiation, we examined 
whether it interferes with tolerance to SLE-specific Ags leading to autoantibody 
production. Using mice with both the anti-Sm 2-12H transgene and the EBV-derived 
LMP2A transgene, we demonstrate that EBV contributes to autoantibody production by 
allowing anti-Sm B cells to bypass the pre-PC tolerance checkpoint. Moreover, LMP2A 
increases the reactivity and sensitivity of B cells to TLR activation. We propose that 
LMP2A facilitates autoreactive B cell activation by the BCR/TLR pathway through 
enhancement reactivity to TLR ligands. 
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C.  MATERIALS AND METHODS 
Mice  
Anti-Sm 2-12H Tg mice and LMP2A TgE mice have been described previously (22, 24). 
Both 2-12H and LMP2A Tg mice are on a mixed background of C57BL/6 and CB17. 2-
12H/LMP2A double Tg mice were generated by crossing 2-12H with LMP2A Tg mice. 
Offspring carrying transgenes were identified by tail genomic DNA as described 
previously (22, 24). All animal protocols were approved by the University of North 
Carolina Institutional Animal Care and Use Committee.  
Flow cytometry  
Cells were prepared and stained as reported previously (28). Fluorochrome-conjugated 
or biotinylated mAbs specific for mouse B220, IgM, IgMa, IgMb, CD43, CD5, CD19, 
CD23, CD21/CD35, CD138, and MHC class II (I-Ab) were obtained from BD 
Pharmingen. For staining of TLRs, splenic B cells were fixed in 1.5% paraformaldehyde 
and permeabilized with methanol according to standard protocols. The cells were stained 
with CD19-FITC (eBioscience) and IgM-allophycocyanin (BD Pharmingen) plus one of 
the following: anti-TLR4-biotin (eBioscience), anti-TLR9-FITC (Imgenex), or anti-
RP105-biotin (eBioscience). PerCP-labeled streptavidin was used as a secondary reagent 
for biotinylated Abs. Cells were analyzed using a FACSCalibur (BD Biosciences). Data 
were analyzed by WinMDI software (The Scripps Institute). In some experiments, anti-
µ-stimulated cells were fixed with 1% formaldehyde and methanol, followed by staining 
with PerCP-labeled anti-B220 and Alexa 647-labeled anti-phospho-ERK(p44/42) Ab 
(Cell Signaling Technology) according to a previous protocol (29). The level of 
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phospho-ERK was detected by flow cytometry on gated B220+ B cells. Cells pretreated 
with 20 µM of a phosphor-ERK inhibitor, PD98059 (Calbiochem), for 20 min at 37°C 
were used as a control.  
For cell sorting experiments, splenic cells were stained with Abs as described in each 
experiment and sorted on a MoFlo high-speed sorter (DakoCytomation). Sorted 
populations were >90% pure as determined by reanalysis.  
ELISA and ELISPOT  
Quantitation of anti-Sm Abs and total IgM in mouse serum was done by ELISA as 
previously described (24). Quantitation of anti-Sm secreting Ab-secreting cells (ASCs) 
was performed using ex vivo ELISPOT assays described elsewhere (30).  
Real-time PCR  
Total RNA from sorted CD138–, CD138int, and CD138high B cells was isolated using a 
RNeasy Mini kit (Qiagen) according to the manufacturer’s instructions. A DNA 
digestion step is included before elution of RNA. Approximately 200 ng of total RNA in 
20 µl was reverse-transcribed with SuperScript II reverse transcriptase and random 
hexamer primers (Invitrogen Life Technologies). The PCR was performed in an ABI 
Prism 7000 Sequence Detection System with the SYBR Green PCR Master Mix reagents 
(Applied Biosystems). The cDNAs were serially diluted (50/10/5/1) to verify the 
efficiency of the PCR to amplify Blimp-1, X-box binding protein 1 (XBP-1), PAX-5, and 
the housekeeping gene hypoxanthine phosphoribosyltransferase (HPRT) transcripts. The 
PCR products were revealed by gel electrophoresis to verify the specificity of the PCR. 
Calculations were performed with the ABI Prism 7000 SDS software and using HPRT as 
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an internal control. Quantification was performed relative to the expression levels of non-
Tg CD138– cells. PCR primer sequences were as follows: Blimp-1 forward, 5'-
TGTTGGATCTTCTCTTGGAAAA-3'; Blimp-1 reverse, 5'-
GTGTAAAGTAGACTGCCTTGA-3'; XBP-1 forward, 5'-
GGTGCAGGCCCAGTTGTC-3'; XBP-1 reverse, 5'-TCCAGAATGCCCAAAAGGAT-
3'; PAX-5 forward, 5'-CAGCACTACTCTGACATCTT-3'; PAX-5 reverse, 5'-
GTTGGCTTTCATGTCATCC-3'; HPRT forward, 5'-
GTTCTTTGCTGACCTGCTGGAT-3'; and HPRT reverse, 5'-
GTCCCCCGTTGACTGATCAT-3'.  
EMSA and Western blotting  
Splenic B cells were purified using a Mouse B cell Recovery Column kit (Cedarlane 
Laboratories) according to manufacturer’s instruction with a slight modification. The 
purity of B cells is monitored by flow cytometry and was always 90%. Nuclear and 
cytoplasmic extracts were prepared as described previously (31). EMSA was performed 
as described using 32P-labeled dsDNA probes containing NF- B binding sites (32). 
Bands were visualized using a PhosphorImager (Molecular Dynamics). For I B Western 
blotting, 40 µg of cytoplasmic extract was resolved by SDS-PAGE using a 10% gel. For 
phosphorylation Western blotting, 3 x 106 of purified B cells were stimulated with 20 
µg/ml goat F(ab')2 anti-mouse µ Abs for 3 and 12 min at 37°C. After lysis, the cell lysate 
was resolved by 10% gels. Proteins were transferred to nitrocellulose membrane and 
detected with Abs against I B , I  B , I B , ERK, phospho-ERK (Santa Cruz 
Biotechnology), phosphotyrosine (Ab-2; Oncogene Research Products), and -actin 
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(Sigma-Aldrich), followed by an HRP-labeled secondary Abs. The bands were 
visualized using ECL development reagents (Amersham Biosciences).  
Proliferation assay  
Column-purified B cells were labeled with CFSE (Molecular Probes) at a concentration 
of 1 µM for 10 min at room temperature. The cells were then cultured in 10% 
FBS/RPMI 1640 at 1 x 106/ml in 24-well plates in the presence and absence of LPS 
(InvivoGen), imiquimod-R837 (InvivoGen), and CpG oligonucleotides (ODNs) 
(InvivoGen) at concentrations as indicated for 3 days. The cells were then stained with 
annexin V-Cy5 or 7-aminoactinomycin D (BD Pharmingen) and analyzed by a 
FACSCalibur.  
Ab secretion assay  
A total of 2 x 105 of purified B cells was cultured in 96-well plates in 200 µl of RPMI 
1640 medium for 3 or 5 days. CpG ODNs, imiquimod, or LPS was added at different 
concentrations as indicated. The supernatant was analyzed by ELISA for anti-Sm and 
total IgM.  
Statistical analysis  
The Student t test was used to assess the significance of the differences between groups. 
A value of p < 0.05 was considered significant. 
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D.  RESULTS 
LMP2A induced a spontaneous anti-Sm response  
 To determine whether LMP2A disrupts anti-Sm B cell regulation, we generated 
mice carrying both the LMP2A and 2-12H transgenes. As shown in Fig. 1A, 2-
12H/LMP2A mice produced significantly higher levels of serum anti-Sm than 2-12H and 
non-Tg controls, indicating that LMP2A-expressing anti-Sm B cells are activated in 
otherwise nonautoimmune mice. Control 2-12H mice had higher levels of serum anti-Sm 
than non-Tg littermates. This result differs from those of earlier studies, which found that 
Tg mice had levels similar to non-Tg mice (24, 33), and could be due to a subclinical 
infection or to background gene differences resulting from continued backcrossing to 
C57BL/6 mice. Total IgM levels in 2-12H/LMP2A mice did not differ from those of 2-
12H Tg or non-Tg controls (Fig. 1A), suggesting that anti-Sm production was selective. 
Consistent with increased serum anti-Sm, there were significantly higher numbers of 
anti-Sm ASCs in the bone marrow and spleens of 2-12H/LMP2A mice compared with 
control mice.  
 LMP2A induced an expansion of the splenic B cell population and a contraction of the 
peritoneal B cell population  
 In keeping with previous studies (22), we found that the population of immature 
IgM+ B cells was markedly reduced in the bone marrow of LMP2A Tg mice (data not 
shown) and that they were replaced by an aberrant population of µH chain-negative B 
lineage cells that survive by virtue of a constitutive, LMP2A-directed survival signal. In 
contrast, IgM+ B cell differentiation was not reduced in the marrow of 2-12H/LMP2A Tg 
mice since all B cells express the 2-12H transgene (data not shown). Further studies 
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showed that the splenic B cell population of 2-12H/LMP2A mice was 3-fold larger than 
that of 2-12H mice (Table I) and that, consistent with previous reports (22, 34), there 
were significantly fewer splenic B cells in LMP2A Tg mice compared with their non-Tg 
littermates. Between 50 and 80% of the CD19+ cells in the spleens of LMP2A Tg mice 
were IgM–, whereas almost all CD19+ B cells in spleens of 2-12H/LMP2A mice were 
IgM+ due to the expression of the 2-12H transgene (Fig. 2A). The frequency of splenic 
anti-Sm B cells in 2-12H and 2-12H/LMP2A mice was similar, while the number of anti-
Sm B cells was higher in 2-12H/LMP2A mice, commensurate with the increased number 
of B cells (Fig. 2A and Table I).       
 To determine whether B cell differentiation in 2-12H mice was altered by 
LMP2A, we examined B cells for CD23 and CD21 expression to discriminate 
transitional, follicular (FO), and marginal zone (MZ) B cells (Fig. 2A and Table I). We 
also examined expression of CD5 and CD43 because splenic B cells of LMP2A mice 
were reported to have a CD5+ B-1 phenotype (34). Thus, it was unexpected that most 
LMP2A splenic B cells showed an ambiguous phenotype. Most were CD23+CD21int, 
similar to FO B cells, and some were CD23low/–CD21high, similar to MZ B cells (Fig. 2B). 
LMP2A splenic B cells had a modestly elevated level of CD5 expression compared with 
B cells from non-Tg mice, but CD43 expression was high mimicking the CD43 level on 
B-1 cells. The phenotype of splenic B cells from 2-12H/LMP2A Tg mice was similar to 
that seen in LMP2A mice, although CD5 expression was not increased and CD43 
expression was somewhat lower (Fig. 2A and data not shown). This 
CD23lowCD43+CD5+/– phenotype was previously observed with B cells that had received 
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a partial signal for B-1 cell differentiation (35), suggesting that they might be arrested at 
an intermediate step in B-1 differentiation.  
 The number of peritoneal B cells was significantly reduced in LMP2A and 2-
12H/LMP2A mice, although this effect of LMP2A expression was partially ameliorated 
by the 2-12H transgene (Fig. 2B and Table II). We also found that LMP2A had 
significant effects on anti-Sm B cells. The majority of 2-12H and 2-12H/LMP2A anti-Sm 
B cells had the CD5+CD43+CD11b+ phenotype of B-1 cells (33) (Fig. 2B), but those in 
2-12H/LMP2A mice had lower levels of CD5 and CD43 (Fig. 2B). 
Anti-Sm B cell regulation at the pre-PC stage was bypassed  
 We recently identified a checkpoint in B cell regulation at an early pre-PC stage 
(IgM+CD138int), beyond which anti-Sm B cells do not mature in nonautoimmune mice 
(26). However, anti-Sm B cells on the autoimmune MRL/lpr background can bypass this 
checkpoint to become CD138high pre-PCs and fully mature PCs (26). To assess the effect 
of LMP2A on regulation at the IgM+CD138int checkpoint, we examined pre-PC 
differentiation in 2-12H/LMP2A mice. As shown in Fig. 3A and Table I, 2-12H/LMP2A 
mice had 6-fold more CD138int and 10-fold more CD138high pre-PCs than 2-12H mice. 
Similar increases were evident in anti-Sm CD138int and CD138high pre-PCs. As noted 
above, LMP2A mice have significantly fewer B cells than the double Tg mice and 
therefore had fewer CD138int B cells than non-Tg mice (Fig. 3A and Table I). Despite 
reduced splenic B cells, LMP2A mice had a larger number of CD138high pre-PCs than 
non-Tg control mice (Table I). The anti-Sm CD138int and CD138high B cells were IgMlow 
and were larger and more granular than CD138– B cells (Fig. 3B), all features shared 
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with anti-Sm pre-PCs in 2-12H MRL/lpr mice (26). Thus, expression of LMP2A 
enhanced the differentiation of anti-Sm B cells to the CD138high pre-PC stage. 
 An anti-Sm ELISPOT assay was used to determine whether anti-Sm B cells and 
pre-PCs were ASCs. Sorted CD138– B cells, CD138int, and CD138high pre-PCs were 
compared for the frequency of anti-Sm ASCs. As shown in Fig. 3C, the frequency of 
anti-Sm ASCs among CD138– B cells of both 2-12H and 2-12H/LMP2A mice was low. 
In contrast, there was a progressive increase in anti-Sm ASCs among CD138int and 
CD138high pre-PCs of 2-12H/LMP2A, but only a small increase among CD138int pre-PCs 
of 2-12H mice. Thus, anti-Sm pre-PCs of 2-12H/LMP2A mice differentiated to ASCs. In 
keeping with their differentiation to ASCs, CD138+ B cells from 2-12H/LMP2A mice 
exhibited changes in gene expression characteristic of normal PC differentiation. As 
determined by real-time PCR, Blimp-1 mRNA levels increased progressively as anti-Sm 
B cells differentiated from CD138– to CD138int and CD138high pre-PCs (Fig. 4). Blimp-1 
activates XBP-1, which controls a variety of PC-specific functions, and represses PAX-5, 
which drives the expression of a series of B cell-specific genes. XBP-1 mRNA levels 
mirrored the progressive increase in Blimp-1 expression, whereas PAX-5 transcripts 
progressively decreased during PC differentiation (Fig. 4). LMP2A mice showed the 
same pattern of Blimp-1 and PAX5 expression, whereas CD138– and CD138int B cells of 
2-12H and non-Tg mice were unchanged in their expression of these genes (Fig. 4). 
LMP2A had no apparent effect on 2-12H BCR stimulation  
 LMP2A is reported to severely impair the ability of B cells to signal through the 
BCR (20, 36). The observation that anti-Sm B cells from 2-12H/LMP2A mice can 
differentiate to ASCs suggests that BCR signaling in these animals is relatively intact. To 
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evaluate this possibility, we examined BCR signaling in 2-12H/LMP2A and control 
mice. In comparison to B cells from non-Tg mice, few B cells from 2-12H Tg mice 
proliferated in response to stimulation with anti-IgM (68 vs 19%, respectively). The 
failure of the majority of 2-12H B cells to proliferate in response to BCR ligation is 
consistent with anergy as a major mechanism of anti-Sm B cell regulation (24, 25). 2-
12H/LMP2A B cells had a higher background proliferative rate than B cells from 2-12H 
mice (4 vs 10%; p < 0.01) and mice from the other two strains (5–6%; p < 0.01) (Fig. 
5A). However, while BCR ligation induced an 5-fold increase in proliferation of 2-12H 
B cells (p < 0.05), it did not induce significantly higher proliferation of 2-12H/LMP2A B 
cells. LMP2A B cells did not proliferate in response to BCR ligation by anti-IgM, which 
is consistent with the observations that many were BCR negative and that LMP2A 
interferes with BCR signaling (20, 36). Thus, for B cells of 2-12H Tg mice, LMP2A 
induced a higher background proliferation but inhibited anti-BCR-induced proliferation.
 The poor proliferative response of 2-12H/LMP2A B cells to BCR cross-linking 
would appear to contradict the selective increase in serum anti-Sm Ab and number of 
anti-Sm CD138high ASCs in 2-12H/LMP2A mice, both of which are indicative of B cell 
activation and differentiation in these animals. To compare BCR signaling by 2-
12H/LMP2A and 2-12H B cells, we examined both BCR ligation-induced intracellular 
protein tyrosine phosphorylation and ERK phosphorylation. Splenic B cells from 2-12H 
and 2-12H/LMP2A mice responded to anti-IgM stimulation with similar overall protein 
tyrosine phosphorylation and ERK-specific phosphorylation (Fig. 5, B and C), and this 
response was similar to that of non-Tg B cells. There was little evidence of protein 
tyrosine phosphorylation in BCR-activated LMP2A B cells (Fig. 5B), and the level of 
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ERK phosphorylation was weak (Fig. 5, C–E), particularly ERK1 phosphorylation (Fig. 
5C). This difference is likely due to low percentage of BCR-expressing B cells in these 
mice (Fig. 2A). Interestingly, B cells from 2-12H and 2-12H/LMP2A mice had higher 
basal intracellular protein tyrosine phosphorylation and ERK phosphorylation than B 
cells from non-Tg mice (Fig. 5, B and C), suggestive of chronic BCR engagement (37). 
Thus, although BCR ligation-induced signaling in 2-12H/LMP2A B cells is equal to or 
greater than that seen in non-Tg B cells, proliferation is not significantly induced.  
LMP2A-expressing B cells exhibit constitutive NF-κB activation  
 Longnecker and colleagues (23) showed that NF-κB is constitutively activated in 
B cells expressing LMP2A. Since NF-κB is involved in B cell activation and 
differentiation, we examined resting 2-12H/LMP2A B cells for evidence of NF-κB 
activation and/or IκB degradation. Fractionated cytoplasmic and nuclear proteins were 
examined for the levels of the NF-κB cytoplasmic inhibitors IκBα,β, and ε and the 
amount of nuclear NF-κB DNA binding activity. As expected, B cells from 2-
12H/LMP2A mice had significantly more nuclear NF-κB activity and less cytoplasmic 
IκB inhibitors than B cells from 2-12H mice (Fig. 5, F and G). A similar difference was 
seen in comparisons of B cells from LMP2A and non-Tg mice. Thus, B cells from 2-
12/LMP2A mice exhibited constitutive activation of NF-κB.  
LMP2A-expressing B cells were hypersensitive to TLR activation  
 TLR signaling has been suggested to be important to the activation of 
autoreactive B cells in autoimmunity (38, 39). Since NF-κB is activated by TLR 
signaling, we hypothesized that LMP2A affects TLR activation. Thus, we examined the 
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responsiveness of B cells from 2-12H/LMP2A and control mice to stimulation through 
TLR4/RP105 by LPS, TLR9 by hypomethylated CpG ODNs, and TLR7 by imiquimod. 
As shown in Fig. 6A, B cells from both 2-12H and 2-12H/LMP2A mice proliferated 
equally well at high concentrations (1 µg/ml) of CpG ODNs, whereas B cells from 2-
12H/LMP2A mice exhibited increased proliferation compared with 2-12H B cells in 
response to a low CpG ODN concentration (0.1 µg/ml) (p < 0.01). B cells from LMP2A 
mice showed a similar hypersensitivity to CpG ODN stimulation when compared with B 
cells from non-Tg mice (Fig. 6A). In contrast, we did not observe a statistically 
significant difference in proliferation between 2-12H/LMP2A and 2-12H in response to 
LPS or imiquimod (Fig. 6A). Thus, LMP2A enhanced the sensitivity of B cells to 
activation by TLR9.  In contrast to proliferation, LMP2A enhanced Ab secretion by all 
three TLR ligands. TLR simulation of B cells from 2-12H/LMP2A mice with CpG 
ODNs, imiquimod, and LPS secreted 2- to 3-fold more IgM than B cells from non-Tg 
mice and 7-fold more IgM than B cells from 2-12H Tg mice (Fig. 6B). For CpG ODNs 
and LPS, increased secretion was seen at concentrations suboptimal for the activation of 
non-Tg B cells. Much of the Ab produced in response to these stimuli was anti-Sm in 
cultures of B cells from 2-12H/LMP2A and 2-12H Tg mice but not in cultures of B cells 
from non-Tg. Thus, LMP2A induces a heightened sensitivity to CpG ODN- and LPS-
induced ASC differentiation by autoreactive B cells.  
LMP2A affected TLR expression  
 To determine whether LMP2A alters TLR expression, we detected the expression 
of LPS receptors, TLR4 and RP105, and the CpG-ODN receptor, TLR9, by flow 
cytometry. As shown in Fig. 7, B cells from 2-12H/LMP2A and LMP2A Tg mice 
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expressed slightly higher levels of TLR4 than B cells from normal and 2-12H mice but 
considerably higher levels of RP105, a homolog of TLR4. TLR9 expression was also 
slightly increased on B cells expressing LMP2A (Fig. 7). IgM+ B cells from LMP2A Tg 
mice have increased expression of each of these receptors compared with IgM– B cells 
from the same mice, supporting a functional role for the BCR in regulation of TLR 
expression in LMP2A-expressing B cells. Thus, LMP2A induces a BCR-dependent 
increase in TLR expression on B cells. 
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E.  DISCUSSION 
 
 This study demonstrates that the EBV gene, LMP2A, induces a spontaneous anti-
Sm response in nonautoimmune mice and induces a loss of tolerance at the CD138int pre-
PC checkpoint. Sorted anti-Sm CD138int pre-PCs of 2-12H/LMP2A mice become ASCs 
and differentiate into CD138high PCs, resulting in an increased frequency relative to B 
cells of 2-12H mice (Fig. 3A and Table I). Differentiation to the PC stage could be 
inferred from the high frequency of anti-Sm ASCs in the bone marrow (Fig. 1B), the 
residence of long-lived PCs in normal mice (40). While the CD138int B cells of 2-12H 
mice exhibit a gene expression profile of a B cell (PAX-5+, Blimp-1–, XBP-1–), the same 
cells of 2-12H/LMP2A mice exhibit a profile consistent with differentiation to a PC 
(PAX-5-/low, Blimp-1+, XBP-1+) (Fig. 4). B cells from LMP2A mice showed a similar 
increase in differentiation to the CD138high pre-PC stage and changes in gene expression. 
Thus, the block in expression of PC-specific genes that occurs in B cells from 
nonautoimmune mice was lost in B cells from 2-12H/LMP2A mice. These changes in 
differentiation and gene expression mirrored the changes observed in B cells from 
autoimmune 2-12H MRL/lpr mice (26). Whether LMP2A disrupts other regulatory 
checkpoints in this model, such as anergy and developmental arrest, has yet to be 
systematically addressed. Longnecker and colleagues (23) reported that expression of 
LMP2A prevented induction of anergy to soluble hen egg lysozyme, suggesting that 
multiple checkpoints are affected.       
 An important question raised by these findings is whether tolerance is lost by an 
Ag-dependent or -independent mechanism. A role for Ag is possible because 2-
12H/LMP2A B cells can signal in response to BCR ligation similar to those from 2-12H 
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Tg mice (Fig. 5B). Since all B cells in 2-12H/LMP2A mice expressed the LMP2A 
transgene, the presence of naive splenic B cells suggests the need for additional signals. 
Moreover, there was a disproportionate increase in serum anti-Sm; 2-12H/LMP2A mice 
had 5-fold higher level of serum anti-Sm Abs than 2-12H mice, even though the levels of 
total serum IgM were similar. Thus, while these data suggest Ag dependence, a 
definitive answer will require a model system in which Ag can be removed.  
 The hypersensitivity of B cells from 2-12H/LMP2A mice to TLR-induced 
differentiation to ASCs suggests a possible mechanism for the anti-Sm response in these 
mice. Marshak-Rothstein and colleagues (38) identified a BCR/TLR9-dependent 
activation pathway for autoreactive B cells, in which activation of B cells producing 
rheumatoid factor or anti-DNA occurs when both the BCR and TLR9 are engaged (38, 
39). Whether TLR signaling is required for anti-Sm B cell activation, and if so, which 
TLR is involved, is not known, although a recent study demonstrates that TLR9 and 
TLR3 are not required for an anti-Sm response by MRL/lpr mice (41). We suggest that 
the sensitivity to TLR-induced activation caused by LMP2A expression increases the 
likelihood that anti-Sm B cells and possibly other autoreactive B cells such as anti-DNA 
and rheumatoid factor B cells will be activated through a BCR/TLR pathway. Since 
activation by this pathway requires a BCR signal, it would be consistent with the 
evidence for Ag dependence. Experiments to test this hypothesis in mice that lack 
functional TLRs are underway. A role for LMP2A in anti-Sm B cell activation is not 
exclusive of the antigenic mimicry hypothesis (16, 17, 18) and in fact could facilitate 
autoreactive B cell activation by EBV Ags.       
 The activation and increased sensitivity of 2-12H/LMP2A B cells to TLR 
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stimulation is unlikely to be explained by changes in receptor levels alone. TLR-induced 
proliferation and secretion do not necessarily correlate (e.g., LPS; Fig. 6) and neither do 
changes in sensitivity and receptor level (Fig. 7). Thus, we suggest that a more likely 
explanation for the increased reactivity by LMP2A-expressing B cells is that LMP2A 
induces a change in TLR signaling. LMP2A expression causes constitutive activation of 
the Ras/PI3K/Akt pathway (19, 42, 43) and of NF-κB (23). Since TLRs, including 
TLR4, TLR7, and TLR9, also trigger the PI3K/Akt pathway leading to increased NF-κB 
activation (44, 45), activation of this pathway by LMP2A may reduce the TLR signaling 
threshold. The increase in Ras activity, which activates the Raf/MEK/ERK pathway in 
addition to the PI3K/Akt pathway, may be responsible for the up-regulation of RP105 
and TLR4 expression. This is based on the understanding that PMA, a protein kinase C 
activator that triggers the MEK/ERK cascade, dramatically increases the expression of 
RP105 but increases TLR4 and TLR9 expression only modestly (46).  
 Whether these findings reflect the action of LMP2A in EBV-infected human B 
cells remains to be tested. There are important differences between this model system 
and EBV-infected human B cells that may affect the action of LMP2A in human B cells; 
whereas in humans EBV infects a small number of mature B cells (9, 47), LMP2A is 
expressed in all LMP2A Tg B cells throughout differentiation because LMP2A 
expression is under the control of an Eµ  enhancer and promoter (22). Hypersensitivity to 
TLR ligands by autoreactive B cells may require that LMP2A be expressed before 
anergy induction. Since this is unlikely to occur in humans, EBV-infected B cells may 
not be hypersensitive to TLR ligand stimulation. Alternatively, TLR hypersensitivity 
may be independent of the functional status of the B cell, and thus, LMP2A may have a 
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role in human autoimmune disease. In this case, based on the data presented here, 
multiple TLRs may be affected, resulting in responses to multiple autoantigens 
characteristic of SLE. It should be noted that LPS is unlikely to play a role because 
human B cells respond poorly to LPS, as TLR4 expression is low (48). We have focused 
on an SLE-specific autoantigen, but since this mechanism could act on B cells of specific 
for autoantigens targeted in other autoimmune diseases, EBV could have a role in the 
etiology of multiple autoimmune diseases such as Sjögren’s syndrome (49), rheumatoid 
arthritis (50), multiple sclerosis (51), and autoimmune hepatitis (52).   
 Increased sensitivity to TLR ligands may facilitate EBV latency. EBV infects 
naive B cells in the oral cavity and induces memory B cell differentiation (reviewed in 
Ref. 53), due in part to the ability of LMP1 and LMP2A to mimic CD40 and BCR 
signals, respectively (19, 54). Once established as memory B cells, EBV can exist as a 
latent infection for as long as the lifetime of the individual. LMP2A’s ability to increase 
sensitivity to TLR stimulation, as suggested here, may affect this process in two ways. 
First, it could facilitate the activation of naive B cells because TLR stimulation is 
required for efficient activation of naive human B cells (55). Second, increased TLR 
sensitivity may provide a survival advantage to EBV-infected memory B cells because 
periodic TLR stimulation may be required for long-term survival of memory B cells 
(56).    
 Since EBV infection is present in >90% of the population worldwide, additional 
genetic and environmental factors are obviously required for chronic autoantibody 
production and development of SLE (57, 58). One relevant factor that could account for 
a role in SLE is the frequency of EBV-infected B cells. SLE patients have a higher EBV 
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load (9) and increased frequency of infected B cells compared with healthy controls (10). 
We have previously shown (59) that the frequency of anti-Sm B cells affects the 
penetrance of the anti-Sm response in murine SLE. Thus, a high EBV infection 
frequency in humans could increase the chances for autoreactive B cell activation 
through a hypersensitive BCR/TLR activation pathway, particularly if, as indicated, 
genetic predisposition leads to an increase in autoreactive B cells in the periphery (60). 
 A question raised by the LMP2A-driven activation of autoreactive B cells is 
whether EBV-infected B cells are in sufficient number to account for autoantibody 
production in disease, even taking into account the higher frequency of EBV-infected B 
cells in SLE (10). This possibility cannot be ruled out given extrafollicular (61) and 
germinal center expansion of autoreactive B cells. EBV-infected PCs have been thought 
to undergo lysis due to the activation of the EBV lytic genes and virus production, 
casting doubt on the possibility of EBV-infected B cells generating serum autoantibody. 
However, recent evidence suggests that as many as 80% of infected PCs do not activate 
the lytic genes and are not replicating virus (62). Thus, a response by EBV-infected B 
cells may be able to generate autoantibody production.     
 Alternatively, the activation of autoreactive EBV-infected B cells could also lead 
to the activation of uninfected B cells through epitope spreading (63, 64), a mechanism 
that does not require PC differentiation. By this mechanism, the development of a 
response to one Ag (e.g., Sm B/B') could lead to the activation of B cells specific for 
other epitopes on the same Ag, epitopes on associated proteins, and even DNA (64). 
Thus, an initial response by EBV-infected B cells could lead to an autoimmune response 
composed of both EBV-infected and uninfected B cells.     
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 In summary, we report that LMP2A induces an anti-Sm B cell response, 
increases B cell sensitivity to TLR activation, and allows ASC differentiation by 
otherwise regulated B cells. We suggest that alterations in TLR ligand reactivity and 
sensitivity increase the likelihood autoreactive B cell activation through a BCR/TLR 
activation pathway. This may have implications for multiple autoimmune diseases in 
which an association with EBV is indicated. The targeting of therapeutic strategies to the 
pathways activated by LMP2A may prove useful for the treatment of these diseases, as 
well as EBV-associated B cell tumors and lymphoproliferative disorders. 
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 FIGURE A2.1 
 
FIGURE A2.1. Activation of anti-Sm B cells in 2-12H/LMP2A mice. A, Serum anti-
Sm IgM and total IgM levels were measured by ELISA. Each symbol represents an 
individual mouse (age 2–12 mo). The amount of anti-Sm IgM was significantly higher in 
2-12H/LMP2A mice than in 2-12H mice (p < 0.0001). The total IgM level was 
significantly lower in LMP2A mice than other groups (p < 0.05). B, The number of Sm-
specific ASCs in bone marrow (BM), spleen, and mesenteric lymph node (MLN) in mice 
of the indicated strains. ASCs were detected by a Sm-specific ELISPOT assay. Four to 
five mice from each group (means ± SEM) have been examined. 
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FIGURE A2.2 
 
FIGURE A2.2. LMP2A significantly affects B cell phenotype analysis. A, Splenic 
cells from each group were stained with indicated Abs to identify B cell subsets. The 
histograms in the first column are gated on lymphocytes, and those of the remaining 
columns are gated on B cell subsets as illustrated. The single parameter overlays are 
gated on CD19+IgM+ cells. B, Analysis of peritoneal B cells. The histograms of the top 
row are gated on lymphocytes, and the single parameter histograms are gated on the anti-
Sm B cells as shown. Single parameter overlays are gated on CD19+IgM+ anti-Sm B 
cells. These analyses of bone marrow, splenic, and peritoneal B cells are representative 
of three or more experiments. MZ, marginal zone B cells; Tr, transitional B cells; and 
FO, follicular B cells. 
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FIGURE A2.3 
 
FIGURE A2.3. Analysis of CD138-expressing B cells indicates that LMP2A allows 
differentiation beyond the pre-PC checkpoint. A, CD138int and CD138high B cells in 
LMP2A and nonexpressing mice. Splenic cells were stained with Sm and Abs to CD19, 
IgM, and CD138. Percentages of CD138int and CD138high B cells are indicated. The dot 
plots of the top and middle rows are gated on lymphocytes, and those on the bottom row 
are gated on anti-Sm B cells, as indicated. The data are representative of four to six mice 
analyzed. B, Forward (FSC) and side (SSC) scatter and surface IgM are compared for 
CD138– (shaded) and CD138+ B cells (line). C, ELISPOT analysis of sorted CD138–, 
CD138int, and CD138high B cells to determine anti-Sm ASC frequency. The CD138+ B 
cells were sorted using the gates depicted in A. The CD138– B cells used were all 
remaining B cells. Shown for each group (n = 4) is the average number (± SEM) of Sm-
specific ASCs per million B cells. *, p < 0.05 and **, p < 0.001 compared with CD138– B 
cells, respectively. 
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FIGURE A2.4 
 
FIGURE A2.4. Real-time PCR comparison of Blimp-1, XBP-1, and PAX-5 
expression in sorted B cell subpopulations indicates differentiation beyond the pre-
PC tolerance checkpoint. Splenic B220+CD138–, CD138int, and CD138high B cell 
populations were sorted from multiple mice of each group based on gates depicted in 
Fig. 3A. CD138+ cells from non-Tg and LMP2A Tg mice were sorted to include both 
CD138int and CD138high subsets. Total RNA was extracted and reverse transcribed to 
cDNA, followed by real-time PCR to amplify Blimp-1, XBP-1, and PAX-5 as well as 
HPRT. Data are relative amount of mRNA to non-PC cells that were set to 1.0. Data are 
means ± SEM of triplicate assays. One of two independent experiments with similar 
results is shown. 
 256 
FIGURE A2.5. 2-12H/LMP2A B cells do not proliferate in response to BCR signals 
but are nevertheless BCR signaling competent. A, Column-purified splenic B cells 
were CFSE labeled and stimulated with 10 µg/ml F(ab')2 anti-mouse µ. After 3 days, 
cultured cells were analyzed by flow cytometry to determine CFSE content of CD19+ 
viable B cells. Data are means ± SEM of two to four mice in each group. *, p < 0.05 
compared with nonstimulated controls. B, Protein tyrosine phosphorylation. Column-
purified B cells from mice of each line were stimulated with F(ab')2 anti-µ for 3 and 12 
min. Cytoplasmic proteins were resolved by SDS-PAGE and immunoblotted with anti-
phosphotyrosine (pTyr) Abs. The molecular weights of protein bands are indicated on 
the right. Data are representative of two independent experiments. C, ERK 
phosphorylation was determined by Western blot analysis. The membranes from B were 
sequentially stripped and reprobed with anti-phospho-ERK (top panel) and anti-ERK 
(lower panel) Abs. The ratios of the intensities of phospho-ERK over total ERK are 
given at the bottom. D, ERK phosphorylation was also assessed by flow cytometry. 
Purified B cells from each strain were stimulated as in B, fixed with formaldehyde, and 
treated with methanol. Cells were then stained with B220-PerCP and phospho-ERK-
Alexa 647 Abs and analyzed by flow cytometry. Shown is the pERK staining on gated 
B220+ B cells. Bottom panel, The ERK phosphorylation for 2-12H/LMP2A B cells 3 min 
after anti-IgM stimulation in the presence or absence of the inhibitor of ERK 
phosphorylation PD98059 as a control for the specificity of the anti-pERK Ab in this 
assay. E, The fold change over unstimulated cells (means ± SD of two independent 
experiments) in the mean fluorescence intensity (MFI) of the cells in D is presented. F, 
NF- B DNA binding activity assay. Nuclear extracts from purified B cells were 
analyzed by EMSA. Lower panel, Oct-1 DNA binding acting as a control for protein 
loading. G, I B expression. Cytoplasmic protein extracts from E were analyzed by 
immunoblotting using Abs recognizing I B , , , and actin. The numbers at the bottom 
are densities of the band. Data are representative of two independent experiments. 
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FIGURE A2.5 
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FIGURE A2.6. LMP2A induces B cell hyperresponsiveness to CpG ODN, LPS, and 
imiquimod. A, CpG ODN induced proliferation. Column-purified B cells were labeled 
with CFSE, stimulated with CpG ODN, LPS, or imiquimod at the indicated 
concentrations for 3 days, and analyzed by flow cytometry to determine the CFSE 
content of CD19+ B cells. The number of cell divisions is indicated on the top of each 
panel. The numbers (means ± SEM of three to five mice) indicated in each histogram are 
percentages of cells that undergo more than two divisions. All cells are gated on live 
cells (annexin V negative). Values of p < 0.01 compared with non-Tg (*) or 2-12H Tg 
(**) mice. B, Ab secretion by CpG ODN, imiquimod, or LPS-stimulated cells. Purified B 
cells stimulated with different concentrations of CpG ODN for 5 days (top panel) or 
imiquimod and LPS for 3 days (lower panel). The total IgM (left panel) and anti-Sm 
IgM (right panel) in the supernatant were measured by ELISA. Data are means ± SEM 
of triplicate assays. Data are representative of three independent experiments. *, p < 
0.001 compared with non-Tg mice. **, p < 0.0001 compared with 2-12H and non-Tg 
mice. 
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FIGURE A2.6 
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FIGURE A2.6, Continued 
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FIGURE A2.7 
 
FIGURE A2.7. LMP2A induces higher TLR expression levels. One parameter 
histograms are shown for TLR4, RP105, and TLR9 expression. The first column is a 
comparison of B cells from non-Tg (shaded) and LMP2A (line) mice. The second 
column is a comparison of expression by B cells from 2-12H (shaded) and 2-
12H/LMP2A (line). Non-Tg and 2-12H B cells do not differ in expression of these 
receptors. The third column is a comparison of non-Tg CD19+ B cells (shaded) with 
IgM+ (thin line) and IgM– (thick line) B cells of LMP2A mice. The data are 
representative of three mice of each strain. 
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